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ASstract 
The results presented in the thesis describe the isolation, characterization 
including inununological properties, in vitro and in vivo modulation of rat liver 
cytosolic high (69 kDa) and a newly identified low (45 kDa) molecular forms of 
neutral cholesteryl ester hydrolase (CEH). Almost all the enzymatic activity of 
predominant, 69 kDa CEH was associated with 0-40% ammonium sulfate fraction 
(ASF) of cytosol, whereas, the enzymatic activity of minor low (45 kDa) molecular 
form of CEH was fractionated in 40-80% ASF of cytosol. The characterization and 
regulation of cytosolic 45 kDa CEH represents an initial demonstration. 
We have developed a sensitive and reproducible colorimetric method for the 
assay of CEH which utilizes p-nitrophenyl fatty acyl esters of long chain fatty 
acids, such as palmitate as the substrate. Being less hydrophobic than cholesteryl 
oleate, the conventional substrate, p-nitrophenyl-palmitate (PNP-palmitate) is more 
accessible to the enzyme and hence exhibits higher activity with CEH in cytosol 
and ammonium sulfate fractions containing high (69 kDa) and low (45 kDa) 
molecular forms. Apart from being sensitive and reproducible, the method is rapid, 
inexpensive and non-hazardous as no radioactivity is involved. Due to high 
sensitivity of this method even low levels of enzymatic activity are detectable. It 
has also been demonstrated that the higher degree of hydrolysis of PNP-palmitate in 
comparison to cholesteryl oleate is not due to non-specific esterase(s) which is true 
in the case of PNP-acyl esters of short chain fatty acids like acetate and butyrate. In 
addition, by utilizing purified CE hydrolases of rat liver cytosol, rabbit liver, 
porcine liver and bovine pancreas, it has been established that PNP-palmitate is 
preferentially hydrolyzed at a faster rate than cholesteryl oleate. 
The apparent molecular weight of the purified high molecular form of CEH 
was found to be 69 kDa which is close to the reported molecular weight for this 
enzyme. The apparent molecular weight of the purified newly identified form of 
CEH was found to be 45 kDa. Consistent with the published reports, cytosohc 
69 kDa CEH has been shown to be a glycoprotein. The results demonstrate that the 
newly identified 45 kDa CEH is not a glycoprotein. The kinetic properties of the 
two CEH en2ynies were similar. The strong inhibition of both the enzymes by 
PMSF indicates the presence of serine at the active site, which is a common feature 
among carboxyesterases. 
Due to contradictory reports published from different laboratories, indicating 
varied effect of bile salt on CEH enzymatic activity from absolute dependence to no 
dependence or even inhibition, we investigated the effect of bile salt on the 
enzymatic activities of the two forms of CEH. The results provide evidence that 
bile salts have an activating effect on both cytosolic and purified 69 kDa and 
45 kDa CEH. However, no absolute dependency of either of the cytosolic or 
purified CEH enzymes on bile salt, was observed. The divalent metal ions Fe^ ,^ 
Cu^ ,^ Zn^\ Cd^\ Ni^^ Co^^ and Hg^\ strongly inhibited the enzymatic activities of 
both Ae molecular forms of CEH. This inhibition was apparently due to a 
generalized effect of divalent metal ions. 5 mM of Mn^ ^ or Mg^ ^ activated the 
cytosolic and partially purified (0-40% ASF) high (69 kDa) molecular form of 
CEH. However, the activation of CEH was blocked at Mn^ ^ or Mg^ * concentra-
tions higher than 5 mM. The 45 kDa CEH activity in 40-80% ASF remained 
una£fected in presence of Mg^ ^ and showed a small increase in the presence of 
Mn^ "^ . The Mn^ -^mediated activation is apparentiy due to direct effect on the 
enzyme. Both ATP (3 mM) and Mg-ATP (2 mM) activated the 69 kDa CEH in 
0-40% ASF but strongly inhibited the enzyme at higher concentrations. Our results 
indicate that activating effect of lower concentrations of Mg , ATP, and Mg-ATP 
is apparentiy due to enzyme modification involving reversible phosphorylation. 
However, ATP or Mg-ATP failed to affect the activity of 45 kDa CEH in 40-80% 
ASF. 
Immunological studies involving westem blot analysis and ELISA, using 
anti-rat hver CEH antiserum and anti-rat pancreatic CEH IgG, revealed that the two 
enzymes are structurally dissimilar. The results provide evidence that the 
predominant CEH isoforms of rat liver (69 kDa), rabbit liver (62 kDa) and porcine 
liver (59 kDa) are similar enzymes. On the other hand, the newly identified, 45 kDa 
XI 
minor CEH isoform of rat liver cytosol and cytosolic CEH of rat and bovine 
pancreas are similar enzymes, but structurally different from 69 kDa CEH of rat 
liver cytosol. The high level of cross-reactivity of anti-rat pancreatic CEH IgG with 
rat liver cytosolic 45 kDa CEH suggests a structural similarity of Ais enzyme with 
pancreatic CEH. 
Dietary induced hyperlipidemia in rats was associated with down-regulation 
of enzyme activities and protein mass of 69 kDa CEH and HMG-CoA reductase. 
The results provide evidence that administration of tocotrienol rich fraction (TRF) 
to normolipidemic rats was associated with a significant decrease in enzyme 
activities of CEH and HMG-CoA reductase. A concomitant decline in CEH and 
HMG-CoA reductase protein mass indicates the involvement of long-term control 
by alteration in protein synthesis and/or degradation. Administration of TRF along 
with atherogenic diet (AD) to rats was associated with fiirther inhibition of 69 kDa 
CEH activity in cytosol and 0-40% ASF, in comparison to hyperlipidemic controls. 
Eight days of TRF treatment to hyperlipidemic rats, after the withdrawal of AD, 
caused a further reduction in the activities and protein mass of 69 kDa CEH and 
HMG-CoA reductase, in comparison to untreated rats. No significant inhibitory 
effect of AD and TRF treatment on enzyme activity and protein mass of 45 kDa 
CEH was seen. The combined results are consistent with the known anti-cholesterol 
properties of tocotrienols. However, the TRF-mediated inhibition of cytosolic 
69 kDa CEH involving the reduction in its protein mass represents an initial 
demonstration. 
Mevalonate is an important precursor of cholesterol biosynthesis and known 
to inhibit HMG-CoA reductase in vivo. Administration of mevalonic acid lactone 
(mevalonolactone) was associated with a significant increase in enzymatic activity 
and protein mass of cytosolic 69 kDa CEH. No significant increase in enzymatic 
activity and protein mass of 45 kDa CEH was observed. Mevalonolactone-mediated 
activation of CEH is apparently due to secondary effect because increased CEH-
i i i 
mediated hydrolysis of cholesteiyl esters is dependent on increased cellular free 
cholesterol demand. 
Administration of cholestyramine, lovastatin or cholestyramine in combina-
tion with lovastatin to rats for 7 days resulted in an activation of 69 kDa and 45 kDa 
CEH. The up-regulation of 69 kDa CEH is apparently mediated by a significant 
increase in its protein mass involving long-term control. However, the protein mass 
of 45 kDa was increased significantly only in cholestyramine plus lovastatin fed 
rats. Prolonged fasting (21-36 h) of rats was associated with a significant elevation 
of the enzyme activity of cytosolic and partially purified 69 kDa CEH which is 
apparently due to an increase in protein mass. Since there is no increase in protein 
mass of 45 kDa CEH, a significant increase in enzymatic activity in lovastatin-fed, 
cholestyramine-fed and fasted rats, remains unexplained. 
The combined in vitro and in vivo results demonstrate that the two CEH 
enzymes of rat liver cytosol are important in the overall regulation of cholesterol 
balance in the liver. In addition, oiu" in vivo studies have established that under 
variety of dietary and/or drug manipulations, the enzymatic activity of cytosolic 
69 kDa CEH is regulated by alterations in protein mass. However, only under 
extreme physiological stress such as administration of cholestyramine, lovastatin, 
cholestyramine plus lovastatin and prolonged fasting to rats, the newly identified 
minor, 45 kDa cytosolic CEH undergoes regulation. 
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Introduction 
Cholesterol is widely distributed in animal kingdom and occurs in free form 
in all cell membranes (Myant, 1981). However, in blood plasma, most of the 
cholesterol is present in esterified fonn. Cholesterol is present in tissues and in 
plasma lipoproteins as free cholesterol or esterified with a long chain fatty acid, as 
esterified cholesterol. Apart from being the integral component of membranes, 
cholesterol is precursor of steroid hormones and bile acids. It is synthesized in 
many tissues from acetyl-CoA and is ultimately eliminated from the body in the 
bile as cholesterol or bile salts. The reactions involved in the biosyntiiesis of 
cholesterol including the branched pathway of isoprenoid metabolism in 
mammalian cells is shown in Figure 1. 
The total body cholesterol is derived from two sources; diet and de novo 
synthesis. Out of total cholesterol needed by the body, a little more than half arises 
from synthesis (about 700 mg/day) and the remaining is derived from the average 
diet. Cholesterogenesis mostly occurs in the liver, which also regulates the level of 
circulating cholesterol and plasma lipoproteins. It is also synthesized by intestine, 
adrenal cortex, reproductive organs and skin. Even though oAer cells and tissues 
also have the genomic information for cholesterol synthesis, they do not synthesize 
cholesterol and under normal circumstances they take up cholesterol from the 
plasma lipoproteins (Swann et al., 1975; Goldstein and Brown, 1977). 
Since cholesterol is water insoluble molecule, its dietary intake and 
distribution to various tissues and organs for utilization and storage is a complex 
process involving carrier proteins for cholesterol transport in plasma. The carrier 
proteins which fimction as transport vehicles for triacylglycerol (TAG) and 
cholesterol are called apolipoproteins. These apolipoproteins carry lipids in micelle 
like particles called lipoproteins. The lipoproteins consist of a non-polar core of 
TAG and cholesteryl esters (CE) surrounded by an amphipathic coating of protein, 
phospholipid and cholesterol. The association of the hydrophobic lipids circulating 
in plasma with proteins, was initially described by Macheboenf (1929). These 
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apolipoproteins are structurally heterogeneous and have entirely different 
metabolic fiinctions (Osborne and Brewer, 1977). Electron microscopic studies 
indicate that the association of lipids with apolipoproteins occur in the smooth 
endoplasmic reticulum after initial apolipoprotein synthesis in the rough 
endoplasmic reticulum (Hamilton et ai, 1972). 
Lipoproteins in plasma are classified on the basis of their electrophoretic 
mobility and hydrated density. Five major classes of lipoproteins have been 
identified. These are (a) chylomicrons, (b) very low density lipoproteins (VLDL), 
(c) intermediate density lipoproteins (IDL), (d) low density lipoproteins (LDL) and 
(e) high density lipoproteins (HDL) (Gofinan et al, 1954). Lipoprotein particles 
undergo continuous processing and recycling so that they have somewhat variable 
properties and compositions (Brown and Goldstein, 1987). Each contains a 
monolayer at the surface, about 2 nm thick containing protein and polar lipids 
(Brown and Goldstein, 1984). The density decreases widi the increasing diameter. 
The protein components of lipoproteins are called apolipoprotiens or simply 
apoproteins. Fourteen major human plasma apoproteins have been identified 
(Brewer et ai, 1988). The principal sites of mammalian plasma lipoprotein 
biosynthesis are the liver (Stein and Stein, 1979) and intestine (Jones and Ockener, 
1971). VLDL and HDL are the primary lipoproteins secreted by the liver, while 
chylomicron is the major lipoprotein of the intestinal origin. Both VLDL and HDL 
may also be produced by the intestine (Wu and Windmueller, 1978). Chylomicrons, 
which transport exogenous TAG and cholesterol fi-om the intestine to the tissues, 
are packaged in the golgj apparatus and secreted through exocytosis into the 
intracellular space at the base of the cell (Shaefer et al, 1978). They, Aen, enter 
lacteals via the endothelial cells fi-om loose junctions and are transported into the 
blood through the thoracic duct. Chylomicrons adhere to the binding sites on the 
endothehum of skeletal muscles and adipose tissue. There most of the TAG is 
hydrolyzed by lipoprotein lipase (Chajek and Eisenberg, 1978), an extracellular 
enzyme which is activated by apoC-Il, present in chylomicrons. The resulting 
monoacylglycerols as well as excess surface components are removed from the 
chylomicron (Eisenberg and Levy, 1975) leaving cholesterol ester rich, TAG poor 
chylomicron remnants, bind to remnant receptor in the liver and internalized by 
endocytosis (Sherrill and Dietschy, 1978). Thus chylomicrons deliver dietary TAG 
to muscle and adipose tissue and dietary cholesterol to the liver (Figure II). 
VLDL is secreted from the liver in much the same way as the chylomicrons 
by the intestine (Glauman et al, 1975). ApoC-11 and apoE are released from HDL 
and reassociate with the hepatogenous TAG rich VLDL secreted by the liver. 
ApoC-U activates Upoprotein lipase, resulting in increased catalysis of TAG 
(Nilsson-Ehle et al, 1980), and VLDL are serially converted to VLDL remnants 
(M Jos et al, 1975), IDL and finally LDL. ApoE and hepatic lipase, a second 
lipolytic enzyme, are required for the efficient conversion of IDL to LDL (Brewer, 
1995). Ehiring the conversion of VLDL into LDL, nearly half of the VLDL 
remnants and IDL are taken up by the liver from the plasma. LDL the final product 
of VLDL metabolism interact with LDL receptor present on the surface of liver, 
adrenals and peripheral cells including fibroblasts and smooth muscle cells 
(Goldstein and Brown, 1979; Yamamoto et al, 1984; Sudhof et al, 1985; 
Goldstein and Brown, 1985). LDL serve the cholesterol supply for metabolic needs 
of the cells, accomplished by the receptor mediated endocytosis of LDL particles 
(Brown and Goldstein, 1979; Brown and Goldstein, 1983) which undergo rapid 
hydrolysis yielding free cholesterol for cellular needs (Figure 11). It has been 
su^ested that at least two third of LDL cleared from plasma each day is taken out 
of the circulation by the liver and 80-90% of this is via LDL receptor (Belheimer 
et al, 1984). The number of receptors displayed on the surface of the cells varies 
with the cellular demand for cholesterol. High intracellular levels of cholesterol 
suppress synthesis of LDL receptor, decreasing the rate of LDL endocytosis. 
Evidence from VLDL turnover studies show that only a portion of plasma VLDL 
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becomes LDL (Kesaniemi et al, 1982), indicating that LDL arise not only from 
VLDL but also from direct secretion of LDL into circulation (Goldberg et al, 1983) 
(Figure II). 
LDL receptors play an important role in the maintenance of plasma 
cholesterol levels since it removes both IDL and LDL from the plasma. The 
remaining IDL is converted to LDL. The serum concentration of LDL thus depends 
on the rate of removal of IDL which in turn depends on the number of ftmctional 
LDL receptors present on the liver cell surface. 
The major role of HDL in hpoprotein metabolism is to transport cholesterol 
from peripheral tissues back to the hver, where it is converted to bile acids or 
secreted as biliary cholesterol. This process is termed as "reverse cholesterol 
transport" (Glomset et al, 1966; Glomset, 1968). Nascent HDL, secreted from 
liver, acquire excess cholesterol from the tissues, and the enzyme lecithin 
cholesterol acyltransferase (LCAT) converts it to CE. With the formation of CE, 
nascent HDL are converted to HDL3. HDL3 are then converted to HDL2 by 
acquiring lipids and apoproteins released during the metabolism of chylomicrons 
and VLDL as well as by esterification of cholesterol removed from the peripheral 
tissues. HDL2 is converted back to nascent HDL via HDL3 in the liver (Glomset 
et al, 1966; Glomset, 1968; Brewer et al, 1988). HDL also delivers CE to VLDL-
IDL-LDL by the cholesteiyl ester transfer protein (CETP) with ultimate transfer of 
cholesterol to the liver by apoB-containing proteins (Tall, 1993). The whole process 
of "reverse cholesterol transport" can be summarized as in Figure ID. 
Although cholesterol is essential to life, yet its deposition in arteries has 
been associated with heart disease and atherosclerosis, leading causes of death in 
humans. Under normal conditions, an intricate balance is maintained between the 
biosynthesis, utilization and transport of cholesterol, keeping its harmfril effects to a 
minimum. In the liver, the major site for cholesterol metabolism, the following 
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processes are supposed to govern the cholesterol balance: 
Decrease is due to (i) efflux of cholesterol from the membrane to cholesterol 
deficient lipoproteins, particularly HDL3 and nascent HDL mediated by LCAT, (ii) 
utilization of cholesterol for synthesis of other steroids and bile acids and (iii) 
esterification by acyl coenzyme A cholesterol: acyltransferase (ACAT; EC 
2.3.1.26). On the other hand, the increase is attributed to (i) uptake of cholesterol-
containing lipoproteins by receptor mediated endocytosis, (ii) uptake of cholesterol-
containing lipoproteins directly, without involving the receptor, (iii) uptake of free 
cholesterol from the cholesterol rich lipoproteins by the cell membrane, 
(iv) cholesterol synthesis and (v) hydrolysis of CE by cholesteryl ester hydrolase 
(CEH; EC 1.1.1.13). The higher level of free cholesterol inhibits its own synthesis 
by inhibiting the enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMG-CoA reductase; EC 1.1.1.34) and also results in the down regulation of LDL 
receptor. Although the cellular pools of esterified cholesterol can change markedly, 
the level of free cholesterol is kept under tight control due to its cytotoxic effects. 
The hepatic free cholesterol levels are thus regulated by the combined activities of 
HMG CoA reductase, which catalyses the conversion of HMG-CoA into mevalonic 
acid, cholesterol 7a-hydroxylase (C7aH; EC 1.14.13.17), the rate limiting enzyme 
in the biosynthetic pathway of bile acids, ACAT, catalyzing the esterification of 
cholesterol and CEH, responsible for the hydrolysis of CE (Figure FV). 
In general, the activities of regulatory enzymes are controlled by (i) short-
and (ii) long-term regulation, (i) The short-term regulation involves mainly 
reversible modification of tiie enzyme without changing tiie actual population of the 
enzyme. This is usually achieved by phosphorylation and dephosphorylation. The 
enzyme is active in either phosphorylated or dephosphorylated state and inactive in 
the other state. Phosphorylation occurs generally on the side chain hydroxyl group 
of serine and less frequently on threonine and tyrosine. Most of the regulatory 
enzymes have specific protein kinase to catalyze the phosphorylation. Besides this. 
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several classes of kinases and phosphatases have a broader range of specificity and 
bring about the phosphorylation and dephosphorylation of several proteins and 
enzymes. These kinases are divided into following major classes; cANfP-dependent 
protein kinases (PKA), cGMP-dependent protein kinases, Ca^^-activated and 
phospholipid dependent kinases (PKC), Ca^^-cahnodulin-dependent kinases, 
double-stranded RNA-dependent kinases and modulator independent kinases. 
Similarly phosphoprotein phosphatases are classified as; modulator independent 
(type I and 2A), Ca^ -^dependent (type 2B) and Mg '^^ -dependent (type 2C), which 
are all serine/threonine phosphatases. Apart fi-om this some tyrosine phosphatases 
are also known, (ii) The long-term regulation involves the change in the en2yme 
protein mass. This is achieved by (a) transcriptional regulation; by alterations in the 
rate of mRNA synthesis, (b) post-transcriptional regulation; by changing the rate of 
degradation of mRNA and (c) post-translational regulation; by alteration in the rate 
of degradation of enzyme. In addition, sometimes the activity of tiie enzyme is also 
regulated by allosteric modification, product inhibition, feedback modulation and 
several other mechanisms. 
Considering the vital role of these enzymes in the overall maintenance of 
cholesterol homeostasis in the body, the following information is available on their 
isolation, characterization and in vitro and in vivo regulation of enzyme activities 
including the regulation of gene expression. 
1.1. 3-Hydroxy-3-iiiethylglutaryl coenzyme A reductase 
Several steps in cholesterol biosynthetic pathway are subject to feedback 
regulation. The primary feedback loop appears to be at the step where HMG-CoA is 
converted to mevalonate. Modulation of the mevalonate synthesis step is of major 
importance in cellular metabolism since mevalonate serves as a precursor for 
several separate matabohc pathways including the formation of haem A, 
famesylated proteins (e.g. ras, lamin B etc.), dohchols, isopentenyl tRNA, 
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cholesterol, etc. (Figure I). This conversion is catalyzed by HMG-CoA reductase 
which, therefore, being the rate limiting enzyme regulates not only the synthesis of 
cholesterol but also other polyisoprenoid compounds at post-mevalonate level 
(Rodwell ei ai, 1976; Goldstein and Brown, 1977; Brown and Goldstein, 1980; 
Ingebritson and Gibson, 1980; Beg et ai, 1981; Beg and Brewer, 1982; Luskey, 
1988). In mammalian cells, HMG-CoA reductase is a transmembrane glycoprotein 
with its active site facing the cytosol and a carbohydrate containing site oriented 
toward the luminal surface of the endoplasmic reticulum (Liscum et ai, 1983a; 
Brown and Simoni, 1984). HMG-CoA reductase is an approximately 100 kDa 
protein (Chin et ai, 1982; Edwards et ai, 1983a; Hardeman et ai, 1983; Chin 
et ai, 1984; Beg et ai, 1985). Proteolysis of the native protein results in a 53 kDa 
molecular weight fragment that contains the active site of the enzyme (Chin et ai, 
1982; Edwards et ai, 1983a; Hardeman et ai, 1983; Liscum et ai, 1983a; Chin 
et ai, 1984; Beg et ai, 1985). HMG-CoA reductase is a protein of 887 amino acids 
containing three potential sites for aspargine-linked glycosylation. The N-tenninal 
half of the peptide is anchored to the membrane and contains seven hydrophobic 
regions, each of which is comprised of 20 amino acids and spans the microsomal 
membrane (Chin et ai, 1984). The N-terminal lacks the signal sequence and the 
hydrophilic C-terminal half of HMG-CoA reductase contains the catalytic site of 
the enzyme (Chin et ai, 1984). Since, the catalytically active hydrophilic tail of the 
enzyme extends into the cytoplasm, it is more accessible to the action of modulators 
and permits the observed multifaceted regulation of HMG-CoA reductase and 
cholesterol synthesis. The complex homeostatic mechanism by which the enzyme 
activity of HMG-CoA reductase and cholesterol biosynthesis are coordinately 
regulated in response to various physiological stimuli has been extensively studied. 
Isolation, purification, and characterization of rat hepatic HMG-CoA 
reductase has been well documented (Kawachy and Rudney, 1970; Heller and 
Gould, 1973; Brown et ai, 1973; Heller and Gould, 1974; HeUer and Shrewsburg, 
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1976; Kleinsek et ai, 1977; Srikantaiah et al., 1977; Edwards et al, 1979). HMG-
CoA reductase has also been studied in several odier species including chicken liver 
(Beg et al, 1978; Beg et al, 1979), human liver (Beg et al, 1982a; Beg et al, 
1982b) and human fibroblasts (Brown and Goldstein, 1983; Beg et al, 1986). 
Several different mechanisms for the regulation of enzymes in metabolic pathways 
have been elucidated such as modulation by isosteric and allosteric effectors, 
regulation of enzyme synthesis and degradation, feed-back control, and covalent 
modification (Siperstein, 1970; Holzer and Duntze, 1971; Segal, 1973; Carlson and 
Kim, 1973; Lee et al, 1976; Greengard, 1978). Three basic control mechanisms for 
HMG-CoA reductase have been reported, (a) Long-term regulation, which involves 
the modulation of HMG-CoA reductase activity by changes in enzyme 
concentration through the regulation at transcriptional level and post-transcriptional 
regulatory mechanisms such as mRNA and enzyme protein degradation (Kirsten 
and Watson, 1974; Jakoi and Quarfordt, 1974; Chan et al, 1981; Koizumi et al, 
1982; Faust et al, 1982; Sinensky and Logel, 1983; Edwards et al, 1983a; 
Edwards et al, 1983b; Liscum et al, 1983b; Clarke et al, 1983; Clarke et al, 
1984). For instance, the product feedback regulation by mavalonate (Kita et al, 
1980; Brown and Goldstein, 1980; Cohen et al, 1982), in vivo inhibition of HMG-
CoA reductase by cholesterol feeding (Arebalo et al, 1981), cholestyramine and 
mevinolin (Eisenberg and Levy, 1975), and mevalonolactone (Arebalo et al, 1980; 
Beg et al, 1984) has been reported. Tocotrienols, a naturally occurring class of 
compounds of vitamin E family, have also been reported to regulate HMG-CoA 
reductase activity at the post-transcriptional level (Pearce et al, 1992; Parker et al, 
1993). (b) Control of HMG-CoA reductase activity tiirough changes in the 
membrane composition and membrane fluidity in the microsomal environment in 
the immediate vicinity of the enzyme (Finkel and Volpe, 1979; Mitropoulous et al, 
1981; Siptal and Sabine, 1981; Richert et al, 1984). (c) Short-term regulation, that 
involves reversible covalent modification (phosphorylation and dephosphorylation) 
of HMG-CoA reductase (Ingebritson and Gibson, 1980; Beg et al, 1981; Beg and 
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Brewer, 1982; Kennelly and Rodwell, 1985). Three separate kinase systems for the 
regulation of HMG-CoA reductase involving short-term covalent modification have 
been demonstrated (Ingebritson and Gibson; 1980, Beg et al, 1987). Studies 
involving incubation of rat hepatocytes with insulin and glucagon or administration 
of glucagon to rats have been shown to modulate the bicyclic cascade system 
involving phosphorylation of both HMG-CoA reductase and HMG-CoA reductase 
kinase (Ingebritson and Gibson, 1980; Gibson, 1985; Beg et al, 1987; Gibson and 
Parker, 1987). 
XJL. Cholesterol 7a-liydroxylase 
C7aH, Ae hepatic microsomal cytochrome P-450 monooxygenase, catalyses 
the initial and rate determining step of the major pathway of bile acid biosynthesis 
(Shefer et al, 1970; Bostrom and Wikvall, 1982). The conversion of cholesterol 
into bile acids is a major pathway for the elimination of cholesterol from the body 
(Danielsson and Sjovall, 1975; Myant and Mitropoulous, 1977) and hence this 
enzyme plays an important role in cholesterol homeostasis. The C7aH enzyme has 
been purified and its gene has been cloned and its amino acid sequence has also 
been deduced. The enzyme is 503 amino acid protein with the molecular weight of 
about 66 kDa (Li et al, 1990). The purification of C7aH and cloning and 
sequencing of its cDNA have provided the tools to study this enzyme at molecular 
level (Jelinek et al, 1990; Li et al, 1990). In the rats and humans (Reihner et al, 
1989; Bertolotti et al, 1991), bile acid returning to the liver via the portal vein 
feedback, regulate their biosynthesis by suppressing C7aH activity (Shefer et al, 
1970; Bjorkhem, 1985; Heuman et al, 1988; Heuman et al, 1989). However, in the 
rat, this feedback loop only pertains to the hydrophobic bile acids, as hydrophilic 
bile acids do not affect C7aH activity (Heuman et al, 1988; Stravitz et al, 1993). 
The C7aH activity is decreased increasingly by bile acids of increasing 
hydrophobicity (cholic<chenodeoxycholic<deoxychohc) (Heuman et al, 1989). In 
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rat liver, C7aH has also been shown to be regulated at the level of gene expression 
by hydrophobic bile aids (Jelinek et al., 1990; Li et al, 1990; Pandak et o/., 1991; 
Stravitz et al, 1993; Twisk et al, 1993). More recent studies of C7aH gene have 
provided the evidence of bile acid responsive element (Hoekman et al, 1993; 
Chiang and Stroup, 1994) which appears to be responsible for this effect. 
Specific hormones have been reported to regulate C7aH activity in vivo 
(Story et al, 1974; Bjorkhem, 1985; Ness et al, 1990; Vlahcevic et al, 1991) in 
primary hepatocytes (Princen et al, 1989) and hepatoma cell lines (Leighton et al, 
1991). Like HMG-CoA reductase, the recognition of the role of hormones in the 
regulation of C7aH was that it also undergoes diurnal changes in rats with 
maximum specific activity at mid dark and minimum at mid light period of the 
diurnal cycle. The C7aH specific activity, mRNA and protein are increased 2-3 
fold during mid dark as compared to mid light (Chiang et al, 1990; Noshiro et al, 
1990). The phenomenon is attributed to &e action of glucocorticoids as 
adrenalectomy aboUshes this effect (Balasubramaniam et al, 1972; Pooler and 
Dnane, 1988). Thyroid hormone has also been reported to increase C7aH activity 
and mRNA level in vivo (Ness et al, 1990). Liver mRNA level of C7aH are also 
increased in response to cholestyramine, a bile acid sequestrant, or cholesterol 
(Jelinek et al, 1990; Li et al, 1990), whereas, the inhibition of cholesterol 
synthesis with the HMG-CoA reductase by lovastatin or Ay9944, inhibitors of last 
step in cholesterol synthesis, results in decrease of C7aH activity and hence, bile 
acid synthesis (Pandak et al, 1990a; Pandak et al, 1990b). These observations 
indicate that the alterations in cholesterol availability are coupled with parallel 
changes in the C7aH gene expression. During cholesterol or mevalonate overload, 
C7aH is up regulated, while in presence of decreased cholesterol supply, the 
enzyme is down-regulated. In either case, cholesterol homeostasis is effectively 
maintained. The short-term modulation of C7aH by ATP, Mg-ATP and divalent 
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metal ions has also been shown by some workers (Sanghvi et al, 1983; Sanghvi, 
1985) but contradicted by others (Berglund et al, 1986). Bile acids have also been 
reported to inhibit C7aH by increasing PKC activity (Stravitz et al, 1995). C7aH 
is also shown to be regulated by hormones, cytosolic factors (Kwok et al, 1981) 
and diurnal rhythm. 
U . Acyl coenzyme A cholesterol: acyltransferase 
ACAT is an intracellular, integral microsomal enzyme that uses cholesterol 
and fatty acyl Co A to form CE (Chang and Doolittle, 1983; Suckling and Stange, 
1985). The enzyme is highly regulated in various cell types and tissues, and is 
believed to play an important role in cholesterol metabolism in intestinal mucosa, 
hepatocytes, arterial wall and steroid producing tissues (Ross and Glomset, 1973; 
Chang and Doolittle, 1983; Suckling and Stange, 1985). The transformation of 
unesterified cholesterol which is potentially cytotoxic into inert CE, protect the cell 
and prevents deterioration of membrane. In afterosclerosis, ACAT activity is found 
to be increased markedly in the arterial wall. Upto 70 fold increase has been 
reported in experimental atherosclerosis in rabbit (Hashimoto et al, 1974, Brecher 
and Chan, 1980), indicating an important role of this enzyme in cholesterol balance 
in arterial endothelium in coordination with LCAT, neutral CEH and acid CEH 
(Ross and Glomset, 1973). ACAT has been studied quite extensively and its gene 
cloning has been reported in several tissues of many species (Becker et al, 1994; 
Chang et al, 1995; Uehnen et al, 1995; Yang et al, 1996; Cao et al, 1996) 
including mouse liver (Uelmen et al, 1995) and human liver (Becker et al, 1994). 
The prototype for the cellular role of ACAT has been the cultured fibroblast, 
the model on which the LDL receptor pathway was originally based (Brown and 
Goldstein, 1976). Several other tissues, as mentioned earlier, however, have a more 
important role to play in the balance of cholesterol in the body and they show a 
more complex pattern of cholesterol metabolism than fibroblast. Most of the 
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detailed studies of ACAT activity have used the enzyme from microsomal fraction 
of rat liver. In general, the results from studies of rat liver have been applicable to 
other tissues as far as the basic properties of ACAT are concerned, but a number of 
important differences also exist. In the liver, uptake of cholesterol leads to an 
increase in the amount of CE within the cell that is dependent on the activity of 
ACAT. The ester can be secreted by the liver in VLDL. Alternatively, free 
cholesterol may be directed towards bile acid syndesis by C7aH, another 
microsomal enzyme. It is well known that microsomal vesicles are heterogeneous 
population. Using sucrose density gradients to fractionate microsomal vesicles 
showed that ACAT activity was associated with rough endoplasmic reticulum. In 
contrast, HMG-CoA reductase and C7aH were bodi associated with smooth 
endoplasmic reticulum (Balasubramaniam et ai, 1978a). The active site of ACAT 
is located towards the cytosolic face of rough endoplasmic reticulum membrane. 
This has been inferred by using a combination of detergent and protease treatments 
(Hashimoto and Fogelman, 1980; Lichtenstein and Brecher, 1980), but whether this 
integral membrane protein spans the entire membrane could not be determined. It 
was also shown that the pools of substrate (i.e., cholesterol) for C7aH and ACAT 
exist separately in endoplasmic reticulum. Hence at the level of endoplasmic 
reticulum in liver, cholesterol can be directed towards bile and bile acid synthesis 
or towards secretion as CE in VLDL (Hashimoto and Fogelman, 1980; Lichtenstein 
and Brecher, 1980). It was thus suggested that the CE synthesized in rough 
endoplasmic reticulum was fimctionally transferred to smooth endoplasmic 
reticulum which acted as a trap for the esters. 
The sterol side chain was found to be important in the interaction between 
the enzyme and the substrate. A sterol of the molecular length of cholesterol proved 
to be optimal (Tawani et al, 1982). The amount of CE formed in the assays could 
be increased by the addition of cholesterol from a detergent, organic solvent or 
liposome vehicle (Balasubramaniam et al, 1978b; Erickson et al., 1980; Stange 
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et al, 1983). The observation indicates that the microsomal pool of cholesterol does 
not saturate the enzyme. Further experiments showed that the enhancement of 
measured activity by cholesterol is not only due to the increase in the supply of 
substrate but cholesterol also acted as a non-substrate modulator of ACAT 
(Hashimoto et al, 1983). The relative increase induced in the ACAT activity by 
cholesterol can be modified by treating the animal subjects with different diets, rich 
or deficient in cholesterol (Stange et al, 1983). From this evidence, it appears that 
one possible in vivo mechanism of enzyme regulation is altering the availability of 
fi-ee cholesterol as substrate leading to a reciprocal variation of the in vitro effect of 
exogenous cholesterol. 25-hydroxycholesterol activated ACAT in vitro (Erickson 
et al, 1980; Leichtenstein and Brecher, 1983; Field and Mathur, 1983). Other 
hydroxysterols, however, found to be inhibitory to ACAT (Erickson et al, 1980). 
Mevalonic acid (MVA) was also shown to activate ACAT in vivo (Drevon et al, 
1980). The effect of 25-hydroxycholesterol and MVA on ACAT were additive, 
si^esting that they act through different mechanisms. These two treatments caused 
an inhibition of HMG-CoA reductase, but the characteristics of inhibition are 
different fi-om those of complementary activation of ACAT (Drevon et al, 1980). 
LDL is known to cause the activation of ACAT in intact CHO cells, which is 
abolished in reconstituted enzyme (DooHttle and Chang, 1982). This is consistent 
with the idea that the effect of LDL cholesterol on ACAT activity requires the 
whole LDL receptor pathway for the internalization and utilization of the 
hpoproteins. 
The activity of ACAT displays a diurnal rhythm in the adrenal gland, with a 
minimum at the onset of darkness coinciding with the peak of diurnal rhythm of 
corticosterone concentration (Beins et al, 1982). The rhythm was mirror image to 
that of HMG-CoA reductase. Acute administration of corticotropin led to about 
50% decrease in ACAT activity. These observations indicate that corticotropin 
plays an important role in generating the diurnal rhythm of ACAT. Erickson et al 
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(1980) have shown that there is no correlation between AC AT and HMG-CoA 
reductase activities in rat liver, as could be thought, as botii of tiiese enzymes are 
microsomal and play an important role in cholesterol balance. No correlation could 
be made between these activities in rat liver microsomes prepared from animals 
subjected to wide range of treatments. These experiments support the notion that 
ACAT activity is limited by supply of cholesterol and is also reflected in tiie 
amount of CE found in the liver, especially in the microsomal fraction. The rate of 
biliary cholesterol secretion correlated inversely with the microsomal level of CE 
and the ACAT activities (Del Pozo et al, 1983). The activity of ACAT has been 
shown to increase in vitro by cAMP in rat liver microsomes (Basheeniddin et al., 
1982; Gavey et al., 1983), whereas, contradictory reports have been presented by 
another group (Suckling et al., 1983a). 
ACAT is found to be very sensitive to the environment. Several studies 
aimed at defining the optimal conditions for the assay of activity have shown that 
ACAT is readily inhibited by detergents such as Triton and organic solvents like 
acetone and ethanol (Balasubramaniam et al., 1978b; Spector et al., 1979; Suckling 
et al., 1983b). In contrast to pancreatic esterase, ACAT is inhibited by taurocholate 
(Norum et al., 1981). This effect also appears to be due to detergent effect of the 
bile acid rather than a more specific interaction. 
1.4. Cholesteryl ester hydrolase 
CEH, the principal enzyme responsible for the hydrolysis of endogenous CE 
to free cholesterol, has been documented in many tissues and cell types using a 
wide range of m vitro and in vivo conditions. 
1.4.1. CEH in non-hepatic tissues 
Pittman et al. (1975) have reported the presence in rat adipose tissue of high 
levels of a CEH activity that shared many of the properties of hormone-sensitive 
18 
lipase. It was suggested that a single enzyme is responsible for the hydrolysis of 
both CE and TAG. The enzyme has been purified from rat adipose tissue to a state 
approaching homogeniety and many of its molecular and catalytic properties have 
been investigated (Fredrikson et al, 1981a; Fredrikson et ai, 1981b). The enzyme 
is known to be activated by phosphorylation, mediated by cAMP-dependent protein 
kinase (Belfrage et al., 1977; Fredrikson et al., 1981a). 
Adrenal cortex contain large amounts of cholesterol esterified to long chain 
fatty acids (Goodman, 1965). The CE are localized mainly in cytoplasmic droplets 
where they appear to function as a reservoir for the cholesterol required for steroid 
biosynthesis. CEH catalyses one of tiie rate-limiting steps in steroidogenesis in the 
adrenal cortex (Boyd and Gorban, 1980). Following the stress induced, which is 
known to elevate the circulating levels of corticotropin, the activity of the CEH is 
elevated (Trzeciak and Boyd, 1973). It is suggested that the increase in the CEH 
activity is the result of the phosphorylation of the enzyme as CEH in adrenal cortex 
has been shown to be activated following incubation with cAMP and Mg-ATP 
(Trzeciak and Boyd, 1974; Wallat and Kunau, 1976; Beckett and Boyd, 1977; 
Naghsineh et al, 1978). The existence of two molecular forms of cholesteryl 
esterase in bovine (Eto and Suzuki, 1972; Wallat and Kunau, 1976) and rat adrenals 
(Pittman and Steinberg, 1977) has been reported but not generally recognized 
(Beckett and Boyd, 1977; Naghsineh et al., 1978; Yeaman et al., 1980; Cook et al., 
1981). 
CEH activity has been shown to have the properties of regulatory enzyme in 
testis (Rommers et al., 1980; Durham and Grogan, 1982; Durham and Grogan, 
1984). Three CEH activities have been reported in testis (Durham and Grogan, 
1982; Durham and Grogan, 1984). These enzymes are imphcated in regulation of 
androgen synthesis and membrane cholesterol levels necessary for normal 
spermatogenesis (Rommers et al., 1980; Durham and Grogan, 1982; Durham and 
Grogan, 1984).Two of these CEH enzymes (Mr 72 kDa and 420 kDa) are found to 
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be temperature-labile and are completely inactivated by elevation of temperature 
from 32T to 37°C (Durham and Grogan, 1982). The temperature stable form has 
Mr 28 kDa and retains activity at 3TC. Both, temperature-labile and temperature-
stable enzymes, are regulated by a cAMP-dependent protein kinase activity (Bailey 
and Grogan, 1986). 
In corpus luteum, a constant supply of cholesterol to the mitochondrial 
cholesterol side chain cleavage enzyme system is essential for steroidogenesis 
(Schuler et ai, 1979). The major source is CE hydrolysis by intracellular CEH. The 
cytosolic enzyme is well characterized in rat corpus luteum (Behrman and 
Armstrong, 1969; Flint and Armstrong, 1973). Besides, considerable CEH activity 
has been reported in tiie microsomal fraction (Coutts and Stansfield, 1968), which 
accounts for about 30% of rat luteal CEH activity (Leaver and Boyd, 1981). The 
cytosolic CEH is known to be activated by hormones acting through cAMP 
(Bisgaiere/a/., 1979). 
In the mammary gland, approximately 20-40% of milk cholesterol originates 
from de novo synthesis within the mammary gland, while the remaining 60-80% is 
derived from plasma lipoproteins (Clarenburg and Chaikofif, 1966; Raphael et ai, 
1975; Gibbons et ai, 1983). Cholesterol from both, de novo synthesis and that 
derived from plasma lipoproteins, may be esterified and stored in the mammary 
gland as CE (Keenan and Patten, 1970; Ross and Rowe, 1984), which may in turn 
be hydrolyzed to unsterified cholesterol when required, with the help of CE 
hydrolases located in the microsomal and soluble cell fractions (Steinberg, 1976; 
Fernandez et ai, 1987). Activities of the mammary gland acid, microsomal and 
cytosolic neutral CEH enzymes are found to be greatly increased during lactation 
(Botham, 1991). Studies of microsomal and cytosolic enzymes provide evidence for 
the modulation of their activity by phosphorylation-dephosphoiylation (Martinez 
and Botham, 1990) suggesting that these enzymes are under hormonal control and 
have a regulating role in mammary gland cholesterol metabolism. 
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Pancreatic CEH, also known as bile salt-stimulated lipase, carboxyl ester 
lipase or non-specific lipase, is also capable of hydrolyzing otiier substrates such as 
phospholipids, lysophospholipids, retinyl esters and mono-, di- and tri-acylgly-
cerols (Rudel and Brockman, 1984) apart fi^om catalyzing the hydrolysis of CE. 
Some studies have shown that a serine residue and a histidine residue play a key 
role in the hydrolytic mechanism (Kissel et al, 1989; Di Persio et al, 1991). The 
enzyme, syntiiesized primarily in the acinar cell of the pancreas and stored in 
zymogen granules, is secreted into the lumen of the intestine via the pancreatic duct 
(Guy and Figarella, 1981) in response to a dietary fat load. The pancreatic CEH is 
also found attached to the surface of intestinal mucosa and has been suggested to 
play a role in the re-esterification of cholesterol before secretion into tihe lymph 
(Gallo et al., 1977). Immunological comparison of the CEH has demonstrated the 
identity of the pancreatic CEH with the enzyme found in the intestine, thus 
supporting the concept that this protein may be involved in both the hydrolysis and 
re-esterification of dietary CE for absorption and transport. Pancreatic CEH 
stimulate not only the rate of re-esterification but also the extent of cholesterol 
uptake (Chobanian and Manzur, 1972). In contrast, uptake in tibe absence of 
exogenous enzyme leads to the little subsequent metabolism. These findings 
suggest an important role for pancreatic CEH in fat digestion, absorption and 
regulation of fi-ee cholesterol transport into the plasma. The pancreatic CEH 
protein has been purified fi^om different species and is found to be a single 
polypeptide with different extents of glycosylation which leads to the difference in 
molecular weights. In all the species tested, molecular weights ranging fi-om 69 kDa 
for the rat enzyme to 76 kDa for the human protein were obtained (Kissel et al, 
1989). cDNA cloning of rat pancreatic CEH (Kissel et al, 1989) and human 
pancreatic CEH (Nilsson et al, 1990) has also been reported. As most of the 
pancreatic digestive enzymes are regulated by the composition of the diet and 
gastric hormones, synthesized in the gut (Wicker et al, 1984; Wicker et al, 1985; 
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Steinhilber et al, 1985; Scheele, 1986; Rothman, 1989), the effect of gastric 
honnones, such as cholecystokinm and secretin, on the biosynthesis of pancreatic 
CEH has been shown to increase CEH biosynthesis. This stimulation was mediated 
by a post-transcriptional modification of CEH mRNA (Huang and Hui, 1991). 
Ghosh and Grogan (1991a) have shown that the pancreatic CEH is not activated by 
the addition of the cofactors for either PKA or PKC, indicating this enzyme is not 
modulated by reversible phosphorylation. 
Arterial cells have been found to accimiulate CE under certain pathological 
conditions e.g., the accumulation of CE in the arterial wall is consistent feature of 
atherosclerotic lesions (Dayton and Hashimoto, 1968; St. Clair et al, 1970; 
Chobanian and Manzur, 1972; Proudlock and Day, 1972; Hashimoto et al, 1973). 
Both neutral and acid CEH activities have been reported in arterial tissue and in 
cultured arterial smooth muscle cells (Sakurada et al, 1976; Brecher et al, 1977; 
Riddle et al, 1977; Severson and Fletcher, 1978; Kritchevsky and Kothari, 1978; 
Shinomiya et al, 1979; Subbiah, 1979). There are contradictions regarding tiie 
properties of arterial neutral CEH like pH optimum ranging fi-om 6.6 to 8.6 and 
presence of the enzyme in particulate and soluble fraction has been reported 
(Sakurada et al, 1976; Brecher et al, 1977; Riddle et al, 1977; Severson and 
Fletcher, 1978; Kritchevsky and Kothari, 1978; Shinomiya et al, 1979; Subbiah, 
1979). Hajjar et al (1983), have shown that the acid and neutral CEH enzymes 
have different preference for forms of substrate dispersion, sensitivity to heat and 
storage, and influence by honnones effectors. The activation of neutral CEH 
involving cAMP-dependent protein kinase has also been reported (Hajjar et al, 
1983) and it has been suggested that the breakdown of cytosolic Upid droplets 
might be affected by glucagon or other hormones or by agents that enhance 
intracellular protein phosphorylation in a similar way as of hormone sensitive 
lipase. In experimental atherosclerotic rabbits, an increase of 70 fold in AC AT 
activity has been reported (Hashimoto et al, 1974; Brecher and Chan, 1980), 
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indicating that the regulation of arterial neutral CEH could be a detennining factor 
in the regulation of cholesterol/CE cycle. 
In the macrophage, cytosolic CEH activity plays an important role in the 
cholesterol/CE cycle. The formation of macrophage derived foam cells is central in 
the development of fatty streaks within the arterial wall, and to the progression of 
atherosclerosis (Gerrity, 1981; Raines and Ross, 1989; Faggioto et al., 1994). The 
unregulated deposition of CE , as lipid droplets within the cytosol of macrophage is 
responsible for the formation of these cells. The process, under normal condition, is 
thought to be regulated by the proper balance between the esterification by ACAT 
and hydrolysis by CEH (Graham et al, 19%). Aviram et al. (1991) have shown 
that treatment of LDL by CEH results in altered LDL uptake by macrophage. 
Uptake by scavenger receptor was abolished and was mediated only via the LDL 
receptor pathway, leading to an overall reduced LDL uptake. The CEH 
modification of LDL may take place in vivo and may have a role in suppression of 
foam cell formation. Furthermore, it has been shown tiiat removal of stored 
cholesterol by HDL, requires the activation of CEH (Khoo et al, 1981). Regulation 
of CEH activity, either by stimulation by cAMP (Small and Engle, 1977; Khoo 
et al, 1981; Goldberg and Khoo, 1990; Bernard et al, 1991) or by cytosohc 
inhibitory activity, found in some macrophage cell lines (Shand et al, 1993), 
appears central to the removal of stored cholesterol fi^om macrophages. 
Modification of LDL resulting in its reduced iq)take, as suggested, may also be an 
additive factor in the arterial lipid laden foam cells. 
The physiological importance of CEH in brain is due to the fact that it is 
involved in the synthesis and maintenance of myelin (Eto and Suzuki, 1973 a; 
Ghosh and Grogan, 1991a). Atleast three distinct CEH enzymes have been 
identified in rat brain. One of these CEH enzymes is not only associated with 
myelin but also appears to correlate with myelination. Activity of this enzyme is 
decreased in Quaking mice and Jimpy mice, which have primary defects in myelin 
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synthesis (Eto and Suzuki, 1973a; Eto and Suzuki, 1973b). Unesterified cholesterol 
is a major constituent of myelin membrane in adult mammalian brain (Norton, 
1977). CE, which are in very low concentration in normal brain, accumulate in 
demyelinating disorders such as multiple sclerosis (Wender et al, 191 A), Wallerian 
degeneration (Mezei, 1970) and experimental allergic encephalomyeUtis (Maggio 
et al, 1972; Roth et al, 1978). Reports from several laboratories have suggested 
that CE accumulation in demyelinating disorders may be due to a decrease in CEH 
activity (Mezei, 1970; Eto and Suzuki, 1973b; Shah and Johnson, 1980). Several 
investigators have reported decreased CEH activity in cerebrospinal fluid of 
multiple sclerosis patients and su^ested that, this decrease reflects a similar change 
in brain tissue (Reiber and Vass, 1980; Johnson and Shah, 1981; Piticanen et al, 
1986). Shah and Johnson (1980), reported greatly decreased CEH and slightly 
decreased ACAT in plaques and periplaque areas from brain of multiple sclerosis 
patients. CEH also decreases in the sciatic nerve during Wallerian degeneration 
(Mezei, 1970) and in the initial stage of experimental allergic encephalomyeUtis 
(Ghosh and Grogan, 1991b). However, the mechamsm(s) by which significant 
decline in CEH activity in above mentioned demyelinating disorders occurs are not 
well known. 
Lysosomal acid CEH is crucial for tiie hydrolysis of CE in eidier lipoprotein 
or other particles that enter flie lysosomal system by endocytotic process. The 
cholesterol liberated by the hydrolytic activity has an important role in cellular 
sterol metabohsm (Goldstein and Brown, 1977). Lysosomal acid CEH has been 
purified to homogeneity from the livers of rats (Brown and Sgoutas, 1980) humans 
(Warner et al, 1981) and rabbits (Imanaka et al, 1982) and is well characterized. 
The enzyme is a hydrophobic glycoprotein which also possesses activity against 
TAG (Warner et al, 1981; Klemets and Lundburg, 1984). A defect of acid CEH 
results in various inborn disorders of metabolism, which are characterized by lipid 
accumulation in several organs, such as Wolman's disease (Klemets and Lundburg, 
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1984) and CE storage disease (Sloan and Fredrikson, 1972). Both of these 
autosomal recessive conditions are characterized by severely depressed acid CEH 
activity, intralysosomal lipid accumulation, and derangement in the regulation of 
cholesterol production. cDNA (Anduson and Sando, 1991) as well as genomic 
DNA cloning (Anduson ei ai, 1994) for human lysosomal acid CEH have been 
done and it was found that mutations in both alleles of tiie gene from a patient with 
Wolman's disease results in the complete disruption of catalytic function of the 
enzyme. Lysosomal acid CEH has also been recognized as an important factor in 
the accumulation of CE in atherosclerotic arteries (Goldstein et ai, 1975; Subbiah 
and Dicke, 1976; Small and Engle, 1977). De Duve (1974), has proposed that the 
accumulation of CE in atherosclerosis is due to a relative deficiency in a lysosomal 
CEH, resulting in an inability of the smoodi muscle cell to metabolize the increased 
influx of Upoprotein-associated CE. However, some investigators have found 
increased acid CEH activity in atherosclerotic lesions in several species including 
humans (Miller et ai, 1966; Bonner et ai, 1972; Kwak et ai, 1973; Brecher et ai, 
1977). Although die importance of acid CEH in Upoprotein metabolism and in the 
determination of the cell cholesterol levels has been recognized, very little is 
known about the enzymes catalytic mechanism or regulation (Balasubramaniam 
et ai, 1977; Hajjar et ai, 1983; Loffler and Kunze, 1992). 
1.4.2. CEHinlwer 
Liver, the major site of hydrolysis of long chain fatty-acyl esters of 
cholesterol in the rat is supposed to have atleast three distinct CE hydrolases, with 
specific function and different subcellular location. Among these three enzymes, 
the best characterized is the lysosomal acid CEH which hydrolyses the CE 
internalized with the lipoprotein particles. The CE stored in cytosol and smooth 
endoplasmic reticulum are mobilized by cytosohc and microsomal CE hydrolases, 
respectively (Deykin and Goodman, 1962; Stokke, 1970; Nilsson, 1976; Cook 
et ai, 1983; Fernandez et ai, 1987). 
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The existence of microsomal CEH remained controversial for a long time 
and thus fewer studies have been done on the function and regulation of this 
enzyme. It is suggested to be involved in preventing the accumulation of CE in the 
smooth endoplasmic reticulum membrane and controlling tiie fate of cell CE 
between the biliary and VLDL secretory pathways (Hernandez ei al, 1993). Rat 
liver microsomal CEH has been partially solubilized (Gandarias et al, 1987). 75% 
of its activity has been found to be on the luminal side of rough endoplasmic 
reticulum (Fernandez et al, 1987). This activity is different from the cytosolic CEH 
activity (Coleman and Haynes, 1983) and from neutral retinyl ester hydrolase, also 
located in the microsomes (Gad and Harrison, 1991). The microsomal CEH has 
been shown to exhibit diurnal rhythm (Martinez et al, 1991) like other enzymes 
involved in cholesterol homeostasis. The activity showed a plateau around mid dark 
while the lowest activity was observed around mid light period. Under changed 
dietary condition, such as during fasting, however, the microsomal CEH diumal 
pattern did not alter as significantly as it did in the case of cytoslic CEH. 
The microsomal enzyme has higji homology with cytosloic CEH as revealed 
by the studies on cDNA (Robb et al, 1990). Microsomal and cytosolic CEH cDNA 
differ only in 14 nucleotides out of which only 3 lie in the coding region and none 
occur in the catalytic loop structure (Ghosh et al, 1995). Inspite of high sequence 
homology, the two enzymes show differences in (i) pH optima which is 6.1 for 
microsomal and 7.2 for cytosolic CEH (Robb et al, 1990), (ii) substrate 
specificities with microsomal enzyme showing more affinity towards short chain 
fatty-acyl ester while the reverse is true for cytosolic CEH, (iii) differential effect of 
divalent cations and (iv) diumal rhythm and change in the rhythm under differential 
dietary status. 
Indirect evidence for the activation of the microsomal CEH by cAMP and 
Ca -calmodulin dependent mechanisms has been reported (Hernandez et ah, 1993; 
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Hoang et al., 1993; Martinez et al., 1994; Martinez et al., 1995) This indicates that 
the microsomal CEH is activated by phosphorylation involving PKA and Ca^ -^
cahnodulin dependent kinases, whereas, deactivation (dephosphoiylation) is 
mediated by phosphoprotein phosphatase (Martinez et al., 1994). On the other 
hand, Botham et al. (1996) have reported activation of the microsomal CEH 
activity by cAMP analogues , 8-chloro cAMP and 8-(4-chIorophenyl thiol) cAMP, 
in hamster hepatocytes, whereas, no effect could be detected on the CEH activity in 
rat hepatocytes. 
Although rat liver has acid lysosomal and microsomal CEH activities, the 
major regulated activity is associated with a unique cytosoUc CEH (Gallo, 1981; 
Ghosh and Grogan, 1989; Ghosh et al., 1990; Ghosh and Grogan, 1991a; Grogan 
et al., 1991). This enzyme is appropriately located, rationally regulated and able to 
rapidly mobilize cholesterol when required (Klauda et al., 1978; Ghosh and 
Grogan, 1989; Ghosh et al, 1990; Ghosh and Grogan, 1991a; Grogan et al, 1991; 
Ghosh et al, 1995). Ghosh and Grogan (1991a) have purified a cytosolic CEH and 
have performed several studies. The purified enzyme catalyzes the hydrolysis of 
cholesteryl oleate (CO), cholesteryl linoleate and triolein at similar rates over a 
broad range of concentrations (Natarajan et al, 1996a). Cytosolic CEH (Natarajan 
et al, 1996a), like microsomal CEH (Morgan et al, 1994), was inhibited by PMSF 
which inhibits serine esterases (Shefer et al, 1970; Hyun et al, 1972), consistent 
with the identification of consensus serine esterase active site (Gavey et al, 1983). 
Of the sulfhydryl specific reagents, only mercuric benzoate inhibited the enzyme 
while N-ethyl maleimide and iodoacetamide did not. This indicates that the 
inhibition by Hg^ "^  probably reflects the general effect of divalent cations as found 
in the case of Cu^^ , Zn^ ^ and Cd^ ^ (Natarajan et al, 1996a). Limited trypsin 
digestion selectively inhibited cholesteryl esterase activity with retention of activity 
towards p-nitrophenyl caprylate, suggesting the involvement of a trypsin labile loop 
in the substrate binding site. Analysis of secondary structure for CEH predicts a 
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loop between cys 87 and cys 116 containing a highly exposed, trypsin cleavage site 
at arg 104, which confers substrate specificity. 
Several lines of research have demonstrated tiiat cytosolic CEH can be 
activated by a cAMP-dependent kinase-mediated phosphorylation in steroidogenic 
and other non-hepatic tissues (Pittman et al., 1975; Small and Engle, 1977; Bisgaier 
et al., 1979; Khoo et al., 1981; Hajjar et al., 1982; Boyd et al., 1983; Bailey and 
Grogan, 1986; Colbran et al., 1986) but tiie regulation of the liver cytosolic CEH 
by reversible phosphorylation remains controversial. Evidence for activation by 
phosphorylation of cytosolic CEH activity by cAMP and Ca^ -^mediated processes 
have been presented in vitro in cell-free rat liver preparations (Ghosh and Grogan, 
1989; Natarajan et al., 1996b; Natarajan et al., 1997). In contrast, evidence 
suggesting inactivation by phosphorylation were presented in rat hepatocyte 
suspensions (Ruiz et al., 1988; Ruiz et al., 1990). However, in cultured hamster 
hepatocytes cAMP analogues, 8-chloro-cAMP and 8-(4-chlorophenyltiiio)-cAMP 
stimulated &e CEH activity, and this effect was mimicked by glucagon and 
theophylline (Hoang et al, 1993). Inactivation (dephophosrylation) of rat liver 
cytosolic CEH enzyme was catalyzed by a cytosolic Mg '^^ -dependent phospho-
protein phosphatase (Ghosh and Grogan, 1989). 
Like HMG-CoA reductase and C7aH (Shapiro and Rodwell, 1971; 
Danielsson, 1972; Edwards et al, 1977), liver CE hydrolases have also been shown 
to display a diurnal rhythm (Martinez et al, 1991). The lysosomal acid CEH shows 
the major peak at mid light period while a small plateau from six hours before mid 
dark to mid dark time. The activity reaching the lowest around three hours after mid 
light. The microsomal CEH showed a small plateau of activity around mid dark and 
minimum activity around the mid hght. In contrast, cytosolic CEH showed two 
activity peaks one each at three hours before mid light and mid dark, which reached 
the minimum about six hours later in each case. The peak at mid dark point was 
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significantly greater than that at mid light time. On changing the dietary status such 
as under fasting condition, the diumal rhythm of acid and cytosolic CEH was 
altered significantly while that of microsomal CEH remained ahnost the same, 
indicating that the later is not as actively involved in cholesterol homeostasis and 
rather it is meant to regulate the lipid composition of endoplasmic reticulum 
membrane. 
Regulation of liver cytosolic CEH activity in vivo by various dietary, 
hormonal and drug perturbations have been reported. Feeding of fat to rats caused 
an increase in CEH activity, whereas feeding of cholesterol alone and cholesterol 
plus fat was associated with down-regulation of cytosohc CEH activity. 
Administration of progesterone caused increase in CEH activity (Grogan et aL, 
1991). Feeding of coconut oil and cholesterol to hamster caused significant 
inhibition and activation of liver cytosolic CEH, respectively. In contrast, both fat 
and cholesterol feeding caused a reduction in microsomal CEH activity (Ochoa 
et al., 1990). Feeding the bile acid sequestrant, cholestyramine, increased both 
cytosohc and microsomal CEH activities in hamster bver (Ochoa et al., 1990). 
Feeding of cholestyramine, simvastatin and both drugs together to male rats was 
associated with elevation of cytosolic CEH activity. The increase in CEH activity 
by the drug combination was additive (Shand and West, 1995). Similar effects were 
observed on microsomal CEH activity, except die drug combination effect was not 
additive (Shand and West, 1995). The mechanism(s) of hepatic CEH regulation 
(short-term and/or long-term) in above manipulations have not been reported. 
Natarajan et al. (1996b, 1997) have studied the age related changes in 
mRNA, protein and catalytic activity of cytosohc CEH in male (Natarajan et al., 
1996b) and female (Natarajan et al., 1997) rats. The age related changes have also 
been observed in the other major cholesterol metabolizing enzymes; HMG-CoA 
reductase (Story et al., 1976; Choi et al., 1987; Stahlberg et al., 1991), C7aH 
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(Story et ai, 1976; Choi et al, 1987; Stahlberg et al, 1991) and ACAT (Stahlberg 
et al, 1991; Little and Hahn, 1992) while Erickson et al. (1995), has done similar 
studies on microsomal CEH. It has been shown that the age related changes in CEH 
activity are not due to the difference in tiie level of en2yme phosphorylation. The 
data suggest transcriptional regulation and indicate important role for CEH in 
cholesterol homeostasis in the developing rat. 
There are enough evidences that bile salt-dependent CEH activities are also 
present in intestine, serum and bile apart from pancreas. The properties of these 
enzyme activities as determined in crude preparations, are all similar and they are in 
turn similar to the properties exhibited by purified rat pancreatic CEH (Harrison, 
1988). However, the studies regarding the bile salt-dependent CEH activity in rat 
liver are not as clear and its identity with the rat pancreatic CEH has remained 
controversial. Among the different bile salts tested for their activating effect on 
CEH activity, sodium taurocholate was found to be tilie most effective one (Ghosh 
and Grogan, 1991a). The so called bile salt-dependent CEH activity varies widely 
among rat liver homogenates from 70-80% inhibition to no inhibition or stimulation 
of hepatic CEH by ten fold (Harrison, 1988; Kissel et al, 1989). Some studies with 
rat liver homogenates have demonstrated the presence of CEH activity that requires 
millimolar concentrations of trihydroxy bile salts for optimal activity (Harrison 
et al, 1979). Ghosh and Grogan (1991a) have reported the purification of a hepatic 
CEH activity which is not the pancreatic en2yme. En2yme activity of purified CEH 
is only observed in the presence of sodium taurocholate; highest activity was 
observed when using 0.5-10 mM sodium taurocholate. Higher concentrations of the 
bile salt strongly inhibit the enzyme activity in sharp contrast to pancreatic CEH 
which exhibits optimal activity at 75 mM cholate (Harrison, 1988). 
In the recent years there have been several report on the presence of some 
proteins which are shown to act as inhibitors of CEH. These inhibitory proteins 
have been reported in rat liver (Shand and West, 1992 a&b), testis (Hines et al. 
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1996), macrophage cell lines (Shand et al, 1993) and gall bladder mucosa 
(Neiderhiser, 1982). These studies suggest tiiat inhibitor proteins may play an 
important role in the overall cholesterol/CE cycle by influencing the activity of 
CEH in several tissues. Several non physiological compounds such as diethyl 
phosphate and N-alkyl carbamates inhibit CEH activity (Harrison et al, 1990) and 
might become useful tools in the investigations related to the control of 
cholesterol/CE cycle. Most of the divalent metal ions tend to inhibit CEH activity 
(Natarajan etal, 1996a). 
It has been known for some time that pancreatic CEH is secreted into 
intestinal lumen, where it participates in the processing of dietary lipids. In 
addition, there is evidence diat pancreatic CEH is internalized by the intestinal 
mucosal cells and participates in the intracellular metaboUsm of CE (Gallo et al, 
1980; Rudd and Brockman, 1984; Kyger et al, 1990). Reve et al (1991) have 
shown that hver does not contain any CEH mRNA. However, Kissel et al (1989) 
and Camulli et al (1989) have reported that the rat liver contained both mRNA and 
protein species indistinguishable from pancreatic CEH mRNA and protein. Camulli 
et al (1989) have also reported the purification of cytosohc, bile salt-dependent 
CEH from rat liver. In order to purify the enzyme, they used an immunoaffinity 
chromatography column constructed with antibodies prepared against the porcine 
pancreatic CEH. They also showed the first eight amino acids in the N-terminal 
sequence of the rat pancreatic and rat liver CEH enzymes are identical. Their 
results indicated tiiat the pancreatic and hepatic CEH enzymes are very closely 
related, if not identical. However, a comparison between the turnover number of the 
purified hepatic (Kissel et al, 1989) and pancreatic (Heuman et al, 1985) enzymes 
showed that the pancreatic enzyme is much more efficient at catalyzing the CE 
hydrolysis in vitro. Harrison (1988) has shown that monospecific, rat antipancreatic 
CEH IgG specifically and completely inhibited the CEH activity in rat serum, 
intestine and liver. These results raised the possibility that the neutral, bile salt-
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dependent CEH activity of rat liver homogenate may be due to the uptake of 
en2yme originating in pancreas. However, given the extensive sequence homology 
among manmialian lipases (Kirchgessner et ah, 1987; Komaromy and Schotz, 
1987), it is possible that antibodies generated against one lipase might cross react 
with others and hence the results may support but not prove the identity of hepatic 
and pancreatic CEH. 
Rojas and Harrison (1994), based on their observations, have proposed that 
the hepatic CEH can exist in a bile salt-dependent, inactive, monomeric form and a 
bile salt-independent, active, multimeric form. The monomer is postulated to 
aggregate into bile salt-independent multimer, in the presence of bile salt. In 
contrast, Ghosh and Grogan (1991a) have reported tiie purification of hepatic, bile 
salt-dependent CEH which shows different amino acid composition and exhibits 
different elution pattern fi-om cation exchange column as compared to pancreatic 
CEH. They have shown that sodium taurocholate had no effect on elution of CEH 
from cation exchange coliunn. However, an additional peak corresponding to Mr of 
400 kDa was eluted in gel permeation HPLC in the absence of bile salt. This 
observation indicates that CEH tends to a^egate in the absence of bile salt, a 
phenomenon just opposite to what was postulated by Rojas and Harrison (1994). 
Also CEH was inhibited by high concentrations of bile salt while pancreatic CEH 
was not. The liver enzyme isolated by them does not cross react with antipancreatic 
CEH antibodies. Gallo et al. (1978) were unable to show any immuno-cross-
reactivity between solubilized CEH from rat liver, adrenals or aorta as suggested by 
Harrison (1988), that CEH activity in liver and otiier tissues might be due to the 
uptake of pancreatic CEH. Ghosh and Grogan (1991a) have also experimentally 
demonstrated some striking differences between tiie liver cytosolic and pancreatic 
CEH. Liver CEH elutes at pH 5.5 as a single peak in isoelectric focusing, whereas, 
pancreatic enzyme elutes at three distinct peaks at pH 4.7, 5.3 and 5.7. N-terminal 
was found to be blocked in rat liver cytosolic CEH and it showed quite different 
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amino acid composition from pancreatic CEH, in contrast to the findings of Camulli 
et al. (1989). Finally, liver CEH is activated by kinases while pancreatic CEH is 
not, as the concentrations of cofactors for PKA (cAMP and Mg-ATP) which 
produced optimal activation of liver CEH had no effect on pancreatic CEH. 
Moreover, the cofactors for PKC (diacylglycerol, phosphatidyl serine and Mg-ATP) 
at concentrations optimal for activation of liver CEH produced a significant 
decrease in pancreatic CEH activity (Ghosh and Grogan, 1991a). This indicates that 
apparently pancreatic CEH is not regulated by reversible phosphorylation. 
There are several indications in various reports of the presence of one or 
more cytosolic CE hydrolases other than the enzyme that is generally recognized 
(Nilsson, 1976; Deykin and Goodman, 1982). Camulli et al. (1989) have suggested 
the presence of more than one CE hydrolases, based on the incomplete 
neutralization of CEH activity in rat liver cytosol by anti-porcine pancreatic CEH 
IgG, which were used in the purification of rat liver cytosolic CEH. Similarly, 
Harrison (1988) has shown that monospecific, antipancreatic CEH IgG completely 
inhibited the CEH activity in rat liver, whereas, Gallo et al. (1978) and Ghosh and 
Grogan (1991a) have contradicted these results and have attributed Harrisons 
finding to a different protein which shows CEH activity and have stressed the needs 
of studying the polymorphism of liver CEH. Also rabbit polyclonal antibodies 
against cytosolic CEH were shown to exhibit high degree of specificity and 
neutralized 70-80% of cytosolic CEH activity (Ghosh and Grogan, 1992). Cytosol 
contained 78% of total CEH activity and 75% of protein while microsomes 
contained 3% activity and 5% protein. These antibodies did not inhibit pancreatic 
CEH. These findings again indicate about the presence of one or more minor forms 
of CEH in the cytosol which might account for the remainder of CEH activity and 
protein as found in the above study. Furthermore, the steroid producing tissues as 
rat testis (Durham and Grogan, 1984) and adrenal gland (Pittman and Steinberg, 
1977) have more than one CEH enzymes. Therefore, it may not be surprising that 
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the liver, being the most important cholesterol metabolizing tissue, may also 
contain more than one cytosolic CEH. 
Assay of CEH has been a problem due to its broad substrate specificities in 
several tissues and tiie main physiological substrates, i.e., CE of long chain fatty 
acids, are water insoluble. Radiometric, colorimetric and flourimetric methods of 
CEH assay have been reported (Erlanson, 1970; Gallo, 1981; Deykin and 
Goodman, 1982; Lombardo, 1982; Hajjar et al, 1983; Noel et al, 1983; Sale et ai, 
1984; Chen et al., 1986; Huang and Hui, 1991; Yeaman et al. 1994; Morgan ei al., 
1994). The radiometric assay of CEH activity involves the use of either ''*C labeled 
fatty acid or cholesterol in the CE. The activity is assayed by quantifying 
radioactivity of released fatty acid or cholesterol after partitioning the substrate and 
its hydrolytic products, in a solvent system (Khoo et al., 1976; Klemecke and 
Binkeley, 1980; Gallo, 1981; Deykin and Goodman, 1982; Hajjar et al., 1983; 
Chen et al., 1986). The colorimetric mediods of CEH assay employ the estimation 
of released cholesterol, from CO, by using oxidase/peroxidase system in presence 
of 4 amino antipyrine to yield a stable coloured product having absorption maxima 
at 500 nm (Gallo, 1981; Noel et al., 1983). Alternatively, chromogen o-diansidine 
could be used with peroxidase to yield a coloured product (Sale et al., 1984). The 
flourimetric method is based upon the estimation of free cholesterol, generated 
from CO, flourometrically using oxidase/peroxidase/3-(p-hydroxyphenyl) propionic 
acid system (Hamada et al., 1985). These methods utilized the CEH substrates 
(usually CO) either dissolved in organic solvent like acetone or ethanol or in the 
form of mixed micelles with a phospholipid and sodium taurocholate (Khoo et al., 
1976; Klemecke and Binkeley, 1980; Gallo, 1981; Deykin and Goodman, 1982; 
Hajjar et al., 1983; Sale et al., 1984; Hamada et ai, 1985; Chen et al, 1986). 
Aqueous emulsion of CE were used by Noel et al. (1983), for the CEH activity 
assay. However, CEH specific activity from rat liver cytosol varies widely, from 
0.25-333 pmol/min/mg protein, when CO was used as substrate (Gallo, 1981; 
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Harrison, 1988; Camulli et al, 1989; Ghosh and Grogan, 1989; Ghosh and Grogan, 
1991a; Ghosh and Grogan, 1992; Camillo and Harrison, 1994). Some workers have 
also utilized water soluble, short-chain, and solvent soluble, long-chain, ^^thetic 
substrates in the assay of CEH (Tsujita and Brockman, 1987; Huang and Hui, 1991; 
Natarajan et al, 1996a). Assay of liver cytosolic CEH with short-chain substrates, 
however, can be done only with purified enzyme, as in crude preparations a high 
degree of non-specific hydrolysis is observed (Natarajan et al, 1996a). CEH assay 
in cytosol or partially purified fi-actions by employing long chain fatty-acyl esters of 
p-nitrophenol has not been reported. 
1.5. Objective of the present study 
The objective of the study undertaken is summarized as follows : 
(i) Development of a simple, reproducible and sensitive method for CEH assay 
had to be taken a top priority. It was necessary to get a clear picture of die outcome 
of the experiments performed, and to ensure the detection of significant but small 
variations in the CEH activity and also the other forms of CEH do not go 
undetected due to lesser sensitivity of available methods of assay, as discussed 
earlier. 
(ii) The effect of bile salt on the CEH activities has remained a matter of 
controversy. The studies to estabUsh whether the CEH enzymes have total, partial 
or no dependency on bile salts, needed proper investigation, 
(iii) Since, there have been contradictory reports on various immunological and 
catalytic properties of CEH, its purification was required to immunologically 
characterize the enzyme and to check its immimological identity to die pancreatic 
CEH. Purified CEH was also required to study the tissue specificity of the enzyme, 
(iv) Some aspects of in vitro and in vivo regulation of CEH were not studied in 
detail earlier. For instance, the modulation of CEH under various physiological 
perturbances including dietary and hormonal challenges and the impact of CEH 
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modulation on overall cholesterol homeostasis needed detailed studies. 
Furtiiermore, tiie regulatory role of various ligands including hypolipidemic a:gents 
such as tocotrienols and lovastatin on the CEH activities in particular was also a 
matter to be investigated. In addition, in certain experiments it is sometimes 
important to correlate the alterations in the CEH activity with the CEH protein 
mass. This required the quantification of CEH protein mass in order to get insight 
into the long-term regulation of CEH. 
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^E:Kverimenta[ 
MATERIALS 
2.1.1. Chemicals 
The chemicals were obtained from various sources listed below. 
Chemical 
Acrylamide 
4-Amino antipyrine 
Ammonium Bicarbonate 
Ammonium persulfate 
Benzamidine 
Bisacrylamide 
Bovine Serum Albumin 
cAMP 
Cholesterol 
Cholesterol Esterase (Porcine liver) 
Cholesterol Esterase (Rabbit Liver) 
Cholesteryl Ester Hydrolase 
(Bovine pancreas) 
Cholesteryl Ester Hydrolase 
(Psedomonas) 
Cholesterol Oxidase 
Cholesteryl l-^ '^C Oleate 
Cholesteryl Oleate 
Cholestyramine 
Commassie Blue-G Colloidal Concentrate-
Commassie Brilliant Blue G-250 
Commassie Brilliant Blue R-250 
Digitonin 
Source 
SRL, India 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
BioRad, USA 
Sigma Chemicals, USA 
SRL, India 
Miles Laboratories Inc., USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Calbiochem, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Polysciences Inc., USA 
Schwarz Mann Biotech, USA 
Sigma Chemicals, USA 
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Dithiothreitol 
HMG-CoA 
Horse Radish Peroxidase 
HPLC molecular weight markers 
Insulin (Bovine Pancreas) 
Isoproterenol 
Leupeptin 
Lovastatin 
Mevalonolactone 
NADPH 
Neuraminidase 
p-Nitrophenol 
p-Nitrophenyl acetate 
p-Nitrophenyl butyrate 
p-Nitrophenyl capiylate 
p-Nitrophenyl palmitate 
p-Nitrophenyl stearate 
PMSF 
Rat feed (pelleted rat chow) 
Rice Bran Oil (Refined) 
SDS-PAGE molecular weight markers 
Sodium Dodecyl Sulfate 
Sodium ortho vanadate 
Sodium Taurocholate 
Streptozotocin 
TEMED 
Thimerosal 
TLCK 
BRL, USA 
Pharmacia, Sweden 
USB, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Bachem California, USA 
Wokhardt, India 
Sigma Chemicals, USA 
Calbiochem, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Hindustan Lever Ltd., India. 
Foods, Fats and Fertilizers Ltd., 
India 
BioRad, USA 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
Ward Blenldnsop & Co., England 
Sigma Chemicals, USA 
SRL, India 
Sigma Chemicals, USA 
Sigma Chemicals, USA 
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TPCK - Sigma Chemicals, USA 
Triton X100 - SRL, India 
Tween-20 - Sigma Chemicals, USA 
Anti-rat hepatic cytsolic CEH antisurum was a kind gift from Dr. Shobha 
Ghosh, Department of Biochemistry, Medical College of Virginia, Virginia 
Commonwealth University, Richmond, Virginia, USA. Anti-rat pancreatic CEH 
IgG was a kind gift from Dr. Linda L. Gallo, Department of Biochemistry, George 
Washington University, Washington D.C. USA. 
All other chemicals and reagents used were of analytical grade. 
2.1^. Animak 
Male albino rats, weighing about 175-200 g were purchased from Central 
Animal House, J.N. Medical College, A.M.U., AUgarh. Rats were acclimatized to 
the animal house environment prior to the experiments and were given pelleted rat 
chow and water ad libitum except in fasting experiment where rats were given only 
water ad libitum. The rats were cycled in a 12 hour light (L, 0700-1900) and 
12 hour dark (D, 1900-0700) period for two weeks and were routinely killed at L3, 
except in the starvation experiment where the rats were killed at L9. The rats were 
killed by decapitation in all experiments except in in vivo experiments, where the 
rats were anesthetized and Hvers were removed. 
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EXPERIMENTAL DESIGN 
All the experimental groups contained five rats each. The daily dose of all 
the substances given through gastric intubation was divided into two halves, one 
half was given in tiie morning and the other half in tfie evening, unless stated 
otherwise. 
2.2.1. Tocotrienol Rich Fraction (TRF) Treatment to Normolipidemic Rats : The 
experimental groups were given TRF in 1 ml normal saline at the dose stated 
below. 
Normolipidemic, treated groups: 
(i) Given 100 mg TRF/rat/day for one week. 
Normolipidemic. control groups: 
These rats were given 1 ml normal saline for one week. 
2.2.2. TRF Treatment to Hyperlipidemic Rats : These rats were given atherogenic 
diet (AD) containing 5% saturated fat, 1% cholesterol and 0.5% cholic acid, 
administered through gastric intubation for the induction of hyperlipidemia. The 
specified doses of TRF/rat/day were given in 1 ml normal saline. 
Hyperlipidemic, treated groups : 
(i) Given AD for three weeks alongwith 100 mg TRF/rat/day. 
(ii) Given AD for three weeks and 25 mg TRF for 5 days after its withdrawal, 
(iii) Given AD for three weeks and 50 mg TRF for 5 days after its withdrawal. 
(iv) Given AD for three weeks and 25 mg TRF for 8 days after its withdrawal, 
(v) Given AD for three weeks and 25 mg TRF for 8 days after its withdrawal, 
(vi) Given AD for three weeks and 12 mg TRF for 8 days after its withdrawal. 
Hyperlipidemic, control groups : 
(i) Given AD for three weeks alongwith 1 ml normal saline. 
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(ii) Given AD for three weeks and 1 ml noimal saline for 5 days after its 
withdrawal, 
(iii) Given AD for three weeks and 1 ml normal saline for 8 days after its 
withdrawal. 
2.2 J . Dietary Stress Experiments : Following dietary manipulations were done : 
Treated groups: 
(i) Lovastatin Treated group ; given 7.5 mg lovastatin solution in 2 ml normal 
saline/rat/day for one week, 
(ii) Cholestyramine Treated group ; given 300 mg cholestyramine suspension in 
2 ml normal saline/rat/day for one week. 
(iii) Lovastatin and Cholestyramine Treated group ; given 7.5 mg lovastatin and 
300 mg cholestyramine in saline, for one week. 
Control group: 
Given 2 ml normal saline/rat/day for one week. 
2.2.4. Fasting E)a)eriment: Rats were starved for the following duration: 
Fasted rat groups: 
(i) 21 hours, 
(ii) 36 hours. 
Control group : 
Given free access to diet and water. 
2.2.5. Mevalonolactone (MVL) Treatment Experiment: 100 mg MVL solution in 
1 ml normal saline/rat was given in a single oral dose. 
Treated groups : 
(i) Given MVL 30 minutes before killing, 
(ii) Given MVL 4 hours before killing. 
Control group : 
Given 1 ml normal saline, 30 minutes before killing. 
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EXPERIMENTAL PROCEDURES 
23.1. Isolation and Purification of Tocotrienol Rich Fraction (TRF) from 
Refined Rice Bran Oil (RBO) 
TRF was extracted by stirring RBO in methanol for 1 h The minimum 
amount of methanol essential for extraction of maximum amount of TRF had been 
worked out to be 7 ml per gram of RBO. Methanol layer containing TRF was 
evaporated at 65°C under vacuum. Purified TRF was isolated fi^om crude TRF as 
reported (He et al., 1996) with minor modification. 100 g sihca gel (230-400 mesh) 
suspended in hexane was layered on a 500 ml sintered glass fimnel connected to a 
water aspirator tube for generating a mild vacuum. The silica gel was washed witii 
500 ml of hexane and then loaded with 0.5 g of crude TRF in 20 ml of hexane. The 
gel was washed with 1.5 lit of hexane in order to remove non-tocotrienol/ 
tocopherol components such as triacylglycerides, sterols, etc. Purified mixtures of 
tocotrienol (T3) and tocopherol (T) was then rapidly eluted with dietfiyl ether. The 
elution was speeded by the application of vacuum produced by water aspirator. The 
solvent was evaporated under vacuum in order to obtain highly purified mixture of 
T3 and T. The silica gel was regenerated by thoroughly washing with medianol, 
which removes all Ae bound components and reused again for the purification of 
crude TRF. 
23.2. Preparation ofCytosol 
Male albino rats were decapitated, liver was taken out and placed in chilled 
saline. The tissue was washed in cold saline, weigjied and homogenized in a 
warring blender (30 seconds) in two volumes of buffer A (20 mM Tris-HCl pH 7.0, 
80 mM KCl, 200 mM sucrose, 0.1 mM TPCK, 0.1 mM TLCK, 0.1 mM benz-
amidine and 0.02 mM leupeptin). The homogenate was centrifuged at 15000 x g for 
20 min at 4°C. The pellet was discarded and the post-mitochondrial supernatant was 
centrifiiged at 100,000 x g for 1 h at 4°C. The cytosol was obtained as supernatant 
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and the microsomal pellet was used for the preparation of washed microsomes. The 
cytosol from liver were aliquoted and stored frozen at -20°C for future use. In order 
to separate the two molecular forms, of CEH, hepatic cytosol was first fractionated 
0-40% with ammoniimi sulfate. The pellet was dissolved in buffer A, stored frozen 
and used for high molecular weight form (69 kDa ) CEH assay. The post 40% 
supernatant was frirther fractionated to a final ammonium sulfate concentration of 
80%. The 40-80% ammonium sulfate pellet obtained after centrifiigation was 
dissolved in buffer A and used for the assay of low molecular weight form (45kDa) 
CEH activity. Same procedure was used for the preparation of pancreas and brain 
cytosol, which were used in immunological studies. 
233. Preparation of Microsomes 
The microsomal pellet was suspended in ten volumes of buffer B (40 mM 
potassium phosphate, pH 7.2, 100 mM Sucrose, 50 mM KCl and 30 mM potassium 
EDTA) by vortexing, as described by Edwards and Gould (1972). The suspension 
was centrifuged at 100,000 x g for 1 hr at 4°C. The washed microsomal pellet was 
frozen at -20°C for fiulher use. 
13A, Solubilization ofHMG-CoA Reductase 
Solubilization was performed as described by Edwards et al. (1979). The 
frozen microsomes were allowed to thaw at 37°C. An equal volume of 50% 
glycerol in buffer C (buffer B with 10 mM DTT) was added which was preheated 
to 37''C. The suspension was homogenized with 10 downward passes of a hand 
driven all glass Potter-Elvehjem homogenizer and then incubated at 37*'C for 1 h. 
The suspension was diluted 3 fold with the same buffer preheated to 37*'C to a final 
glycerol concentration of 8.3%, rehomogenized with 10 downward passes of the 
homogenizer pestle, and centrifiiged at 100,000 x g for 60 min at 25°C. The 
supernatant which contained solubilized reductase was decanted and used for 
enzyme assay or stored at -20 **C for fiirture use. 
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23.5. Preparation of Substrates ofCEH 
PNP-acetate, PNP-butyrate, PNP-caprylate, PNP-palmitate, PNP-stearate or 
CO (cold or radiolabelled) was dissolved in acetone at the concentration of 4 mM 
(40X) and was used as droplet dispersion. Emulsion of CO was prepared as 
previously reported by Noel et al. (1983). 10 ^mole of the substrate was dissolved 
in 25 \JL of benzene to which 175 jil of Triton-XlOO was added and the contents 
were vortexed. 40 \]\ of this emulsion was added dropwise by a hamilton syringe to 
1 ml of a rapidly vortexing saline. 
23.6. Assay ofCEH 
An improved and sensitive colorimetric method for the assay of CEH was 
developed in our laboratory which utilizes p-nitrophenyl ester of palmitic acid as a 
substrate. CO and other p-nitrophenyl esters of short and long chain fatty acid were 
also used in comparative studies. 
Hydrolysis of acetone solutions of PNP-acetate, PNP-butyrate, PNP-
caprylate, PNP-palmitate and PNP-stearate by CEH enzyme was measured 
colorimetrically in 100 mM tris-HCl, pH 7.0, containing 50-400 pg protein of 
cytosol or ammonium sulfate fractions as a source of enzyme and 0.1 mM PNP-
acetate, PNP-butyrate, PNP-caprylate, PNP-palmitate or PNP-stearate in a total 
volume of 250 i^l. The reaction was started by the addition of substrate and 
incubated for 10 min at 3TC. The reaction was stopped by incubating the assay 
tubes in an ice chiUed water bath. The tubes were centrifuged at 10,000 rpm for 2 
min at 4°C and the absorbance of the hydrolytic product, p-nitrophenol in the 
supernatant was measured at 405 nm in a semi-autoanalyzer (Vitalab 31, The 
Netherlands). The CEH activity was calculated by utilizing p-nitrophenol as a 
standard. One unit of enzyme activity was defined as the amount of CEH required 
to hydrolyze one mnole of substrate into p-nitrophenol and corresponding fatty 
acids per min. at 37 °C. 
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When the above method of CEH assay was compared with other previously 
pubhshed radiometric or colorimetric me^ods, incubation conditions described for 
PNP-esters (above) were used. Hydrolysis of radiolabeled CO (0.1 mM; 60,000 
dpm) was measured by the radiometric method as described previously (Chen et al., 
1986). When CO substrate (0.1 mM) was used as emulsion or acetone solution, free 
cholesterol released, following incubation with cytosoUc CEH, was extracted in 
isopropanol and measured colorimetrically involving an enzyme coupled assay as 
described previously (Gallo, 1981, Noel et al, 1983). One unit of CEH activity is 
defined as the activity which hydrolysed one nmole of cold or radiolabeled CO per 
min at 3T*C. 
23.7. Assay ofHMG CoA Reductase 
HMG-CoA reductase activity in solubilized fraction of microsomes was 
assayed spectrophotometrically by the method of Kleinsek et al. (1977) with minor 
modifications. The activity of the solubilized HMG-CoA reductase was determined 
at 37 °C in a total volume of 0.25 ml using Beckman DU 640 spectrophotometer. 
Assay was carried out in buffer C containing 0.16 M potassium phosphate, pH 6.8, 
200 mM KCl, 4 mM EDTA and 20 mM 2-Mercaptoethanol. The reaction cell 
contained 100-200 i^g protein, 0.2 mM NADPH and 0.1 mM HMG-CoA, whereas, 
control cell contained only 100-200 i^g protein and 0.2 mM NADPH. Before the 
addition of HMG-CoA, the tubes were preincubated for 15 minutes. The reaction 
was stopped in cold water bath at 4°C after incubation for 5 min at 37°C. The 
change in absorbance from zero time was monitored at 340 nm against blank 
containing all the reagents except NADPH. The linear rate of oxidation of NADPH 
in control cell was subtracted from the linear rate obtained in the reaction cell. 
One unit of enzyme activity is defined as the amount of enzyme required to 
oxidize 2 nmoles of NADPH or 1 nmole of mevalonate per minute at 37 °C. 
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2^.S. Purification of CEH 
The cytosol was first fi-actionated by ammoniuin sulfate precipitation into 
0-40% ASF and 40-80% ASF in order to separate high and low molecular forms of 
CEH, respectively. The two fi^actions were dissolved in buffer A and aliquats were 
run separately on the non-denaturing gel electrophoresis at 4*'C. At the end of the 
run, the gels were cut into 1 mm shces and a portion of each sUce was assayed for 
flie presence of CEH activity. The gel slices from several runs, containing peak 
activities of high and low molecular weight forms of CEH were pooled separately 
and the enzyme protein was eluted by incubating die gel slices in 20 mM 
ammonium bicarbonate for 16 h at 4''C. The pooled enzyme fractions of the two 
molecular forms of CEH were concentrated in 30,000 molecular weight cut 
Centricon concentrators by centrifugation at 7000 x g at 4°C. 
2 J.9. Sodium Dodecyl Sulfate - Polyaaylamide Gel Eletrophoresis (SDS-PAGE) 
SDS-PAGE was performed as described by Laemmli (1970). However, in 
certain runs, the stacking gel was omitted. The staining was routinely done by 
commassie brilliant blue R250 (0.05%) solution in water containing 25% 
isopropanol and 10% acetic acid. The destaining was done with a solution of 10% 
acetic acid and 10% methanol in water. For detecting very small amount of protein 
on gels, Conunassie blue-G colloidal concentrate was used. 
23.10. Non-Denaturing (non-SDS) PAGE 
Non SDS-PAGE was done hke SDS-PAGE except SDS and 2-mercapto-
ethanol were omitted. 
23.11. Enzyme-Linked Immunosorbant Assay (ELISA) for CEH Mass 
ELISA for CEH mass was developed in our laboratory. Assays were done in 
96 well maxisorp E plates (Nalge NUNC). Wells were filled witii 3-9 ng protein of 
0-40% ASF or 10-50 ng protein of 40-80% ASF, diluted in 0.05 M carbonate-
bicarbonate buffer pH 9.6, to a volume of 300 jil. This was allowed to sit overnight 
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at 4°C. The protein was then removed and the wells were washed one time each 
with Tween-Tris buffered saline (TTBS; 20 mM Tris-HCl, 500 mM NaCl, pH 7.4, 
0.05% Tween 20) and Tris buffered saline (TBS; 10 mM Tris, 150 mM NaCl, pH 
7.4). The wells were then filled with 300 nl non fat dry milk 5% in TBS. This was 
allowed to incubate for 3-4 h at room temperature. The blocking solution was then 
removed and plates were washed one time each with TTBS and TBS, respectively. 
100 \i\ of primary antibody, anti-rat hepatic CEH antiserum at 1:200 dilution for 
0-40% ASF containing 69 kDa CEH and anti-rat pancreatic CEH IgG at dilution of 
1:10,000 for 40-80% ASF containing 45 kDa CEH, was added to corresponding 
wells and were incubated for 1-2 h at 37*'C. Wells were again washed once with 
TTBS and once with TBS, after the removal of primary antibody. After washing, 
100 (il of secondary antibody conjugate, goat anti rabbit IgG-HRP conjugate, at 
1:2000 dilution was added and left for 1-2 h at room temperature. Again washing 
was done once with TTBS and TBS, respectively. Colour was developed by the 
addition of 3,3',5,5'-tetramethyl benzidine-peroxidase system and incubation at 
3TC for 30 min. The colour development was terminated by the addition of 100 |J 
of 1 M phosphoric acid. The absorbance was read at 450 nm by automatic 
microplate reader (MR-600 Dynatech USA). 
The standard plot for the estimation of cytoslic high (69 kDa) and low 
(45 kDa) molecular forms of CEH proteins was made by using several 
concentrations (0.2-5.0 ng) of purified high and low molecular forms of CEH or 
commercial rabbit liver and bovine pancreatic CE hydrolases. The primary 
antibodies used were anti-rat hepatic CEH antiserum and anti-rat pancreatic CEH 
IgG, respectively. 
2 J. 12. Western Blotting 
Western blotting was performed as described in Millipore transfer 
membrane user guide. SDS-PAGE of 20-25 iig protein of cytosol, 0-40% or 
40-80% ASF or 1-2 ng of purified proteins was performed. After electrophoresis. 
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the gels washed with double distilled water and were electroblotted 3 h, at 4°C at 
200 volts, onto Immobilon-Polyvinylidene difluoride (PVDF) membranes using tiie 
BioRad transblot cell. The transfer buffer contained 25 mM Tris, 192 mM glycine, 
pH 8.3, 20% v/v methanol and 0.02% SDS. After the transfer was over, the PVDF 
membrane was taken out and kept in 5% non fat dry milk dissolved in TBS (10 mM 
Tris-HCl, pH 7.4, 150 mM NaCl) for 2 h at room temperature. The membrane was 
washed with TTBS (lOmM Tris-HCl, pH 7.4, 150 mM NaCl and 0.02% Tween 20) 
and TBS. The primary antibody, diluted in TBS was added and incubated at room 
temperature for 2 h with constant shaking. After removing tiie primary antibody, 
membrane was washed thrice with TTBS and once with TBS (8 min each). 
Secondary antibody HRP conjugate diluted in TBS was added after washing and 
allowed to stay for 1 h at room temperature. The membrane was washed again 
thrice with TTBS and once with TBS (8 miu each). The membrane was then 
submerged in HRP colour substrate system (50 mM Tris-HCl, pH 8.0, 0.48 mM 
4-chloro-l-naphthol, 200 mM NaCl and 17% metiianol). The reaction was started 
with tile addition of H2O2 to the concentration of 0.01% v/v. The colour was 
allowed to develop until the bands became visible. The substrate was removed and 
the membrane was dried and photographed the same day. 
2 J. 13. Estimation of Total, Free and Esterified Cholesterol in Liver Homogenate 
The total lipid was extracted from the liver homogenates as described by 
Folch et al. (1957). Total and free cholesterol were determined by the method of 
Annino and Giese (1976). 1 ml of the rat liver lipid extract was added to 4 ml 
isopropanol and mixed by vortexing. 1 ml of this mixture was taken and treated 
with ferric chloride reagent (70 mg ferric chloride hexahydrate per 100 ml of glacial 
acetic acid), mixed immediately followed by the addition of 2 ml of sulfiiric acid 
with instant mixing. Parallel controls (no Upid extract) and cholesterol standards 
were also run. The absorbance was taken at 550 nm, 5 min after the addition of 
sulftiric acid. 
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For free cholesterol, 1ml of the lipid extract-isopropanol mixture was treated 
with 2 ml of acetone and one ml of 1% digitonin (1 g digitonin in 100 ml of 60:40 
ethanol water mixture). The tubes were allowed to stand for 30 min in ice bath and 
then centrifiiged at 4000 rpm for 10 min. The supernatant was completely decanted, 
the precipitate which contained free cholesterol was again washed with 3 ml of 
acetone and dissolved in 1 ml isopropanol, after centrifrigation. The separated free 
cholesterol was then determined by same procedure as used for total cholesterol. 
Esterifred cholesterol, for the corresponding tissue, was estimated by 
subtracting the value of free cholesterol from total cholesterol. The absorbance 
reading were taken on Beckman DU 640 Spectrophotometer. 
23.14. Protein Estimation 
The protein was determined by the method of Bradford (1976), using bovine 
serum albumin as standard. Crude samples such as homogenates, cytosol and 
ammonium sulfate fractions of cytosol were first precipitated with 20% trichloro 
acetic acid. The peUets were dissolved in IN NaOH and suitable aliquots were used 
for protein determination. 
2.3.15. Neuraminidase Treatment 
High (69 kDa) and low (45 kDa) forms of purified CEH protein fractions 
(approximately 1.5 ng protein) were incubated with 0.1 unit of neuraminidase for 
18 h at 37°C. The protein samples were then electrophoresed on SDS-gel with the 
corresponding untreated CEH protein and molecular weight standards. 
2.3.16. Statistical Analysis 
Statical analysis of data was done by employing two tailed Student t-test 
(Bennet and Franklin, 1967), P values less than 0.05 were considered significant. 
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^suCts 
3.1. ISOLATION AND CHARACTERIZATION OF CYTOSOLIC HIGH 
(69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF NEUTRAL 
CHOLESTERYL ESTER HYDROLASE (CEH) 
3.LL Assay of Cvtosolic CE Hydrolases 
3.L1.1. Development of a colorimetric method for the assay of CEH involving 
p-nitrophenyl (PNP) esters of long-chain fatty acids : 
Assay of CEH enzymes has been a problem because they have broad 
substrate specificities and cholesteryl esters of long-chain fatty acids are water 
insoluble. For example, purified rat liver cytosohc CEH hydrolyzed cholesteryl 
oleate (CO), cholesteryl linoleate and triolein at similar rates over a broad range of 
concentration (Natarajan et al, 1996). FurAermore, the identity of hepatic 
hydrolases has also been a subject of controversy. In addition, the reported specific 
activity of liver cytosolic CEH enzymes vary widely by several fold in different 
published reports using the same substrate, CO. Therefore, we have developed a 
rapid, sensitive and reproducible colorimetric method for the assay of CEH activity 
in rat liver cytosol. The assay is based on the en2yme-mediated hydrolysis of 
substrate, PNP esters of long-chain fatty acids such as palmitate and stearate, to 
generate the product p-nitrophenol with an absorption maxima at 405 nm. This 
method has been compared with other previously published colorimetric and 
radiometric methods which utilize CO as a substrate. 
It was first necessary to define the assay conditions for cholesteryl ester 
(CE) hydrolases in cytosol. The results depicted in Figure 1 demonstrate the 
optimal assay conditions for cytosolic CEH activities for time (A), protein amount 
(B) and substrate concentration (C). 100 jig of cytosolic protein was assayed in the 
presence of 100 jiM PNP-pahnitate, added as droplet dispersion, at indicated time 
intervals as described in experimental procedures. The linearity of the reaction was 
maintained upto 20 min., after which the increase in the rate of PNP-palmitate 
hydrolysis was slowed and plateaued at 60 min. (Figure 1,A). Figure 1,B shows the 
protein dependency at indicated concentrations (10-1000 |ig). CEH activity was 
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FIG. 1. CHARACTEIZATION OF RAT LIVER CYTOSOLIC CEH ACTIVITY ASSAYED 
WITH PNP-PALMITATE (PNPP). 
[A] TIME CURVE: substrate concentration, 0.1 mM; protein, 100 ng/assay. 
[B] PROTEIN DEPENDENCE: substrate concentration, 0.1 mM; incubation time, 
10 min. 
[C] DEPENDENCE ON SUBSTRATE CONCENTRATION: protein, 100 ^g/assay; 
incubation time, 10 min. 
Mean values from two separate experiments carried out in duplicate. The average 
en-or on the data points in these assays was mean ± 9.0%, 10.9% and 8.2% for 
[A], [B] and [C], respectively. 
assayed for 10 min. in the presence of 100 \JM PNP-palmitate. The reaction was 
linear upto 450 ng of cytosolic protein. Figure 1,C depicts the result of CEH assay 
conducted at increasing concentration of PNP-palmitate at 100 |xg protein assayed 
for 10 min. The reaction showed a rapid linear increase with increasing concen-
tration of PNP-palmitate from 10 nM to 50 ^M. A little non-linear increment in the 
hydrolysis rate between 50 |iM and 100 i^M was observed which remained constant 
beyond 100 \iM (Figure 1,C). 
Next, we assayed the CEH activity in different ammonium sulfate fractions 
(ASF) of cytosol by employing the mediod described above. Consistent with 
pubUshed results, all the CEH activity associated with high molecular form was 
found in 0-40% ASF of cytosol. Since, we detected some CEH activity in post 40% 
ASF supernatant, frirther fixictionation of the supernatant was done. It was 
interesting to note that 20-30% of the total cytosolic CEH activity was detected in 
40-80% ASF. Determination of molecular weight of CEH associated with 0-40% 
ASF and 40-80% ASF revealed a value of 69 kDa and 45 kDa, respectively (for 
details see section 3.1.2). The optimal conditions for the assay of 69 kDa (in 0-40% 
ASF) and 45 kDa (in 40-80% ASF) were determined. Figures 2 and 3 show the 
results of CEH assay optimized for incubation time (A), protein concentration (B) 
and substrate concentration (C) for high (69 kDa) and low (45 kDa) molecular 
forms of CEH. As seen in Figures 2,A and 3,A, the linearity with time was 
17.5 min. and 25 min. for 0-40% and 40-80% ASF, at 50 ng and 400 |ig protein, 
req)ectively. The substrate concentration was 100 |iM. The PNP-palmitate 
(100 (iM) hydrolysis was found to be linear upto 350 ng and 600 p,g protein of 
0-40% ASF and 40-80% ASF, respectively, when the incubation time was 10 min. 
(Figures 2,B and 3,B). Panel C of Figures 2 and 3 shows a linear increase in CEH 
activity with increasing concentration of PNP-palmitate upto 50 jiM. There was a 
small non-linear increase in the hydrolysis rate between 50-100 i^M of substrate. 
Assays were done for 10 min. at 50 \ig and 400 \x% (equal enzyme activity units) 
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FIG. 2. CHARACTERIZATION OF RAT LIVER CYTOSOLIC 69 KDa CEH ACTIVITY IN 
0-40% ASF, ASSAYED WITH PNP-PALMITATE (PNPP). 
[A] TIME CURVE: substrate concentration, 0.1 mM; protein, 50 ^g/assay. 
[B] PROTEIN DEPENDENCE: substrate concentration, 0.1 mM; incubation time, 
10 min. 
[C] DEPENDENCE ON SUBSTRATE CONCENTRATION: protein, 50 ^g/assay; 
incubation time, 10 min. 
Mean values from two separate experiments carried out in duplicate. The average 
error on the data points in these assays was mean ±7.9%, 10.% and 8.8% for 
[A], [B] and [C], respectively. 
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FIG. 3. CHARACTERIZATION OF RAT LIVER CYTOSOLIC 45 KDa CEH ACTIVITY 
IN 40-80% ASF, ASSAYED WITH PNP-PALMITATE (PNPP). 
[A] TIME CURVE: substrate concentration, 0.1 mM; protein, 400 ng/assay. 
[B] PROTEIN DEPENDENCE: substrate concentration, 0.1 mM; incubation time, 
10 min. 
[C] DEPENDENCE ON SUBSTRATE CONCENTRATION: protein, 400 ng/assay; 
incubation time, 10 min. 
Mean values from two separate experiments canied out in duplicate. The average 
error on the data points in these assays was mean ±11.1%, 9.2% and 8.0% for 
[A], [B] and [C], respectively. 
protein of 0-40% and 40-80% ASF, respectively. These results demonstrate that 
pattern of substrate dependency with respect to the CEH activity present in cytosol, 
0-40% ASF and 40-80% ASF was similar. 
3.1.1^. Hydrofysis of PNP-fatty acyl esters of various chain lengths by CEH 
in cytosol, 0-40% and 40-80% ASF: 
As seen in Table 1, the substrate specificities of CE hydrolases in cytosol, 
0-40% ASF (69 kDa) and 40-80% ASF (45 kDa) were compared. Highest specific 
activity with PNP-acetate was obtained in all the three fi-actions, followed by PNP-
butyrate, PNP-c^rylate, PNP-palmitate and PNP-stearate. In comparison to PNP-
palmitate, the CEH specific activity with PNP-acetate was 3.55, 2.50 and 8.54 fold 
higher in cytosol, 0-40% and 40-80% ASF, respectively. When PNP-caprylate was 
used as a substrate, the fold increase in CEH activity for the diree enzyme fi'actions 
was 1.97, 1.65 and 3.20, respectively. The CEH specific activity with PNP-butyrate 
was in between PNP-acetate and PNP-caprylate. CEH-mediated hydrolysis of PNP-
stearate generated a specific activity slightly lower tiian PNP-palmitate (Table 1). 
These results suggest that high enzyme activities of cytosol, 0-40% and 40-80% 
ASF toward short-chain PNP-fatty acyl esters may be due to tiie presence of 
additional esterase(s) in cytosol, with greater specificity for these substrates. Water 
solubility of PNP-acetate and PNP-butyrate appears to be an additional contributory 
factor for substantially higher CEH-mediated hydrolysis rate of these substrates. 
The results also indicate that PNP-palmitate and PNP-stearate are specific 
substrates for CEH in cytosol and ammonium sulfate flections. 
3.1.1 J. Comparison of CEH activities of rat liver cytosol, 0-40% ASF (69 kDa 
CEH) and 40-80% ASF (45 kDa CEH) by different methods of assay : 
When the above described method was compared with other previously 
published radiometric or colorimetric methods, incubation conditions described for 
PNP-esters, in experimental procedures, were used. The data presented in Table 2 
provides a comparison of efficiency of CEH assay in hver cytosol, 0-40% ASF and 
40-80% ASF, by the newly developed method which utilizes acetone solution of 
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TABLE 1 
ENZYMATIC ACTIVITY OF CEH IN CYTOSOL, 0-40% ASF CONTAINING 
69 kDa FORM OF CEH AND 40-80% ASF CONTAINING 45 kDa FORM OF CEH 
AS A FUNCTION OF p-NITROPHENYL FATTY ACYL ESTERS OF VARYING 
CHAIN LENGTH (CARBON NUMBER) 
Substrate Used CEH Specific Activity 
(units/mg) 
Percentage Relative 
to CEH Value in (D) 
Cytosol 0-40% 40-80% Cytosol 0-40% 40-80% 
(A) PNP-Acetate (C2) 
(B) PNP-Butyrate (C4) 
(C) PNP-Capiylate (C8) 
(D) PNP-Paimitate (C16) 
(E) PNP-Stearate (C18) 
4.30 6.S8 
(±0.26) (±0.37) 
3.12 6.31 
(±0.28) (±0.41) 
2.38 4.27 
(±0.18) (±0.33) 
1.21 2.63 
(±0.08) (±0.13) 
1.09 2.38 
(±0.09) (±0.23) 
2.49 
(± 0.16) 
1.15 
(± 0.09) 
0.94 
(± 0.04) 
0.29 
(± 0.02) 
0.25 
(± 0.03) 
355 250 854 
258 240 395 
197 165 325 
100 100 100 
90 90 85 
100 ^g of cytosol, 50 ^g of 0-40% ASF and 400 ^g of 40-80% ASF, were assayed with 
p-nitrophenyl fatty acyl esters of indicated chain length, for 10 min. at 3TC, as described in 
experimental procedures. Final concentration of each substrate was 0.1 mM in the reaction 
mixture. Values in parentheses represent the mean ± SD of triplicate determinations and the 
data shown here is represmtatrve of three experiments. 
All values are significantly different from the respective value in (D) at p<0.001. 
TABLE 2 
COMPARISON OF CEH A C n v m E S OF RAT LIVER CYTOSOL, 0-40% ASF 
(69 kDa) AND 40-80% ASF (45 kDa) BY DIFFERENT METHODS OF ASSAY 
Substrate Used 
(A) PNPP in Acetone 
(B) PNPS in Acetone 
(C) CO in Acetone 
(D) CO Emulsion 
(E) RadiolabeUed CO 
in acetone 
CEH Specific Activity 
(units/mg) 
Cytosol 0-40% 40-80% 
1.11 2.56 0.315 
(±0.08) (±0.11) (±0.008) 
0.98 2.23 0.270 
(±0.09) (±0.08) (±0.010) 
0.17 0.43 0.045 
(± 0.008) (± 0.021) (± 0.004) 
0.18 0.46 0.047 
(± 0.012) (± 0.041) (± 0.010) 
0.20 0.49 0.054 
(± 0.017) (± 0.054) (± 0.030) 
Percentage Relative 
to CEH Value in (A) 
Cytosol 
100 
88 
15 
16 
18 
0-40% 
100 
87 
17 
18 
19 
40-80% 
100 
86 
14 
15 
17 
Final concentration of each substrate was 0.1 mM in the reaction mixture. Values in 
parentheses represent the mean ± SD of triplicate determinations and the data shown here is 
representative of several experiments performed. 
All values are significantly different from the respective value in (A) at p<0.001. 
PNP-palmitate or PNP-stearate, with the previously published radiometric or 
colorimetric methods. The last three procedures (C-E) employ either cold or 
radiolabeled CO as substrate. For the above three fractions, high CEH specific 
activity values of 1.11, 2.56 and 0.315 units/mg were obtained for PNP-palmitate 
solution in acetone (A). When PNP-staerate solution in acetone (B) was used as a 
substrate, the CEH specific activity for cytosol, 0-40% ASF and 40-80% ASF was 
slightly reduced by 12%, 13% and 14%, respectively. In contrast, when CEH 
activities in cytosol, 0-40% ASF and 40-80% ASF were assayed colorimetrically by 
using acetone solution (C) or emulsion (D) of CO, a low specific activity was 
obtained in comparison to CEH activities obtained witii PNP-palmitate. The CEH 
specific activities of these three fractions were found to be 5-7 fold lower, when 
compared with PNP-palmitate (Table 2,A). Similarly, when CEH was assayed by 
the radiometric method with CO (E), a specific activity of 0.2, 0.49 and 0.054 
units/mg was obtained for cytosol, 0-40% ASF and 40-80% ASF, respectively. 
These results demonstrate the CEH activity in the three firactions (above) obtained 
by the hydrolysis of CO solution in acetone, CO emulsion and radiolabeled CO 
acetone solution, were almost identical to each other (Table 2,C-E). However, in 
comparison to specific activities obtained by the CEH-mediated hydrolysis of PNP-
palmitate or PNP-stearate solution in acetone (Table 2,A and B), the values 
obtained with CO were consistently and significantly lower (Table 2). In 0-40% 
ASF, expressed CEH specific activities were 2.2-2.6 fold higher than cytosolic 
value, when assayed using PNP-palmitate/PNP-stearate and CO as substrates 
(Table 2). By employing PNP-palmitate and PNP-stearate, a specific activity of 
0.315 and 0.27 units/mg was associated with a newly discovered 45 kDa molecular 
form of CEH, fractionated in 40-80% ASF (Table 2,A and B). However, the 
specific activities of 45 kDa CEH with CO acetone solution and emulsion and 
radiolabeled CO in acetone were significantly lower (Table 2,C-E) than the specific 
activity obtained with PNP-palmitate (Table 2,A). These results demonstrate that 
CEH-mediated hydrolysis of PNP-palmitate is significantly higher than CO in 
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cytosol, 0-40% ASF and 40-80%. In addition, the combined results represent an 
initial demonstration of an additional CEH activity associated with a low molecular 
weight (45 kDa) protein present in 40-80% ASF. Identification of low (45 kDa) 
molecular form of rat hver cytosolic CEH, associated with 40-80% ASF is 
consistent with an earlier report where a significant amount of CEH activity was 
detected in 40-60% ASF by employing CO as a substrate. However, no 
characterization of this form of CEH was reported (Ghosh et ai, 1990). 
In order to establish that high level of CEH-mediated hydrolysis of PNP-
palmitate, in comparison to CO, is specific, enzymatic activities of CE hydrolases 
in the above three fractions were assayed in presence of taurocholate, which is 
knovm to activate CEH enzymes (see section 3.1.3.1.). As shovra in Table 3, 5 mM 
of taurocholate caused a maximal activation of CEH in cytosol, 69 kDa CEH in 
0-40% ASF and 45 kDa CEH in 40-80% ASF by 43%, 44% and 42%, respectively, 
when PNP-palmitate was used and 40%, 47% and 44%, respectively, when CO was 
used. Likewise, at other indicated concentrations of taurocholate also, the change in 
enzymatic activities was similar when cytosolic CEH, 69 kDa CEH and 45 kDa 
CEH activities were assayed with PNP-palmitate or CO (Table 3). Furthermore, the 
percent activation of purified 69 kDa and 45 kDa CEH activities at 5 mM 
taurocholate and the decline in activation at 20 mM taurocholate was also similar 
when assayed with PNP-palmitate or CO (Table 7). These results demonstrate that 
increase in activities of cytosolic, 69 kDa and 45 kDa CEH mediated by 
taurocholate is reflected equally, when assayed either with PNP-palmitate or CO. 
The results also indicate that like CO, the hydrolysis of PNP-palmitate is specific to 
cytosolic high (69 kDa) and low (45 kDa) molecular forms of CEH. In addition, the 
results suggest that the high rate of hydrolysis with PNP-palmitate is not 
contributed by non-specific esterases but by CEH enzymes. 
Next, comparison of hydrolysis of PNP-palmitate and CO was done with 
cytosolic, 69 kDa (0-40% ASF) and 45 kDa (40-80% ASF) CEH, isolated fi-om rats 
treated with tocotrienols (in tocotrienol rich fi-action, TRF), which have been shown 
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TABLE 3 
COMPARISON OF ACXIVmES OF CEH IN CYTOSOL, 0-40% ASF AND 
40-80% ASF IN PRESENCE OF BILE SALT USING PNP-PALMTTATE AND CO 
AS SUBSTRATES 
Fraction 
Cytosol 
0-40% ASF 
40-80% ASF 
mM Sodium 
Taurocholate 
0 
2.5 
5.0 
10.0 
20.0 
0 
2.0 
5.0 
10.0 
20.0 
0 
2.0 
5.0 
10.0 
20.0 
CEH Specific Activity 
(units/mg) 
PNPP 
1.23 ± 0.09 
1.53 ±0.11 
1.76 ± 0.13 
1.57 ± 0.12 
1.56 ± 0.08 
2.58 ± 0.14 
3.12 ± 0.17 
3.72 ± 0.19 
3.15 ± 0.15 
3.04 ± 0.12 
0.33 ± 0.012 
0.40 ± 0.017 
0.47 ± 0.019 
0.44 ± 0.013 
0.41 ±0.011 
CO 
0.221 ± 0.010 
0.281 ± 0.013 
0.309 ± 0.018 
0.278 ± 0.016 
0.274 ± 0.014 
0.561 ± 0.021 
0.668 ± 0.026 
0.825 ± 0.032 
0.696 ± 0.023 
0.645 ± 0.024 
0.061 ± 0.003 
0.073 ± 0.003 
0.088 ± 0.005 
0.080 ± 0.003 
0.077 ± 0.002 
% Change in 
Activity 
PNPP 
0 
+24 
+43 
+28 
+27 
0 
+21 
+44 
+22 
+18 
0 
+21 
•Ht2 
+33 
+24 
CO 
0 
+27 
+40 
+26 
+24 
0 
+19 
+47 
+24 
+15 
0 
+19 
+44 
+31 
+27 
100 ^g, 50 i^g and 400 ^g protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed with PNP-palmitate (PNPP) and CO at indicated 
concentrations of sodium taurocholate for 10 min. at 3TC. Values are mean ± SD of two 
separate determinations in triplicate. 
All values were significantly different from respective controls at ^p<0.01. 
to inhibit CEH activity in vivo (see section 3,3.2.). As seen in Table 4, in TRF-
treated rats, CEH activities of cytosol and 0-40% ASF (69 kDa CEH), when 
assayed with PNP-pahnitate showed an inhibition of 41% and 42%, respectively, 
whereas an inhibition of 38% and 38%, respectively, was obtained when assay was 
done with CO. No inhibition of enzymatic activity of 45 kDa CEH present in 
40-80% ASF was observed following assay with PNP-palmitate or CO (Table 4). 
These results confirm the earlier findings that cytosolic, high and low molecular 
forms of CEH fi-om normal and TRF-treated rats preferentially hydrolyzed PNP-
palmitate than CO which may be due to lower hydrophobicity of PNP-palmitate. 
In order to completely rule out the possibility that PNP-palmitate may also 
be hydrolyzed by the presence of additional esterase(s) in cytosol, CEH enzymatic 
activities were measured in 1 mm gel slices after non-SDS-PAGE of cytosolic 
protein, by utilizing PNP-palmitate and highly specific substrate, CO. As shown in 
Figure 4, measurement of CEH enzymatic activities in gel slices with either of the 
substrates revealed tiiat peak enzymatic activity of 69 kDa CEH was associated 
with the same gel slice. However, activity obtained wifli PNP-palmitate was 
approximately 2.5 fold higher in comparison to CO. Similarly, CEH activity of 
45 kDa molecular form was also associated with same gel slices, when assayed 
with either PNP-palmitate or CO. Again, the magnitude of CEH activity with PNP-
palmitate was 3 fold higher. Throughout the gel, no other enzyme activity peak was 
detected when PNP-palmitate or CO was employed. 
In another experiment, 0-80% ASF of cytosol, containing both high (69 kDa) 
and low (45 kDa) molecular forms of CEH, was subjected to gel permeation HPLC 
and enzymatic activities were determined in 100 jil fi-actions by employing both 
PNP-palmitate and CO substrates. As seen in Figure 5,A, die peak activities for 
69 kDa and 45 kDa molecular forms of CEH were associated with fi-actions 12 and 
15, respectively, when assayed witii PNP-palmitate or CO. Consistent witii earlier 
results in cytosol, 0-40% ASF and 40-80% ASF (Table 2) and in gel slices 
(Figure 4), enzymatic activity of both the forms of CEH was 2.5-3 fold higher when 
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TABLE 4 
COMPARISON OF EIYDROLYSIS OF PNP-PALMITATE AlVD CHOLESTERYL 
OLEATE (CO) WITH CYTOSOLIC HIGH (69 kDa) AND LOW (45 kDa) 
MOLECULAR FORMS OF CEH ISOLATED FROM LIVER OF RATS TREATED 
WITH TOCOTRIENOL RICH FRACTION (TRF) FOR ONE WEEK 
Group/Fraction PNPP CO 
Specific Activity % Change Specific Activity % Change 
(units/mg) fromNLP-C (units/mg) fromNLP-C 
NLP-C 
Cytosol 
0-40% ASF 
40-80% ASF 
NLP-T 
Cytosol 
040% ASF 
40-80% ASF 
0.83 ± 0.09 
L60 ± 0.25 
0.24 ± 0.071 
0.49 ± 0.04 
0.92 ± 0.08 
0.28 ± 0.025 
0 
0 
0 
-41^ 
-42^ 
+ 7 
0.138 ± 0.009 0 
0.271 ±0.011 0 
0.034 ± 0.004 0 
0.088 ±0.010 -38^ 
0.168 ± 0.014 - 38^ 
0.0 33 ±0.005 +2 
100 ^g, 50 ^g and 400 |xg.protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively was assayed with 0.1 mM PNP-pahnitate (PNPP) or CO as 
described in experimental procedures. Values are mean ± SD of two separate determinations in 
triplicate. 
Significantly different from respective controls at *p<0.001. 
NLP-C, Normolipidemic Control; NLP-T, Nonnolipidemic Treated (100 mg TRF/day). 
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cut into 1 mm slices and the GEH activity was determined with 
PNPP (—•—) and CO (—o—) as described in experimental pro-
cedures. 
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FIG. 5. [A] ELUTION PROFILE OF HIGH AND LOW MOLECULAR FORMS OF 
CYTOSOLIC CEH ON GEL PERMEATION HPLC. 
0-80% ASF of cytosol, containing both molecular forms of CEH, was 
run on Shodex GS 51OM gel penmeation HPLC column at 4 oC at 
a flow rate of 0.25 ml/min and 0.1ml fractions were collected. The 
CEH activity was determined with PNPP (—•—) and CO (—o—) 
in the pooled fractions of several runs as described in experi-
mental procedures. 
[B] R /^R^ Vs LogM PLOT OF STANDARD MARKER PROTEINS. 
The proteins include; a, Ribonuclease (13,700); b. Myoglobin (17,800); 
c, a Chymotrypsin (25,700); d. Ovalbumin (45,000); e, Serum 
Albumin (68,000); f, Phosphorylase b (97,000). The approximate 
molecular weights of high and low molecular forms of CEH are 
indicated as 1 and 2, respectively. 
assayed with PNP-palmitate, in comparison to CO. Other than these two CEH 
peaks, no esterase activity was detectable in any of the fractions, either witii PNP-
pahnitate or CO. 
The results indicate that all the measurable cytosolic CEH activity was 
associated with the two forms of CEH after non-SDS PAGE and gel permeation 
HPLC, when assayed either with PNP-palmitate or CO. Consistent with earlier 
results, PNP-palmitate appears to be hydrolyzed more efficiently than CO, 
indicating that accessibility PNP-palmitate towards the en2yme is greater than CO 
apparently due to lower hydrophobicity of PNP-palmitate. 
3.1.1.4. Comparison of hydrolysis of PNP-fatty acyl esters of various chain 
lengths by purified rat liver cytosolic, 69 kDa CEH and 45 kDa CEH 
and Afferent commercial CE hydrolases: 
Catalytic activities of highly purified rat liver cytosolic, 69 kDa and 45 kDa 
CE hydrolases and purified preparations of esterases fi-om rabbit liver, porcine 
liver, bovine pancreas and pseudomonas were measured with PNP-esters of fatty 
acids of increasing chain lengths and decreasing water solubility. As seen in 
Table 5, in comparison to 69 kDa CEH specific activity witii PNP-palmitate, the 
specific activities obtained with PNP-acetate, PNP-butyrate, PNP-caprylate and 
PNP-stearate were 314%, 300%, 171% and 86%, respectively. The rate of 45 kDa 
CEH-mediated hydrolysis with PNP-acetate and PNP-butyrate was significantly 
higher (approximately 100%) in comparison to rates of hydrolysis of these 
substrates by cytosolic 69 kDa CEH, when compared to respective values with 
PNP-palmitate. The change in specific activities of 45 kDa CEH with PNP-
caprylate and PNP-stearate were substantially similar to the values obtained for 
69 kDa CEH. These results are consistent with the relative CEH activities of 
cytosol, 0-40% ASF (69 kDa) and 40-80% ASF (45 kDa) toward PNP-esters with 
fatty acids of different chain lengths. Enzyme activity was maximum with PNP-
acetate and then declined gradually with increasing chain length upto PNP-
palmitate (CI6). The difference in specific activities obtained for either of the 
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forms of CEH with PNP-palmitate and PNP-stearate were similar (Table 5). The 
order of preference of hydrolases from rat liver, porcine liver and bovine pancreas, 
in terms of PNP-esters of fatty acids of different chain lengths were found to be the 
same, except in pseudomonas where PNPrbutyrate was most preferred substrate. It 
is interesting to note that increase in specific activity with short chain substrates 
relative to specific activity with PNP-palmitate was highest in porcine liver 
followed by rabbit liver. The results confirm the earUer observations with cytosol 
preparations (Table 1) that disproportionately higher activity of various purified 
esterases toward PNP-acetate and PNP-butyrate is in part due to water solubility of 
these substrates. 
Next, we compared flie hydrolysis of PNP-palmitate and CO with highly 
purified cytosolic, 69 kDa and 45 kDa forms of CEH and four purified, 
commercially procured CE hydrolases. As shown in Table 6, in comparison to CO, 
the hydrolysis of PNP-palmitate by purified 69 kDa and 45 kDa CEH was 
approximately 3 fold higher. With purified hydrolases from rabbit liver and porcine 
liver the efficiency of PNP-palmitate hydrolysis was increased by 13-14 fold, in 
comparison to CO. However, as expected, the rate of hydrolysis for PNP-palmitate 
was only slightly higher (1.23-1.25 fold) tiian CO, when hydrolases from bovine 
pancreas and pseudomonas were used (Table 6). These results confirm the earlier 
observations with cytosol and 0-40% ASF that PNP-palmitate is a specific substrate 
for CE hydrolases and preferentially hydrolyzed at a much faster rate in comparison 
to CO, when they are presented as acetone droplet dispersion. The Kn, and Vmax 
values of cytosolic high (69 kDa) and low (45 kDa) molecular forms of CEH with 
PNP-palmitate and CO lend fiirther support to these observations (see 
section 3.1.4.). 
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TABLE 6 
COMPARISON OF HYDROLYSIS OF PNP-PALMITATE AND CHOLESTERYL 
OLEATE (CO) BY THE PURIFIED RAT LIVER CYTOSOUC 69 kDa AND 
45 kDa CE HYDROLASES WITH THE FOUR COMMERCIALLY PROCURED 
CE HYDROLASES 
Source of 
Hydrolase 
Rat Liver 69 kDa 
Rat Liver 45 kDa 
Pseudomonas * ^ 
Bovine Pancreas * ^ 
Porcine Liver * ^ 
Rabbit Liver * ^ 
Soecific Activitv (SA) (units/me) 
PNPP CO 
38.9 ± 1.52 
32.7 ± L87 
119110'±2465 
16x10'±1838 
3 x l 0 ' ± 879 
1 X 10 ' ± 479 
13.7 ± 1.03 
12.0 ± 0.78 
95 X 10 ' ± 1986 
13 X 10 ' ± 1559 
211 ±13.9 
80 ±5.88 
Ratio of SA 
PNPP/CO 
2.84 
2.73 
1.25 
1.23 
14.21 
12.50 
Each enzyme was assayed with FNP-pahnitate (PNPP) and CO as described in methods. Each 
value represents mean ± SD of triplicate determinations. 
* Commercially procured enzyme, ^  Cholesteryl ester hydrolase, ^  Cholesterol esterase. 
3.1.2. Isoiarion of High and Low Molecular Weight Forms of CEH From Rat 
Liver Cvtosol 
High and low molecular forms of CEH associated witfi 0-40% ASF and 
40-80% ASF of cytosol, respectively, were purified to electrophoretic homogeneity 
as described under experimental procedure. As depicted in Figure 4, analysis of 
enzyme activity in gel slices (1 mm) revealed that greater tiian 55% of recovered 
CEH activity of high molecular form was associated with single gel slice (number 
25), whereas -65% of recovered activity of low molecular form of CEH was 
associated with slice number 34 of the gel. The two pooled protein fractions eluted 
JBrom several gels representing high and low molecular forms of CEH were purified 
on 30,000 molecular weight cut Centricon concentrators. As seen in Figure 6,A, on 
SDS-PAGE gel, a single protein band corresponding to a molecular weight of 
69 IcDa for high molecular form of CEH was obtained. The purified low molecular 
form of CEH migrated as single electrophoretic band with a monomer molecular 
weight of 45 kDa (Figure 6,A). Western blotting of the two purified proteins 
confirmed that the bands corresponding to 69 kDa and 45 kDa molecular weight on 
SDS gel were indeed the two molecular forms of CEH (Figure 6,B). An apparent 
molecular weight of approximately 67 kDa and 45 kDa was obtained for the high 
and low molecular forms of CEH, respectively, by gel permeation HPLC on Shodex 
GS 510M column, calibrated with proteins of known molecular weight 
(Figure 5,B). The combined results are consistent with published reports (Ghosh 
and Grogan, 1991a), where a molecular weight of 66 kDa was reported for higher 
molecular weight form of CEH. For the newly discovered, low molecular form of 
CEH, which has not been reported earlier, an apparent molecular weight of 45 kDa 
was obtained. 
Based on earlier reports that both liver and pancreatic cytosolic CEH are 
glycosylated, the molecular weight of 69 kDa and 45 kDa CEH were determined 
after neuraminidase digestion. As seen in Figure 7,A, the molecular weight of 
higher molecular form of CEH was reduced from 69 kDa to 66 kDa indicating 
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FIG. 6. [A] SDS-PAGE OF PURIFIED HIGH AND LOW MOLECULAR FORMS OF 
CYTOSOLIC CEH. 
SDS-PAGE of approximately 2 ^g purified protein of low (lane 1) and 
high (lane 2) molecular form of CEH, and the mixture of standard molecular 
weight markers, (lane 3) was performed on 11% polyacrylamide gel without 
stacking gel as described in experimental procedures. 
[B] IMMUNOBLOT OF TWO MOLECULAR FORMS OF CEH. 
Approximately 2 ^g of purified high (lane 1) and low (lane 2), molecular 
form of CEH, after SDS-PAGE, was transferred to a nitrocellulose membrane 
and immunoblotted as described in experimental procedures. 
[C] LogM Vs R /R PLOT OF STANDARD PROTEINS. 
The marker proteins include; a, Phosphorylase b (97,400); b, Semm Albumin 
(66,200); c. Ovalbumin (45,000); d. Carbonic Anhydrase (31,000); e, Tripsin 
Inhibitor (21,500); f, Lysozyme (14,400). The approximate molecular weights 
of high and low molecular forms of CEH are indicated as 1 and 2 respectively 
B 
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FIG. 7. [A] SDS-PAGE OF PURIFIED HIGH AND LOW MOLECULAR FORMS OF 
CYTOSOLIC GEH AFTER NEURAMINIDASE TREATMENT. 
Approximately 2 ^g purified protein of low (45 kDa) (lane 1) and high (69 kDa) 
(lane 3) molecular forms of GEH was treated with neuraminidase, and analyzed 
by SDS-PAGE, as described in experimental procedures followed by SDS-PAGE 
on 11% polyacrylamide gel without stacking gel. Lanes 2 and 4 represent untreated 
purified low (45 kDa) and high (69 kDa) molecular forms of GEH, respectively, and 
lanes 5 and 6 contained BSA and protein molecular weight standards, respectively. 
[B] IMMUNOBLOT OF TWO MOLECULAR FORMS OF CEH. 
Neuraminidase-treated and untreated purified high (69 kDa) (lane 2 and 1, respec-
tively) and low (45 kDa) (lane 4 and 3, respectively) molecular forms of CEH, were 
separated by SDS-PAGE and probed with both anti-liver CEH antiserum and 
anti-pancreatic CEH IgG by western blot analysis, as described in experimental 
procedures. 
removal of carbohydrate, following treatment with neuraminidase, hi contrast, the 
molecular weight of newly identified 45 kDa CEH remained unchanged after 
neuraminidase treatment (Figure 7,A). Western blotting of a parallel SDS-gel 
confirmed the shift in molecular weight of 69 kDa CEH protein. On the odier hand, 
no change was inmiuno-detected in the migration of 45 kDa CEH protein 
(Figure 7,B). These results are consistent with earlier findings that rat liver 
cytosoUc 69 kDa CEH is a glycoprotein. The above results also indicate that rat 
liver cytosolic 45 kDa CEH is apparently not modified post-translationally 
involving glycosylation. 
3.1J. Properties of Cytosolic and PartiaUv Purified 69 kPa (in 0-40% ASF) 
and 45 kPa (in 40-80% ASF) CEH Activities 
3.13.1. Effect of taurocholate'. 
As shown in Figure 8, assay of CEH activities in cytosol, 0-40% ASF and 
40-80% ASF in the presence of increasing concentrations of sodium taurocholate, 
increased the hydrolysis of PNP-palmitate. At 5 mM taurocholate, a maximum 
activation of 42%, 46% and 42% was obtained for cytosolic and partially purified 
high and low molecular weight CEH, respectively. The taurocholate-mediated 
activation of CEH activities was concentration-dependent upto 5 mM. However, at 
higher concentration of taurocholate, the activation was significantly reduced in all 
the three fi-actions. A reduction of 40%, 78% and 52% in CEH activation in 
cytosol, 0-40% ASF and 40-80% ASF, respectively, was obtained at 15 mM 
taurocholate which remained constant upto 20 mM. Based on the activation effect 
of taurocholate on CEH in cytosoUc preparations, the purified en2ymes were 
assayed in the presence of 5 mM and 20 mM taurocholate. Addition of 5 mM 
taurocholate increased the CEH activity of purified 69 kDa and 45 kDa forms by 
72% and 67%, respectively, whereas, at 20 mM taurocholate, the activation was 
reduced by 89% and 76%, respectively (Table 7). Similar activation at 5 mM and 
decline in activation at 20 mM taurocholate was observed using CO. These results 
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FIG. 8. EFFECT OF SODIUM TAUROCHOLATE ON THE ENZYMATIC 
ACTIVITIES OF CEH IN CYTOSOL, 69 KDa CEH IN 0-40% ASF AND 
45 KDa CEH IN 40-80% ASF. 
100 ^g of cytosol (—o—), 50 ^g of 0-40% ASF (—•—) and 400 ^g of 
40-80% ASF (—A—) were assayed In the presence of indicated con-
centrations of sodium taurocholate for 10 min. and the CEH activity 
was determined as described in experimental procedures. The 
absolute value for 100% CEH activities (units/mg) were: Cytosol, 
1.11; 0-40% ASF, 2.48 ; 40-80% ASF, 0.31. Each value represents 
the mean of several experiments carried out in triplicate. The average 
error on the data points was mean ±15.6%. 
TABLE 7 
EFFECT OF TAUROCHOLATE ON THE PURIFIED 69 kDa AND 45 kDa CEH 
ACTIVITIES OF RAT LIVER CYTOSOL ASSAYED WITH FNP-PALMITATE 
AND CHOLESTERYL OLEATE 
Molecular 
form of CEH 
69 kDa 
45 kDa 
Bile Salt 
(mM) 
0 
5 
20 
0 
5 
20 
PNPP 
38.9 ±L52 
66.7 ± L98 
42.0 ±L80 
32.7 ±L87 
54.7 ± 2.08 
38.0 ±2.11 
Soecific Activity (uiiits/m£) 
% Change 
0 
+ 72* 
+ 8 
0 
+ 67* 
+ 16^  
CO 
12.7 ±1.03 
22.0 ±1.35 
13.3 ±0.99 
12.0 ±0.78 
19.7 ±1.55 
13.8 ± 1.27 
% Change 
0 
+ 73* 
+ 5 
0 
+ 64* 
+ 15^  
0.15 ^g protein of both molecular forms of CEH was assayed at the indicated concentrations of 
sodium taurocholate for 10 min. at 3TC. Values are mean ± SD of determinations in triplicate. 
Significantly different from respective controls at *p<0.001 and V<0.01. 
demonstrate that the activities of cytosolic CEH, partially purified and purified high 
and low molecular forms of CEH, though activated by taurocholate, are not totally 
dependent on bile salt for the expression of their basal activities. However, the 
degree of activation by taurocholate for purified CE hydrolases, was significantly 
higher, when compared to bile salt-mediated activation of partially purified CE 
hydrolases. 
3.13.2. Effect of temperature: 
As seen in Figure 9, assay of CEH in cytosol, 69 kDa (in 0-40% ASF) and 
45 kDa (in 40-80% ASF) at indicated temperature revealed that the maximum 
activity is obtained at 37°C. Thus, the result demonstrate that die optimal 
temperature for the enzymatic activities of both the forms of CEH is 37°C. 
3.1 J J. Effect ofpHi 
The effect of pH (6.6-8.0) was examined in order to determine the pH 
optima of the cytosolic CEH and partially purified high and low molecular forms of 
CEH. As shown in Figure 10, all the CEH flections had little enzymatic activity 
below pH 7.0. The activity of cytosolic and high (69 kDa) CEH was optimum 
between pH 7.0 and 7.3, whereas, the optimum pH for low molecular form, 
associated with 40-80% ASF was found to be between pH 7.0 and 7.2. A signi-
ficant decline in CEH activity of cytosol and high molecular weight form (in 0-40% 
ASF) was seen above pH 7.3, whereas, for low molecular weight form of CEH, the 
decline in activity started after pH 7.2. 
3.1.4. Kinetic Properties 
Kinetic parameters of CEH activities in cytosol, 0-40% ASF (69 kDa CEH) 
and 40-80% ASF (45 kDa CEH) were investigated. Figure 11,12 and 13), illustrate 
Lineweaver-Burke plots of enzymatic activity of the three fi-actions with PNP-
palmitate (A) and CO (B) substrates. The apparent K^ and Vmax values for cytosolic 
CEH activity were 28.6 (iM and 0.95 nmole/min, respectively, for PNP-palmitate 
and 12.5 ^M and 0.022 nmole/min, respectively, for CO (Figure 11,A and B). The 
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FIG. 9. EFFECT OF TEMPERATURE ON THE ENZYMATIC ACTIVITIES 
OF CEH IN CYTOSOL, 69 KDa CEH IN 0-40% ASF AND 45 KDa CEH 
IN 40-80% ASF. 
100 ng of cytosol (—o—), 50 ng of 0-40% ASF (—•—) and 400 ng of 
40-80% ASF (—A—) were assayed, at indicated temperature, as described 
in experimental procedures. Each value represents the mean of 
triplicate determinations. The average error on the data points was ±8%. 
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FIG. 10. EFFECT OF pH ON THE ENZYMATIC ACTIVITIES OF CEH IN 
CYTOSOL, 0-40% ASF CONTAINING HIGH (69 KDa) MOLECULAR 
FORM AND 40-80% ASF CONTAINING LOW (45 KDa) MOLECULAR 
FORM OF CEH. 
100 ng of cytosol (—o—), 50 ^g of 0-40% ASF (—•—) and 400 ^g 
of 40-80% ASF (—^—) were incubated In assay buffer containing 
0.1M Tris-HCI at the indicated pH, and the CEH activity was detennined 
as described in the experimental procedures. Each value represents the 
mean of triplicate determinations. The averse enror on the data points 
was mean ± 7.5%. 
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FIG. 11. DETERMINATION OF Km OF CYTOSOLIC CEH ASSAYED AT 
INCREASING CONCENTRATIONS OF PNP-PALMITATE(PNPP) 
[PANEL A] AND CHOLESTERYL OLEATE (CO)[PANEL B], 
100 nQ and 200 ^g of cytosol was assayed with the increasing con-
centrations of PNPP [A] for 10 min. and CO [B] for 30 min., respec-
tively. Each value represents the mean of two experiments carried 
out in triplicate. The average error on the data points was mean ± 
10.1 % and 11.7% for [A] and [B], respectively. 
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FIG. 12. DETERMINATION OF Km OF CYTOSOLIC 69 KDa CEH ASSAYED 
AT INCREASING CONCENTRATIONS OF PNP-PALMITATE(PNPP) 
[PANEL A] AND CHOLESTERYL OLEATE {CO)[PANEL B]. 
50 ng and 200 )ig of 0-40% ASF was assayed with the increasing con-
centrations of PNPP [A] for 10 min. and CO [B] for 30 min., respectively. 
Each value represents the mean of two experiments carried out in tripli-
cate. The average error on the data points was mean ± 13.5% and 17.8% 
for (A) and (B), respectively. 
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FIG. 13. DETERMINATION OF Km OF CYTOSOLIC 45 KDa GEH ACTIVITY 
ASSAYED AT INCREASING CONCENTRATIONS OF PNP-PALMITATE 
(PNPP )[PANEL A] AND CHOLESTERYL OLEATE (CO) [PANEL B]. 
400 ng protein of 40-80% ASF was assayed with the increasing concen-
trations of PNPP [A] for 10 min. and CO [B] for 30 min., respectively. 
Each value represents the mean of two experiments carried out in 
triplicate. The average error on the data points was mean ± 9.2% and 
14.0%, for [A) and [B], respectively. 
K,„ and V„ax values of partially purified 69 kDa CEH, associated with 0-40% ASF, 
were 24.5 i^M and 0.13 nmole/min, respectively, for PNP-palmitate and 11.1 |iM 
and 0.04 nmole/min, respectively, for CO (Figure 12,A and B). The low molecular 
form of CEH, present in 40-80% ASF, exhibited apparent Kn, and Waax. values of 
30.8 )iM and 0.08 nmole/min, respectively, for PNP-pahnitate and 14.3 ^M and 
0.009 nmole/min, respectively, with regard to CO (Figure 13,A and B). 
3.1.5. Modulators of Rat Liver Cvtosolic CE JHvdrolases 
3.1.5.1. Effect of Mn^* and Mg^^: 
As depicted in Figure 14,A, Mn^ "^  mediated the activation of cytosolic and 
partially purified 69 kDa CEH in a concentration-dependent manner with an 
optimal activation of 145% and 161%, respectively, at 5 mM. At 2 mM, N4n^ * 
caused an increase of 124% and 131% in the enzymatic activities of cytosolic and 
69 kDa CEH, respectively, whereas, at 7.5 mM Mn^ ^ concentration, die activation 
of CEH was reduced to 116% and 119%, respectively. A fiirdier increase in Mn^ "^  
concentration (10-20 mM), failed to fiuther block die CEH activation to any 
significant level (Figm e^ 14,A). Preincubation of 40-80% ASF (containing 45 kDa 
CEH) with Mn caused a significant activation of 24% at 5 mM, which remained 
essentially unchanged upto 20 mM Mn^^ . 
As seen in Figure 14,B, like Mn^ ,^ preincubation of cytosol, 0-40% ASF 
(containmg 69 kDa CEH) and 40-80% ASF (containing 45 kDa CEH) with Mg '^ 
caused an activation of cytosolic and 69 kDa CEH in a concentration-dependent 
manner. However, 45 kDa CEH activity remained essentially unaffected at the 
indicated concentrations of Mg^ .^ At 5 mM Mg^ ,^ the CEH activities of both the 
cytosol and 0-40% ASF exhibited a maximal increase of 61% and 71%, 
respectively. The bulk of CEH activation (-80%) for cytosohc and partially 
purified 69 kDa CEH was achieved at 2 mM Mg^^ Higher levels of Mg "^ (7.5-
20 mM) consistently reduced the CEH activation and at 10 mM Mg^\ 90% of the 
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FIG. 14. EFFECT OF Mn2+ (PANEL A) AND Mg2+ (PANEL B) ON THE 
ENZYMATIC ACTIVITIES OF CEH IN CYTOSOL, 69 KDa CEH IN 
0-40% ASF AND 45 KDa CEH IN 40-80% ASF. 
100 ^g cytosol (^o—), 50 ^g 0-40% ASF (—•—) and 400 ng 40-80% 
ASF i—^—) were preincubated with indicated concentrations of MnCI 
2 
or MgCl for 20 min. and the CEH activity was detemnined as described 
in experimental procedures. Each value represents the mean ± SD of 
triplicate determinations of two separate experiments. The absolute value 
for respective 100% CEH activities (units/mg) for A and B are: Cytosol, 
1.09 and 1.12; 0-40% ASF, 2.27 and 2.30 ; 40-80% ASF, 0.28 and 0.29. 
activation was blocked. At 15 and 20 mM Mg^ ,^ the inactivation level of CEH 
remained unchanged (Figure 14,B)-
Since activating effect of Mn^ "^  on the CEH activities was considerably 
higher than Mg^ ,^ and at higher concentrations (7.5-20 mM), activation caused by 
5 mM Mn^ "^  was only partially blocked, we investigated the possible mechanism of 
differential effects of these two cations. Data presented in Table 8 demonstrate that 
a 20 min. preincubation of partially purified 69 kDa CEH (0-40% ASF) with 5 mM 
Mn^ * followed by 10 min. incubation, resulted in 159% activation. This Mn '^ 
mediated activating effect was reduced to 96% when Mn^ * was present only during 
10 min. incubation. Furthermore, when 0-40% ASF was preincubated for 20 min. 
witii 5 mM Mn^ ^ followed by an addition of 20 mM EDTA and an incubation for 
10 min., the activating effect of Mn^ ^ was reduced to 32%. This activation was 
similar to control value of 38%, when 20 mM EDTA was added alongwith 5 mM 
Mn^ ,^ at the start of preincubation (Table 8). These results demonstrate that bulk of 
activating effect of Mn^ * on CEH is time independent, does not require any 
preincubation in order to modify CEH involving endogenous cofactors and appears 
to directly affect the hydrolysis of substrate by CEH during 10 min. incubation. 
Based on these results, the Mg^ "^  mediated activation of CEH in cytosol and 0-40% 
ASF, which appears to involve endogenous ATP and cAMP-dependent protein 
kinase (PKA), was reinvestigated. The data summarized in Table 8 revealed that 
treatment of CEH in 0-40% ASF with 5 mM Mg^' during 20 min. preincubation 
and 10 min. incubation or during 20 min. preincubation only, resulted in a 70% and 
63% activation of CEH, respectively, in comparison to control CEH value of 35% 
when 20 mM EDTA was added alongwith Mg^ " at the start of preincubation. 
Addition of 5 mM Mg^ ^ during 10 min. incubation only increased the CEH activity 
by approximately 27%. These results indicate that unlike Mn^ ,^ the activating effect 
of Mg ^ on CEH is time dependent, requires 20 min. preincubation to fully activate 
the CEH enzyme, which is apparently mediated by endogenous phosphorylating 
agents including PKA, involving activation (phosphorylation) of partially purified 
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TABLE 8 
IN VITRO MODULATION OF ENZYMATIC ACTIVITY OF PARTIALLY 
PURIFIED 69 kDa CEH ACTIVITY BY MANGANESE (Mn^^ AND MAGNESIUM 
Additions Preincubation Incubation CEH Activity % Change From 
(units/mg) Control (no ligand) 
None 
.2+ Mn'% 5 mM 
Mn^\ 5 mM 
Mn^ % 5 mM 
Mn'^ 5 mM 
Mg^^ 5 mM 
Mg'^ 5 mM 
Mg^ % 5 mM 
Mg^\ 5 mM 
+ 
+ 
+ 
-** 
_** 
+ 
+ 
• * * 
_** 
2.79 ± 0.10 
7.24 ± 0.28 
5.48 ± 0.17 
3.67 ± 0.33 
3.86 ± 0.10 
4.75 ± 0.25 
3.55 ± 0.26 
4.56 ± 0.13 
3.78 ± 0.13 
0 
+159* 
+96* 
+32* 
+38* 
+70* 
+27* 
^^3* 
+35* 
100 ^ g protein of 0-40% ASF was preincubated for 20 min. at 37'C with indicated ligands and 
CEH activity was determined after incubation for 10 min. at 3T'C as described in eiperimental 
procedures. Each value represents the mean ± SD of triplicate determinations. 
* Signifies that the ligand was not present during preincubation. 
** Signifies that Mn^ * or Mg^ * was chelated by the addition of 20 mM EDTA during 
preincubation and/or incubation. 
Significantly different fi'om respective controls at *p<0.001. 
CEH. The different effects of Mn^ "^  and Mg^ "^  on CEH activity was consistent with 
the Vmax and K^ values obtained in the presence of each cation. A Vmax value of 
0.24 and .018 nmole/min. and a Km value of 22.0 and 13.3 |jiM was obtained for 
CEH in presence of Mn^ * and Mg^^ , respectively, when compared to control values 
of 0.13 nmole/min. and 24.5 |iM obtained in absence of Mg^ "^  or Mn^ ^ (Figure 15 
and 16). 
3.1.5.2. Effect of A TP and Mg-A TP: 
As shown in Figure 17,A, preincubation of ATP with cytosol and partially 
purified 69 kDa flection of CEH was associated with a concentration dependent 
increase in CEH activity, with an optimal activation of 95% and 105% at 3 mM 
ATP. Addition of 4.5 mM ATP completely blocked this activation of CEH, 
whereas, 6 mM ATP not only completely blocked the activation but also inhibited 
basal en2yme activity by 95% and 86%, respectively. At 10 mM ATP, the basal 
CEH activity was completely inhibited. No change in CEH activity of 45 kDa 
molecular form was seen in the presence of ATP (Figure 17,A). As seen in 
Figure 17,B, the enzyme activity of cytosol and 69 kDa CEH (in 0-40% ASF) were 
significantly enhanced, when complexed Mg-ATP was added. A maximum 
activation by 75% and 105% of cytosol and 69 kDa CEH activity was obtained at 
2 mM Mg-ATP, respectively. Higher levels of Mg-ATP (3-5 mM) consistently 
reduced this activation and at 5 mM Mg-ATP, more than 95% of the basal activity 
was also inhibited. Mg-ATP had no efifect on the en2yme activity of low (45 kDa) 
molecular form of CEH (Figure 17,B). 
The combined results demonstrate that enzyme activity of newly identified 
low (45 kDa) molecular form of CEH is not subject to in vitro activation-
inactivation cycle. These results indicate that inactivating effect of high levels of 
ATP and Mg-ATP on CEH activation, and almost complete inhibition of the basal 
CEH activity at 5 and 10 mM of ATP and Mg-ATP, might be associated with an 
endogenous Mg-ATP-dependent phosphatase-mediated dephosphorylation (inacti-
vation) of CEH enzyme in cytosol and 0-40% ASF. Activation of such type of 
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FIG. 15. THE EFFECT OF Mn2* ON THE Km OF CYTOSOLIC [PANEL A] AND 
PARTIALLY PURIFIED CYTOSOLIC 69 KDa CEH [PANEL B]. 
[A] 100 ^g of Cytosol, preincubated with 2mM MnCI for 20 min. and was 
assayed at increasing concentrations of PNPP for the detemnination of Km. 
[B] 50 i^Q of 0-40% ASF of cytosol was preincubated with 2mM MnCI for 
20 min. and was assayed at increasing concentrations of PNPP for the 
determination of Km. Each value represents the mean of two experiments 
carried out in triplicate. The average error on the data points was mean ± 
8.9% and 12.0%, for (A) and (B), respectively. 
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FIG. 16. THE IMPACT OF Mg2* ON THE Km OF CYTOSOLIC [PANEL A] AND 
PARTIALLY PURIFIED, CYTOSOLIC 69 KDa CEH [PANEL B]. 
[A] 100 ^g of Cytosol, preincubated with 2mM MgCI for 20 min. and was 
assayed at increasing concentration of PNPP for the determination of Km. 
[B] 50 ^g of 0-40% ASF of cytosol was preincubated with 2mM MgCI for 
20 min. and was assayed at increasing concentration of PNPP for the deter-
mination of Km. Each value represents the mean of two experiments carried 
out in triplicate. The average error on the data points was mean ± 10.2% and 
15.3%, for (A) and (B), respectively. 
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FIG. 17. EFFECT OF ATP (PANEL A) AND Mg-ATP (PANEL B) ON THE 
ENZYMATIC ACTIVITIES OF CEH IN CYTOSOL, 69 KDa CEH 
IN 0-40% ASF AND 45 KDa CEH IN 40-80% ASF. 
lOOngof cytosol(—o—), 50 (xgof 0-40% ASF( • ) and 400 ^g of 
40-80% ASF ( A ) were preincubated with indicated concentrations 
of ATP or Mg-ATP for 20 min. and the CEH activity was detemnined 
as described in experimental procedures. The absolute value for 
100% CEH activities (units/mg) were: Cytosol, 1.23; 0-40% ASF, 2.58; 
40-80% ASF, 0.28. Each value represents the mean of two experi-
ments carried out in triplicate.The average error on the data points 
was mean ± 8.0%. 
phosphatase at high levels of ATP and Mg-ATP will counteract tiie cAMP-
dependent protein Idnase/cAMP and Mg-ATP promoted activation in a similar 
order of potency reducing CEH activity to the control level or even completely 
inactivating the basal CEH activity (Khan, 1999). 
3.1.53. Effect of other divalent metal ions : 
When cytosol, 0-40% ASF (containing 69 kDa CEH) and 40-80% ASF 
(containing 45 kDa CEH) were preincubated with increasing amounts of Fe , Cu , 
Zn^ ,^ Cd^ ,^ Ni^ ,^ Co^ ^ and Hg^^ , a concentration dependent inhibition was observed 
for CEH (Figure 18-21). At 5 mM concentration of Fe^\ Qv^\ Zn^^ Cd^', Ni^^ 
Co^ ^ and Wi\ CEH activities of cytosol, 0-40% ASF and 40-80% ASF were 
inhibited in the range of 60-90%. The degree of inhibition for the enzymatic 
activity of 45 kDa CEH by Cd^ ^ was significantly lower flian cytosolic and 69 kDa 
CEH. At 5 mM Cd^\ inhibition of 45 kDa CEH activity was 52%, whereas, for 
cytosolic and 69 kDa CEH was -83%. However, at higher concentration (15 and 
20 mM) of Cd^ ,^ the extent of inhibition for 45 kDa CEH became similar to 
cytosolic and 69 kDa CEH (Fig. 20,B). Like Cd^ "^ , 10 mM of Co^ ^ caused lesser 
inhibition of 45 kDa CEH enzymatic activity in comparison to cytosolic and 69 kDa 
CEH. These results indicate that inhibition by tiiese metal ions probably reflects a 
general effect of divalent cations. However, preincubation of above CEH fi^actions 
v^th 1-20 mM Ca^ ^ did not produce any significant effect on CEH activity 
(Figure 21,B). 
3.1.5.4. Effect of other modulators : 
Since mevalonolactone (MVL), y-tocotrienol (y-TS), 3-hydroxy-3-methyl-
glutarate (HMG), 7-ketocholesterol and 25-hydroxycholesterol are known to reduce 
in vivo HMG-CoA reductase activity and in turn cholesterol production, the in vitro 
effect of these modulators on en2>'matic activity of cytosolic CEH was investigated. 
Incubation of cytosol with 0.2-1 mM of MVL or HMG failed to influence the CEH 
activity (Figure 22,A). Concentration of 20-100 ^M of y-TB or 7-ketocholesterol or 
25-hydroxycholesterol also did not affect the enzymatic activity of cytosolic CEH 
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FIG. 18. EFFECT OF Fe2+ (PANEL A) AND Cu2+ (PANEL B) ON THE ENZYMATIC 
ACTIVITIES OF CEH IN CYTOSOL, 69 KDa CEH IN 0-40% ASF AND 
45 KDa CEH IN 40-80% ASF. 
100 ng of cytosol (—o—), 50 ^ig of 0-40% ASF ( • ) and 400 ng of 
40-80% ASF ( A ) were preincubated with indicated concentrations 
of FeSO or CuCI for 20 min. and the CEH activity was determined as 
described in experimental procedures. The absolute value of 100% 
activities (units/mg) were: Cytosol, 1.23; 0-40% ASF, 2.58; 40-80% ASF, 
0.29. Values represent the mean of duplicate detenminations. 
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FIG. 19. EFFECT OF Zn2+ (PANEL A) AND Cd2+ (PANEL B) ON THE ENZYMATIC 
ACTIVITIES OF CEH IN CYTOSOL, 69 KDa CEH IN 0-40% ASF AND 
45 KDa CEH IN 40-80% ASF. 
100 ng cytosol (—o- ), 50 ^g 0-40% ASF (—•—) and 400 ^g 40-80% 
ASF ( '> ) were preincubated with indicated concentrations of ZnSO 
or CdCI for 20 min. and the CEH activity was determined as described 
in experimental procedures. The absolute value for 100% CEH activities 
activities (units/mg) for (A) and (B), respectively, were as follows: cytosol, 
1.1 land 1.05; 0-40% ASF, 2.46 and 2.34; 40-80% ASF, 0.29 and 0.31. 
Values represent the mean of duplicate determinations. 
10 
Ni2+ (mM) 
100-
80-
c 
o 
2 60H 
o 
u 
< 
40 
20 
0 -
10 
I 
15 
—T" 
20 
Co2+ (mM) 
FIG. 20. EFFECT OF Ni2+ (PANEL A) AND Co2+ (PANEL B) ON THE ENZYMATIC 
ACTIVITIES OF CEH IN CYTOSOL, 69 KDa CEH IN 0-40% ASF AND 
45 KDa CEH IN 40-80% ASF. 
100 ng of cytosol (—o—), 50 ng of 0-40% ASF ( • ) and 400 ^g of 
40-80% ASF ( '"^  ) were preincubated with indicated concentrations 
of NiSO or CoCI for 20 min. The CEH assay was done as described 
4 2 
in experimental procedures. The absolute value of 100% CEH activities 
(units/mg) for (A) and (B), respectively, were as follows; Cytosol, 0.92 
and 0.86; 0-40% ASF, 1.96 and 1.96; 40-80% ASF, 0.19 and 0.26. Values 
represent the mean of duplicate determinations. 
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FIG. 21. EFFECT OF Hg2+ (PANEL A) AND Ca2+ (PANEL B) ON THE ENZYMATIC 
ACTIVITIES OF CEH IN CYTOSOL, 69 kDa CEH IN 0-40% ASF AND 
45 kDa CEH IN 40-80% ASF. 
100 ^g of cytosol (—o—), 50 ^g of 0-40% ASF (—•—) and 400 ^g of 
40-80% ASF (—^ ~) were preincubated with HgCI or CaCI for 20 min. 
at indicated concentrations. The CEH activity was determined as des-
cribed in experimental procedures. The absolute value for 100% CEH 
activities (units/mg) were: Cytosol, 1.17; 0-40% ASF, 2.46; 40-80% ASF, 
0.28. Values represent the mean of duplicate determinations. 
c 
o O 
o 
'> 
U 
< 
X 
lU 
o 
S 
c 
o O 
% 
i 
> 
"G O 
« 
X 
UJ 
o 
140-
120-
100-
80 
60-
40-
20 -
1 — 
0.0 
140 
120-
100-
80-
60-
40-
20 
B 
0.2 
— I — 
0.4 
— 1 — 
0.6 
—r~ 
0.8 
—r-
1.0 
Effector Concentration (mM) 
—r-
20 
40 60 —r-
80 
100 
Effector Concentration (^M) 
FIG. 22. EFFECT OF MEVALONOLACTONE [MVL], 3-HYDROXY-3-METHYL-
GLUTARIC ACID [HMG] (PANEL A), y-TOCOTRIENOL, 7-KETO-
CHOLESTEROL [7-KETO CHO.] AND 25-HYDROXY CHOLESTEROL 
[25-OH CHO.] (PANEL B) ON THE CEH ACTIVITY OF CYTOSOL. 
100 |ig cytosol was preincubated with MVL (—o—), HMG (—•—), 
y-tocotrienol (—^—), 7-Keto oho. {~^~) and 25-OH oho. i~~°—) for 
20 min. at indicated concentrations and the CEH activity was deter-
mined as described in experimental procedures. The absolute value 
for 100% CEH activity (units/mg) for Cytosol was 1.23. Each value 
represents the mean of triplicate determinations. The average error 
on the data points was mean ± 8.5% and 10.2%, for (A) and (B), 
(Figure 22,B). These results demonstrate that y-T3 and MVL, which are known to 
modulate CEH activity in vivo (Table 13 and 20), failed to affect the enzyme 
activity in vitro. 
3.1.5.5. Effect of PMSF: 
As shown in Figure 23, preincubation of cytosol, 0-40% ASF and 40-80% 
ASF with 50-500 ^M PMSF for 16 h at 4°C resulted in inhibition of CEH activities 
in a dose-dependent manner. A maximum inhibition of 95% was obtained at 
450 p.M PMSF for tiie CEH activities associated with the tiiree enzyme fractions. 
Fractions of 69 kDa CEH (in 0-40% ASF) and 45 kDa CEH (in 40-80% ASF), after 
further purification by gel permeation HPLC, were preincubated with increasing 
concentrations of PMSF (25-250 nM) for 16 h at 4*'C which was also associated 
with a strong inhibition of CEH activities. A maximal inhibition (84%) of 69 kDa 
CEH activity was obtained at 125 ^M PMSF, whereas, newly identified 45 kDa 
CEH activity was inhibited maximally (92%) at 225 ^M PMSF (Figure 24). These 
results indicate the presence of serine esterase active site in both the molecular 
forms of CEH. 
3.2. IMMUNOLOGICAL CHARACTERIZATION OF fflGH (69 kDa) 
AND LOW (45 kDa) MOLECULAR FORMS OF NEUTRAL 
CHOLESTERYL ESTER HYDROLASE FROM RAT LIVER 
CYTOSOL 
3.2. L Specificitv of Antiserum and Tissue Cross-reactivity 
Antiserum to rat liver cytosolic CEH (66 kDa) was a generous gift from 
Dr. Shobha Ghosh, Department of Biochemistry, Medical College of Virginia, 
Virginia Commonwealth University, Richmond, Virginia, USA. The antiserum was 
tested for antibodies directed against neutral CEH in cytosol, 0-40% ASF 
containing 69 kDa CEH and 40-80% ASF containing 45 kDa CEH, from rat liver, 
by ELISA as described in experimental procedures. As seen in Figure 25,A and B, a 
strong positive reaction was observed with CEH in rat liver cytosol and 69 kDa 
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FIG. 23. EFFECT OF PMSF ON THE ENZYMATIC ACTIVITIES OF CEH IN 
CYTOSOL, 69 kDa CEH IN 0-40% ASF AND 45 kDa CEH IN 
40-80% ASF. 
100 ng of cytosol (—o—), 50 ^g of 0-40% ASF (—•—) and 400 .^g 
of 40-80% ASF ( '^  ) were preincubated with indicted concentra-
tions of PMSF solution in ethanol, for 16 h at 4 oC, followed by 2 min. 
preincubation at 37 oC prior to CEH activity assay. The absolute value 
for 100% CEH activities (units/mg) were: Cytosol, 1.20; 0-40% ASF, 2.52; 
40-80% ASF, 0.34. Each value represents the mean of triplicate determin-
ations. The average error on the data points was mean ± 7.4%. 
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FIG. 24. EFFECT OF PMSF ON THE PARTIALLY PURIFIED 69 kDa AND 
45 kDa CEH ENZYMATIC ACTIVITIES. 
69 kDa in 0-40% ASF (—o—) and 45 kDa in 40-80% ASF ( • ) 
were partially purified by gel pemneation HPLC on a Supeico G3000 
SWXL, TSKgel column. 4 ^g of 69 kDa and 3 ^g of 45 kDa partially 
purified fractions were preincubated at indicated concentrations of 
PMSF solution in ethanol for 16 h at 4 °C. The samples were prein-
cubated for 2 min. at 37 °C followed by assay of activity. The 
absolute value for 100% activities (units/mg) for partially purified 
69 kDa and 45 kDa CEH were 10.32 and 4.05, respectively. Each 
value represents the mean of triplicate determinations. The average 
enror on the data points was mean ± 6.4%. 
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FIG. 25. CROSSREACTIVITY OF PROTEINS FROM RAT LIVER CYTOSOL (PANEL A), 
0-40% ASF (PANEL B), 40-80% ASF (PANEL 0), RAT PANCREATIC CYTOSOL 
(PANEL D) AND RAT BRAIN CYTOSOL (PANEL E) WITH POLYCLONAL ANTI-
BODIES TO RAT LIVER CEH. 
Indicated concentrations of proteins from above fractions were quantified for imm-
uno-reactive CEH mass by ELISA, as described in experimental procedures. Each 
data point is the mean of triplicate determinations and the average error on the data 
points was 13%, 15%, 11%, 9% and 18%, for (A), (B), (C), (D) and (E), respectively. 
CEH fractionated in 0-40% ASF. However, a weak reaction was observed with 
cytosolic low (45 kDa) molecular form of CEH (Figure 25,C). The level of cross-
reactivity of anti-rat hepatic CEH (high molecular form) with newly discovered rat 
liver cytosolic low (45 kDa) molecular form of CEH was 5% as compared to cross-
reactivity with cytosolic 69 kDa CEH. Similar results were obtained by western 
blot analysis for CEH in cytosol, 0-40% ASF and 40-80% ASF. As shown in 
Figure 26, a positive reaction was observed with 69 kDa CEH present in cytosol 
(Lane 3) and 0-40% ASF of cytosol (Lane 1). In contrast, the cross-reactivity of 
anti-rat liver CEH (high molecular form) antiserum with 45 kDa CEH, associated 
with cytosol (Lane 3) and 40-80% ASF of cytosol (Lane 2), was quite weak. The 
combined results confirmed the specificity of polyclonal antibodies raised against 
high molecular form of CEH and surest Aat tiiis enzyme is immunologically 
different from other proteins in rat liver cytosol. The results also demonstrate that 
antibodies raised against rat liver cytosolic CEH is specific to 69 kDa CEH protein 
present in cytosol. In addition, a weak cross-reactivity of these antibodies with 
newly identified low (45 kDa) molecular form of CEH surest that this enzyme is 
immunologically different from 69 kDa CEH. 
Cross-reactivity of anti-rat hepatic CEH antiserum with cytosolic fraction of 
pancreas and brain was also probed by ELISA. As seen in Figure 25,D, similar to 
rat liver cytosolic 45 kDa CEH in 40-80% ASF, a positive but weak reaction with 
cytosolic CEH of pancreas was observed, whereas, no reaction was observed with 
brain cytosolic CEH (Figure 25,E). 
Anti-rat pancreatic CEH IgG fraction (a gift from Dr. L. L. Gallo, Depart-
ment of Biochemistry, George Washington University, Washington D.C., USA) 
was tested for immunocross-reactivity with liver cytosol (containing both molecular 
forms of CEH), 69 kDa CEH present in 0-40% ASF and 45 kDa CEH in 40-80% 
ASF, by ELISA and western blot analysis. The level of cross-reactivity of the IgG 
with 45 kDa CEH (in 40-80% ASF) was more than five fold higher than the cross-
reactivity with 69 kDa CEH (in 0-40% ASF). Cross-reactivity of anti-rat pancreatic 
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FIG. 26. WESTERN BLOT ANALYSIS OF RAT LIVER CEH IN CYTOSOL, 0-40% 
ASF AND 40-80% ASF OF CYTOSOL USING ANTI-RAT LIVER CEH 
ANTISERUM. 
20 ^g protein each of 0-40% ASF (lane 1), 40-80% ASF (lane 2) and cytosol 
(lane 3) were separated by SDS-PAGE, and probed with anti-rat liver CEH 
antiserum, by western blot analysis, as described in experimental procedures. 
CEH IgG revealed about five fold higher reaction with cytosolic CEH fi-om 
pancreas (Figure 27,D), in comparison to 45 kDa CEH associated with 40-80% 
ASF of rat liver cytosol (Figure 27,C). No reaction was observed with cytosolic 
CEH of rat brain (Figure 27,E). A similar positive cross-reactivity with 45 kDa 
CEH, associated with 40-80% ASF, was observed on western blot analysis. A 
positive but weak reaction was observed with 69 kDa CEH in cytosol and 0-40% 
ASF (Figure 27,A and B). The combined results indicate that rat liver cytosolic 
69 kDa CEH and 45 kDa CEH are different enzyme proteins. In addition, a strong 
cross-reactivity of 45 kDa CEH with anti-rat pancreatic CEH IgG suggests a 
structural similarity of this enzyme with pancreatic CEH. In contrast, a relatively 
weak immunoreaction of rat liver cytosolic high (69 kDa) molecular form of CEH 
with anti-rat pancreatic IgG indicates its structural and immunological dissimilarity 
with pancreatic CEH. 
3.2.2. Imnmno-cross-reactivity of Piirified Rat Liver Cytosolic 69 kPa and 
45 kDa CEH and Commercial Purified CE Hydrolases from Rabbit 
Liven Porcine Liven Bovine Pancreas and Psendomonas with Anti-Rat 
Liver Cytosolic CEH Antiserum and Anti-Rat Pancreatic CEH IgG 
As shown in Figure 28, western blot analysis of purified 69 kDa CEH and 
45 kDa CEH with anti-rat liver CEH antiserum revealed a strong positive reaction 
with purified 69 kDa CEH (Lane 5), whereas, a weak band was observed with 
purified 45 kDa CEH (Lane 6). Immuno-cross-reactivity was also tested for purified 
commercial CE hydrolases fi-om rabbit liver, porcine liver, bovine pancreas and 
pseudomonas, by western blot analysis. A positive reaction was observed witii CEH 
fi-om rabbit liver (Lane 2) and porcine liver (Lane 1), whereas, a positive but weak 
reaction was observed with bovine pancreatic CEH (Lane 3). No reaction was 
observed with CEH from pseudomonas (Lane 4). Figure 29 depicts the results 
obtained with purified rat liver cytosolic 69 kDa CEH (Panel A), rat liver cytosolic 
45 kDa CEH (Panel B), purified esterases from rabbit liver (Panel C), porcine liver 
(Panel D), bovine pancreas (Panel E) and pseudomonas (Panel F), by using ELISA 
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FIG. 27. CROSSREACTIVITY OF PROTEINS FROM RAT LIVER CYTOSOL (PANEL A), 
0-40% ASF (PANEL B), 40-80% ASF (PANEL C), RAT PANCREATIC CYTOSOL 
(PANEL D) AND RAT BRAIN CYTOSOL (PANEL E) WITH POLYCLONAL ANTI-
BODIES TO RAT PANCREATIC CEH. 
Indicated concentrations of proteins from above fractions were quantified for imm-
uno-reactive CEH mass by ELISA, as described in experimental procedures. Each 
data point is the mean of triplicate determinations and the average error on the data 
points was 12%, 15%, 14%, 12% and 17%, for (A), (B), (C), (D) and (E), respectively. 
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FIG. 28. WESTERN BLOT ANALYSIS OF PURIFIED CE HYDROLASES FROM 
RAT LIVER, RABBIT LIVER, PORCINE LIVER, BOVINE PANCREAS 
AND PSEUDOMONAS, USING ANTI-RAT LIVER CEH ANTIISERUM. 
SDS-PAGE of purified porcine liver CEH (2 ^g) (lane 1), rabbit liver 
CEH (2 ^g) (lane 2), bovine pancreatic CEH (4 .^g) (lane 3), CEH from 
pseudomonas (4 ng) (lane 4), rat liver 69 kDa CEH (2 ^g) (lane 5) and 
rat liver 45 kDa CEH (4 ^g) (lane 6), was performed and western blots 
were developed by using anti-rat liver CEH antiserum, as described in 
experimental procedures. 
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FIG. 29. CROSSREACTIVITY OF PURIFIED RAT LIVER CYTOSOLIC 69 kDa CEH 
(PANEL A). RAT LIVER CYTOSOLIC 45 kDa CEH (PANEL B), RABBIT 
LIVER CEH (PANEL C), PORCINE LIVER CEH (PANEL D) BOVINE PAN-
CREATIC CEH (PANEL E) AND CEH FROM PSEUDOMONAS (PANEL F) 
WITH POLYCLONAL ANTIBODIES TO RAT LIVER CEH. 
Indicated concentrations of the purified proteins were probed for cross-reac-
tivity with anti-liver CEH antiserum, by ELISA, as described in experimental 
procedures. Each data point is the mean of triplicate determinations and the 
average en-or on the data points was 14%, 17%, 9%, 12%, 10% and 15%, 
for (A), (B). (C), (D), (E) and (F), respectively. 
involving anti-rat liver CEH antiserum. The level of cross-reactivity for the above 
esterases was consistent with the results observed from western blot analysis. In 
comparison to purified rat liver cytosolic 69 kDa CEH, the magnitude of cross-
reactivity of anti-rat liver CEH antiserum witii purified rat hver cytosolic 45 kDa 
CEH was -9%, whereas, the cross-reactivity levels of esterases from rabbit liver, 
porcine liver and bovine pancreas were 58%, 42% and 5%, respectively. No 
reaction was observed with CEH from pseudomonas. The combined results 
demonstrate tiiat the specificity of anti-rat liver CEH antiserum towards purified rat 
liver cytosolic 69 kDa and 45 kDa CEH is consistent with the results obtained with 
partially purified 69 kDa and 45 kDa CEH associated with 0-40% ASF and 40-80% 
ASF, respectively. The results provide ftuther evidence tiiat the predominant CEH 
isoform of rat liver (69 kDa), rabbit liver (62 kDa)and porcine liver (59 kDa) are 
similar enzymes, whereas, the newly identified (45 kDa), minor CEH isoform of rat 
liver cytosol and bovine pancreatic CEH (56 kDa) are different enzymes in 
comparison to 69 kDa CEH of rat liver cytosol. 
Immuno-cross-reactivity of anti-rat pancreatic CEH IgG was also tested with 
purified 69 kDa and 45 kDa CEH from rat liver cytosol, esterases from rabbit liver, 
porcine liver, bovine pancreas and pseudomonas by western blot and ELISA. 
As seen in Figure 30, in western blot analysis, a positive and strong reaction 
was observed with purified rat liver cytosolic 45 kDa CEH (Lane 6) and bovine 
pancreatic CEH (Lane 3). Faint bands indicating a weak immuno-reaction were 
observed for rat liver cytosolic 69 kDa CEH (Lane 5), rabbit liver CEH (Lane 2) 
and porcine liver CEH (Lane 1). Consistent with earher results, no reaction was 
observed with CEH from pseudomonas (Lane 4). Level of cross-reactivity of anti-
rat pancreatic CEH IgG toward these esterases, obtained with ELISA, was similar 
to results by western blot analysis. As shown in Figure 31, the cross-reactivity of 
anti-rat pancreatic IgG with bovine pancreatic CEH (Panel A) and newly identified 
rat liver cytosolic 45 kDa CEH (Panel B) was similar. However, the cross-reactivity 
with esterases from rat liver cytosol (69 kDa, Panel C), rabbit liver (Panel D) and 
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FIG. 30. WESTERN BLOT ANALYSIS OF PURIFIED CE HYDROLASES FROM 
RAT LIVER, RABBIT LIVER, PORCINE LIVER, BOVINE PANCREAS 
AND PSEUDOMONAS, USING ANTI-RAT PANCREATIC CEH IgG. 
SDS-PAGE of purified porcine liver CEH (4 ^g) (lane 1), rabbit liver 
CEH (4 ^g) (lane 2), bovine pancreatic CEH (2 )ig) (lane 3), CEH from 
pseudomonas (4 ^g) (lane 4), rat liver 69 kDa CEH (2 ng) (lane 5) and 
liver 45 kDa CEH (2 ng) (lane 6), was performed and probed with 
anti-rat pancreatic CEH IgG, by western blot analysis, as described in 
experimental procedures. 
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FIG. 31. CROSSREACTIVITY OF PURIFIED BOVINE PANCREATIC CEH (PANEL A) 
RAT LIVER CYTOSOLIC 45 kDa CEH (PANEL B), RAT LIVER CYTOSOLIC 
69 kDa CEH (PANEL C), RABBIT LIVER CEH (PANEL D) PORCINE LIVER 
CEH (PANEL E), AND CEH FROM PSEUDOMONAS (PANEL F) WITH 
POLYCLONAL ANTIBODIES TO RAT PANCREATIC CEH. 
Indicated concentrations of the purified proteins were probed for cross-reactivity 
with anti-pancreatic CEH IgG, by ELISA, as described in experimental procedures. 
Each data point is the mean of triplicate detemninations and the average error on 
the data points was 10%, 8%, 13%, 12%, 18% and 15%, for (A), (B), (C), (D). (E) 
and (F), respectively. 
porcine liver (Panel E) was well below 10% in comparison to reactivity with bovine 
pancreatic CEH. As expected, no cross-reactivity was observed with CEH from 
pseudomonas (Panel F). The combined results demonstrate that predominant 
cytosolic CEH isoforms of rat liver and pancreas are different proteins, whereas, 
newly identified 45 kDa CEH from rat liver cytosol and CEH from rat pancreatic 
cytosol are similar proteins. These results also indicate a high degree of homology 
between rat and bovine pancreatic CEH proteins. Furthermore, the results are 
suggestive of a quite high homology among cytosolic CE hydrolases of rat 
(69 kDa), rabbit (62 kDa) and porcine (59 kDa) liver. 
33. REGULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS 
OF HIGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CYTOSOLIC CEH UNDER DIFFERENT PHYSIOLOGICAL PER-
TURBATIONS IN RATS 
The results described below underline the changes in the activity and protein 
mass of tile two molecular forms of CEH in rat liver under the conditions which are 
known to alter the cholesterol flux through the liver. 
33.1. Effect of Cholesterol and Saturated Fat Rich Diet 
It has been well established that feeding of cholesterol and fat rich to rats 
drastically inhibits its own synthesis at the level of rate-controlling enzyme, HMG-
CoA reductase, by negative feed-back. Since any change in liver cholesterol pool 
may effect the CEH enzyme activity, we have investigated the impact of cholesterol 
and fat rich diet on CEH in rats. 
As seen in Table 9, feeding of an atherogenic diet, AD (1% cholesterol, 5% 
saturated fat and 0.5% cholic acid) to rats for three weeks was associated with a 
decline of 23% and 19% in the activity of cytosolic and 69 kDa (in 0-40% ASF) 
CEH. The activity of 45 kDa (in 40-80% ASF) CEH remained unaffected. The 
protein mass of 69 kDa form of CEH showed a significant decrease of 11% in HLP 
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TABLE 9 
REGULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOLIC fflGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN HYPERUPIDEMIC RATS AFTER 5 AND 8 DAYS OF WITHDRAWAL 
OF ATHEROGENIC DIET 
Group/Fraction Specific Activity % Change Protein Mass % Change 
(units/mg) fromNLP-C (ng/mg) from NLP-C 
NLP-C 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-C 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-UCl 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-U 2 
Cytosol 
0-40% ASF 
40-80% ASF 
0.86 ± 0.08 
1.72 ± 0.19 
0.193 ± 0.082 
0.66 ± 0.09 
1.39 ± 0.09 
0.200 ± 0.015 
0.77 ± 0.06 
1.57 ± 0.05 
0.216 ± 0.069 
0.83 ± 0.02 
1.57 ± 0.08 
0.214 ± 0.107 
0 
0 
0 
-23^ 
-19^ 
+ 4 
-10^ 
-9^ 
+ 8 
- 3 
- 9 
+ 7 
-
109 ±12 
30 ±1.7 
-
97 ±07 
31 ± 2.2 
-
100 ±17 
32 ± 3.7 
-
104 ± 12 
32 ± 3.1 
-
0 
0 
-
-11^ 
+ 03 
-
- 8 
+ 7 
-
- 5 
+ 7 
100 ^g, 50 ^g and 400 ^g protem of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 3TC. Protein mass of CEH was 
determined by ELISA as described in experimental procedures. Values are mean ± SD of two 
separate determinations in triplicate. 
Significantly different from respective controls at V'^-Ol and 'p<0.05. 
NLP-C, NormoUpidemic Control; HLP-C, Hyperlipidemic Control; HLP-D 1, Hyperlipide-
mic Untreated (5 days); HLP-U 2, Hyperlipidemic Untreated (8 days). 
rats as compared to NLP control rats. No significant change was observed in the 
protein mass of 45 kDa CEH (Table 9). 
Impact of hyperlipidemia on enzyme activity and protein mass of cytosolic 
CEH was investigated in rats after 5 and 8 days of withdrawal of cholesterol and fat 
rich diet (AD). The results presented in Table 9 demonstrate that in HLP rats, 
5 days after the withdrawal of AD, en2yme activity of cytosolic CEH and 69 kDa 
CEH inhibition were significantly reduced to 10% and 9%, respectively, from the 
initial level of 23% and 19% CEH activity inhibition exhibited at the end of 3 week 
feeding of AD as compared to NLP control values (Table 9). No decrease in the 
CEH activity and protein mass of 45 kDa form was observed. The decline in 
immunoreactive protein mass of 69 kDa CEH was reversed, when compared to a 
significant reduction of 11% in 69 kDa CEH mass after 3 week feeding of AD. 
After 8 days of withdrawal of AD, CEH activity levels were increased to a level 
similar to values shown in NLP control rats (Table 9). Consistent witii CEH activity 
levels, no change was seen in protein mass of 69 kDa CEH. As expected, enzyme 
activity and protein mass of 45 kDa CEH was not affected. These results are 
consistent with previously published reports that feeding of cholesterol and 
saturated fat to rats, down-regulates the enzyme activity of cytosolic high (69 kDa) 
molecular form of CEH. Furthermore, 8 days after the withdrawal of AD, the 
69 kDa CEH enzymatic activity and protein mass were restored to normal levels. 
The enzyme activity and protein mass of newly discovered 45 kDa form of CEH 
was not regulated in experimental hyperlipidemia in rats. The combined results 
suggest that reduction in the protein mass of 69 kDa CEH may be partially 
responsible for cholesterol-mediated down-regulation of enzyme activity of 69 kDa 
CEH. 
In another experiment, ingestion of cholesterol and fat rich diet to rats for 
3 weeks was associated with a significant decline of 21% in the activit>' of partially 
purified 69 kDa CEH - responsible for the hydrolysis of stored esterified 
cholesterol. The immunoreactive protein mass of 69 kDa CEH was significantly 
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reduced by 10% (Table 10 and 11). Hepatic HMG-CoA reductase activity was 
severely inhibited (75%) in HLP rats as compared to NLP control. Immunoreactive 
HMG-CoA reductase protein mass was also significantly reduced (67%). 
Consistent with these results, hepatic levels of total cholesterol (TC), esterfied 
cholesterol (EC) and free cholesterol (FC) were significantly increased by 198%, 
249% and 88%, respectively in HLP rats in comparison to NLP control rats 
(Table 12). Eight days after the withdrawal of AD, the CEH inhibition was reUeved 
and enzyme activity along with CEH protein mass levels returned to normal control 
levels. In a similar fashion, bulk of HMG-CoA reductase activity inhibition was 
relieved and reduced to 27% in comparison to CEH activity of NLP-C rats. 
Similarly, 8 days after the withdrawal of AD, HMG-CoA reductase protein mass 
level was elevated and percent decline was only 25 (Table 10 and 11). After 8 days 
of withdrawal of AD, hepatic TC, EC and FC levels were significantly reduced by 
52%, 59% and 24%, as compared to HLP control rats (Table 12). These results 
demonstrate that feeding of a cholesterol-fat rich diet to rats was associated with a 
mailced increase in hepatic TC level accompanied with a severe inhibition of HMG-
CoA reductase activity and protein mass followed by a moderate degree of down-
regulation in enzyme activity and protein mass of 69 kDa CEH. Eight days after the 
withdrawal of AD, enzymatic activity and protein mass of CEH were restored to 
normal levels, whereas the levels of hepatic TC, HMG-CoA reductase activity and 
protein mass were close to normal values. 
33.2. In Vivo Modulation of CEH Activities in Normolipidemic and Hyper-
lipidemic Rats Treated with Tocotrienol Rich Fraction (TRF) 
Tocotrienols, present in TRF, have been shown to be powerfiil hypo-
cholesterolemic agents in normal and hyperlipidemic animal and human models. 
The tocotrienols are highly effective in lowering total blood cholesterol and LDL-
cholesterol, apparently by reducing HMG-CoA reductase - the rate limiting enzyme 
in the biosynthetic pathway of cholesterol (Parker et al., 1993). Therefore, the role 
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TABLE 10 
REGULATION OF ENZYMATIC ACTIVmES OF LIVER CYTOSOLIC fflGH 
(69 kDa) MOLECULAR FORM OF CEH AND MICROSOMAL HMG-CoA 
REDUCTASE IN NORMAL AND HYPERLIPIDEMIC RATS TREATED WITH 
TRFFOR8DAYS 
Enzyme 
69 kDa CEH 
(0-40% ASF) 
HMG-CoA 
Reductase 
(SolubUized) 
Experimental 
Group 
NLP-C 
HLP-C 
HLP-UC 
HLP-T 
NLP-C 
HLP-C 
HLP-UC 
HLP-T 
Specific Activity 
(units/mg) 
2.59 ± 0.25 
2.05 ±0.17 
2.56 ± 0.28 
1.93 ± 0.20 
7.88 ± 0.20 
1.97 ± 0.19 
5.74 ± 0.22 
2.23 ± 0.12 
% 
NLP-C 
0 
-21* 
- 1 
-25* 
0 
-75* 
-27^ 
-72* 
Chanee from 
HLP-C 
-
0 
+ 25* 
- 6 
-
0 
+ 191* 
+ 13 
1 
HLP-UC 
. 
-
0 
-25* 
-
-
0 
-61* 
50 ^g of 0-40% ASF (for 69 kDa CEH) was assayed for 10 min. at 3rC. 100 ^g protein of 
solubilized fraction from microsomes was used for the assay of HMG-CoA reductase activity, 
as described in experimental procedures. Values are mean ± SD of two separate determina-
tions in triplicate. 
Significantly different from respective controls at *p<0.001 and^p<0.01. 
NLP-C, Normolipidemic Control; HLP-C, Hyperlipidemic Control; HLP-UC, Hyperlipi-
demic Untreated Control; HLP-T, Hyperlipidemic Treated (12 mg TRF/day). 
TABLE 11 
REGULATION OF ENZYME PROTEIN MASS OF LIVER CYTOSOLIC HIGH 
(69 kDa) MOLECULAR FORM OF CEH AND MICROSOMAL HMG-CoA 
REDUCTASE IN NORMAL AND HYFERLIPIDEMIC RATS TREATED WITH 
TRFFOR8DAYS 
Enzyme 
69 kDa CEH 
(0-40% ASF) 
HMG-CoA 
Reductase 
(SolubUized) 
Experimental 
Group 
NLP-C 
HLF-C 
HLP-UC 
HLP-T 
NLP-C 
HLP-C 
HLP-UC 
HLP-T 
Protein Mass 
(ng/mg)* 
106 ±12 
95±11 
104 ±10 
93 ±08 
239 ± 10 
79 ±11 
179 ± 15 
81 ±6 
% 
NLP-C 
0 
-10^ 
-2 
-12* 
0 
-67^ 
-25^ 
-66^ 
Chanee from 
HLP-C 
-
0 
+ 7^  
-2 
-
0 
+ 127* 
-24 
HLP-UC 
-
-
0 
-If 
-
-
0 
-55* 
Protein mass of CEH and HMG-CoA reductase was determined by ELISA as described in 
experimental procedures. 
^Values are mean (ng/mg of cytosolic protein for CEH and ng/mg of microsomal protein for 
EDVIG-CoA reductase) ± SD of two separate determinations in triplicate. 
Significantly difTercnt from respective controls at ^ pO.OOl and V<0.01. 
NLP-C, Normolipidemic Control; HLP-C, Hyperlipidemic Control; HLP-UC, Hyperlipi-
demic Untreated Control; HLP-T, Hyperlipidemic Treated (12 mg TRF/day). 
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of TRF in the modulation of enzymatic activity and protein mass of high (69 kDa) 
and low (45 kDa) molecular foims of CEH in nonnal and hyperlipidemic rats has 
been investigated. 
3 J J. l . TRF treatment to normolipidemic (NLP) rats: 
As seen in Table 13, one week feeding of 100 mg TRF/day to NLP rats 
caused a significant decline of 41% in the CEH activity of cytosol. The decline in 
69 kDa CEH activity associated with 0-40% ASF was 42%, when compared to the 
control value. The activity of low (45 kDa) molecular form of CEH showed no 
significant change in TRF-treated rats. The protein mass of the high (69 kDa) 
molecular form of CEH, associated with 0-40% ASF revealed a significant decrease 
of 13%, whereas, the protein mass of 45 kDa CEH, associated with 40-80% ASF, 
remained unchanged. On the other hand, the activity and protein mass of HMG-
CoA reductase showed a high degree of decline by 55% and 48%, respectively. The 
decline in protein mass of HMG-CoA reductase appears to account for ahnost all 
flie decline in enzymatic activity (Table 13). 
The results demonstrate that feeding of 100 mg TRF/day to NLP rats for one 
week resulted in a significant decrease in the 69 kDa CEH activity and protein 
mass. The enzymatic activity of low (45 kDa) molecular form of CEH remained 
unaffected in TRF-treated rats. 
3 J.2.2. TRF treatment to rats fed an atherogenic diet (AD) : 
Feeding of AD (1% cholesterol, 5% saturated fat and 0.5% cholic acid) to 
rats alongwith 100 mg TRF/day for three weeks resulted in a significant decrease of 
14% in both, cytosolic and 69 kDa (in 0-40% ASF) CEH activities, as compared to 
rats fed with only AD for three weeks. Enzymatic activity of the low (45 kDa) 
molecular form of CEH was not inhibited in the rats fed with AD alongwith TRF 
(Table 14). The protein mass of 69 kDa CEH in the treated rats was reduced 
insignificantly by 7%, whereas, no decline in the protein mass of 45 kDa CEH was 
observed. 
33.23. TRF treatment to hyperlipidemic (HLP) rats : 
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TABLE 13 
IN VIVO MODULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOLIC fflGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH AND MICROSOMAL HMG-CoA REDUCTASE IN RATS FED WITH TRF 
FOR ONE WEEK 
Group/Fraction Specific Activity % Change Protein Mass % Change 
(units/mg) from NLP-C (ng/mg) from NLP-C 
CEH 
NLP-C 
Cytosol 
0-40% ASF 
40-80% ASF 
NLP-T 
Cytosol 
0-40% ASF 
40-80% ASF 
HMG-CoA Reductase 
NLP-C 
NLP-T 
0.83 ± 0.09 
L60 ± 0.25 
0.24 ± 0.071 
0.49 ± 0.04 
0.92 ± 0.08 
0.28 ± 0.025 
7.3 ± 1.2 
3.3 ± 0.8 
0 
0 
0 
-41^ 
-42^ 
+ 7 
0 
-55^ 
-
106 ±11 
34 ± 2.3 
-
92 ±10 
33 ± 3.9 
225 ± 18 
118 ±09 
-
0 
0 
-
-13^ 
+ 9 
0 
-48* 
100 Jig, 50 ^g and 400 jig protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively was assayed for 10 min. at 3TC. 100 ^g protein of solubilized 
fraction from microsomes was used for the assay of HMG-CoA reductase activity. Protein 
mass of CEH and HMG-CoA reductase was determined by ELISA as described in experimen-
tal procedures. Values are mean ± SD of two separate determinations in triplicate. 
Significantly different from respective controls at *p<0.001. 
NLP-C, Nonnolipidemic Control; NLP-T, NormoUpidemic Treated (100 mg TRF/day). 
TABLE 14 
REGULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOUC HIGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN THE RATS GIVEN ATHEROGENIC DIET ALONGWITH TRF 
Group/Fraction 
HLP-C 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-T 
Cytosol 
0-40% ASF 
40-80% ASF 
Specific Activity 
(units/mg) 
0.66 ± 0.09 
1.39 ± 0.09 
0.200 ± 0.015 
0.57 ± 0.10 
1.19 ± 0.09 
0.215 ± 0.016 
% Change 
from HLP-C 
0 
0 
0 
-14^ 
-14^ 
+ 8 
Protein Mass 
(ng/mg) 
-
97 ±07 
31 ± 2.2 
-
90 ±07 
32 ± 1.9 
% Change 
from HLP-C 
-
0 
0 
-
- 7 
+ 3 
100 Kg, 50 \ig and 400 ^g protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 3TC. Protein mass of CEH was 
determined by ELISA as described in experimental procedures. Values are mean ± SD of two 
separate determinations in triplicate. 
Significantly different from respective controls at ^p<0.001 and V<0*01. 
NLP-C, Normolipidemic Control; HLP-T, HyperUpidemic Treated (100 mg TRF/day). 
Experimental hyperlipidemia was induced in rats by AD (1% cholesterol, 
5% saturated fat and 0.5% cholic acid) for three weeks. At the end of three weeks, 
HLP rats were treated with 25 mg and 50 mg TRF/day for 5 and 8 days. When 
compared to saline-fed hyperlipidemic control (HLP-UC), cytosolic CEH activity 
was significantly decreased by 8% at 25 mg TRF and 10% at 50 mg TRF after 
5 days. The enzymatic activity of high (69 kDa) molecular form of CEH showed a 
significant decline of 15% in HLP-Tl and 19% in HLP-T2 (Table 15). Enzymatic 
activity of low (45 kDa) molecular form of CEH, associated with 40-80% ASF, 
showed a reduction of 10% at 25 mg TRF and 12% at 50 mg TRF when compared 
to HLP-UC. However, the decrease was statistically insignificant. No significant 
change in immunoreactive protein mass in either 69 kDa or 45 kDa CEH was 
observed (Table 15). After 8 days of TRF treatment to HLP rats, cytosolic CEH 
activity was reduced by 20% and 16% in HLP-Tl and HLP-T2, respectively. The 
percent decUne in 69 kDa CEH activity at 25 mg and 50 mg TRF was 19 and 15, 
respectively, whereas protein mass of 69 kDa CEH showed a significant reduction 
of 10% and 9% respectively. TRF treatment in HLP-Tl and HLP-T2 failed to 
exhibit any significant impact on the enzymatic activity and protein mass of 45 kDa 
molecular form of CEH (Table 16). 
In another experiment, HLP rats, after the withdrawal of AD after 3 weeks 
of feeding, were treated with 12 mg TRF/day/rat for 8 days. In this experiment in 
addition to impact of TRF on activity and protein mass of high molecular form of 
CEH, the effect of TRF on hepatic HMG-CoA reductase activity, TC, EC and FC 
content was also determined. TRF treatment to HLP rats for 8 days resulted in a 
significant decline of 25% in CEH activity as compared to HLP-UC values. The 
69 kDa CEH immunoreactive protein mass was significantly decreased by 11%. 
The results demonstrate that after 8 days of removal of AD, CEH activity in HLP-
UC rats (2.56 ± 0.28 units/mg) was restored to normal level (2.59 ± 0.25 units/mg), 
similar to NLP control rats (Table 10 and 11). Feeding of AD for 3 weeks was 
associated with a 75% inhibition of enzymatic activity and 67% decline in the 
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TABLE 15 
REGULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOLIC HIGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN HYFERLIPIDEMIC RATS AFTER 5 DAYS OF TRF TREATMENT 
Group/Fraction Specific Activity % Change Protein Mass % Change 
(units/mg) fromHLP-UC (ng/mg) from HLP-UC 
HLP-UC 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-Tl 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-T2 
Cytosol 
0^40% ASF 
40-80% ASF 
0.77 ± 0.06 
L57 ± 0.05 
0.254 ± 0.069 
0.71 ± 0.10 
1.33 ± 0.04 
0.228 ± 0.070 
0.69 ± 0.01 
1.27 ± 0.04 
0.223 ± 0.084 
0 
0 
0 
-8^ 
-15^ 
-10 
-10^ 
-19^ 
-12 
-
100 ±17 
33 ± 3.7 
-
97 ± 0.15 
34 ±0.068 
-
98 ± 0.06 
32 ± 0.036 
-
0 
0 
-
- 3 
+ 3 
-
-2 
- 3 
100 ^g, 50 ^g and 400 ^g protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 37°C. Protein mass of CEH was 
determined by ELISA as described in experimental procedures. Values are mean ± SD of two 
separate determinations in triplicate. 
Significantly different from respective controls at ^p<0.01 and ^ p<0.05 
HLP-UC; Hyperlipidemic Untreated Control, HLP-Tl; Hyperlipidemic Treated (25 mg 
TRF/day), HLP.T2; HyperUpidemic Treated (50 mg TRF/day). 
TABLE 16 
IN VIVO MODULATION OF ENZYMATIC ACTIYTTY AND PROTEIN MASS OF 
CYTOSOLIC fflGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN HYPERLIFIDEMIC RATS AFTER 8 DAYS OF TRF TREATMENT 
Group/Fraction Specific Activity % Change Protein Mass % Change 
(units/mg) from HLP-UC (ng/mg) from HLP-UC 
HLP-UC 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-Tl 
Cytosol 
0-40% ASF 
40-80% ASF 
HLP-T2 
Cytosol 
0-40% ASF 
40-80% ASF 
0.83 ± 0.02 
L57 ± 0.08 
0.215 ± 0.107 
0.66 ± 0.07 
1.27 ± 0.12 
0.215 ± 0.086 
0.70 ± 0.09 
1.33 ± 0.22 
0.223 ± 0.099 
0 
0 
0 
-20^ 
-19* 
0 
-16^ 
-15^ 
+ 4 
-
104 ± 12 
33 ± 3.1 
-
94 ±13 
33 ± 3.5 
-
95 ±11 
35 ± 4.2 
-
0 
0 
-
-10^ 
0 
-
-9^ 
+ 6 
100 Jig, 50 ng and 400 jig protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 3TC. Protein mass of CEH was 
determined by ELISA as described in experimental procedures. Values are mean ± SD of two 
separate determinations in triplicate. 
Significantly different from respective controls at ^ p<0.001 and V<0.01. 
HLP-UC, Hyperlipidemic Untreated Control; HLP-Tl, Hyperlipidemic Treated (25 mg 
TRF/day); HLP-T2, Hyperlipidemic Treated (50 mg TRF/day). 
protein mass of microsomal HMG-CoA reductase in comparison to NLP control 
rats. In addition, 12 mg TRF treatment for 8 days after the withdrawal of AD, 
inhibited the HMG-CoA reductase activity by 61% and its protein mass by 55%, in 
comparison to HLP-UC (Table 10 and 11). Eight days after tiie withdrawal of AD, 
the inhibition of HMG-CoA reductase enzymatic activity and protein mass (75% 
and 67%, respectively) caused due to feeding of AD, was reduced to 27% and 25%, 
respectively (73% and 75% of NLP control values). On tiie other hand, in HLP-
treated rats, due to TRF administration for 8 days, HMG-CoA reductase activity 
and protein mass remained inhibited by 72% and 66%, respectively, in comparison 
to NLP control rats. Feeding of AD to rats for 3 weeks caused a significant increase 
in the levels of hepatic TC, EC and FC by 198%, 249% and 88%, respectively as 
compared to NLP control (Table 12). After 8 days of withdrawal of AD (HLP-UC), 
TC, EC and FC levels were significantly decreased by 52%, 59% and 24%, 
respectively. Treatment of HLP rats with 12 mg TRF/day for 8 days resulted in a 
significant decline of 23%, 28% and 12% in TC, EC and FC, respectively 
(Table 12). These results demonstrate that in HLP rats, EC fi^action of TC was 
increased by 249% whereas FC was increased by 88%. However, 8 days after TRF 
treatment to HLP rats, the TC, EC and FC levels were restored to normal levels. 
These results indicate that decline in CEH enzymatic activity and protein mass in 
HLP rats appears to be mediated by TRF via reduction in HMG-CoA reductase 
activity and protein mass. 
The combined results demonstrate that TRF-mediated down-regulation of 
CEH activity in NLP and HLP rats appears to be due to reduction in protein mass. 
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333. In Vivo Modulation of Enzymatic Activity of Liver Cvtosolic High 
(69 kPa) and Low (45 kPa) CEH in Fasted Rats 
It is well known that fasting is associated with profound inhibition of hepatic 
HMG-CoA reductase activity followed by a decline in cellular cholesterol levels in 
rats. Therefore, the impact of 21 h and 36 h of fasting on enzymatic activity of the 
two molecular forms of hepatic CEH was investigated in rats. The residts are 
presented in Table 17. Twenty one hours of fasting resulted in a significant increase 
of 81%, 100% and 18% in the activity of cytosolic CEH, 69 kDa CEH and 45 kDa 
CEH, respectively in comparison to control values. Additional fasting upto 36 h 
caused a slight increase in the activity of cytosolic and 69 kDa CEH (95% and 
108% higher than control, respectively), whereas no further increase in the activity 
of 45 kDa CEH (18%) was observed. The protein mass of 69 kDa CEH was 
increased by 57% whereas protein mass of 45 kDa form was increased (2%) 
insignificantly after 21 h of fasting. Although the enzymatic activity of cytosolic 
and 69 kDa CEH were further increased in 36 h fasted rats, the 69 kDa CEH 
protein mass was slightly reduced (42% higher than control) as compared to the 
value of 57%, obtained after 21 h of fasting. The immunoreactive mass of 45 kDa 
CEH did not show any significant change in comparison to control values 
(Table 17). The results demonstrate that fasting in rats is associated with a 
significant elevation in the enzymatic activity of cytosolic and 69 kDa CEH, which 
may be due to increase in the protein mass. Since there was no increase in the 
protein mass of 45 kDa CEH, a significant increase of 18% in the enzymatic 
activity in fasted rats remains unexplained. 
33.4. Regulation by Lovastatin (Mevinolin) 
Lovastatin has been shown to be a potent anti-cholesterol drug in patients 
with hypercholesterolemia. It exerts its hypocholesterolemic action by being a 
competitive inhibitor of HMG-CoA reductase - the rate-limiting enzyme in the 
cholesterol biosynthetic pathway. 
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TABLE 17 
REGULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOLIC mGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN FASTED RATS 
Group/Fraction 
FST-C 
Cytosol 
0-40% ASF 
40-80% ASF 
FST-I 
Cytosol 
0-40% ASF 
40-80% ASF 
FST-n 
Cytosol 
0-40% ASF 
40-80% ASF 
Specific Activity 
(units/mg) 
1.29 ± 0.08 
2.95 ± 0.15 
0.338 ± 0.027 
2.34 ±0.11 
5.90 ± 0.27 
0.400 ± 0.030 
2.52 ± 0.18 
6.15 ± 0.29 
0.400 ± 0.019 
% Change 
from Control 
0 
0 
0 
+ 81* 
+ 100* 
+ 18* 
+ 95* 
+ 108* 
+ 18* 
Protein Mass 
(ng/mg) 
-
116 ±13 
49 ± 4.4 
-
182 ± 19 
50 ±6.1 
-
165 ± 13 
48 ± 5.1 
% Change 
from Control 
-
0 
0 
-
+ 57* 
+ 2 
-
+ 42* 
- 2 
100 ng, 50 i^g and 400 ng protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 37°C. Protein mass of CEH was 
determined by ELISA as described in experimental procedures. Values are mean ± SD of two 
separate determinations in triplicate. 
Significantly difTerent from respective controls at ^p<0.001. 
FST-C, Control; FST-I, Fasted (21 h before killing); FST-H, Fasted (36 h before killing). 
As seen in Table 18, feeding of lovastatin (7.5 mg/rat/day) to NLP rats for 
one week resulted in an increase in CEH activity of cytosol and high (69 kDa) 
molecular form of CEH, associated with 0-40% ASF of cytosol. Lovastatin-
mediated action on CEH activity was also evident in low (45 kDa) molecular form 
of CEH, associated with 40-80% ASF of cytosol. Lx)vastatin treatment significantly 
increased the CEH activity of cytosol, 69 kDa CEH and 45 kDa CEH by 88%, 82% 
and 22%, respectively. The increase in protein mass of 69 kDa CEH was 40% in 
lovastatin fed rats whereas, flie protein mass of 45 kDa CEH increased (2%) 
insignificantly (Table 18). These results suggest that part of activation of 69 kDa 
CEH activity is due to lovastatin-mediated increase in CEH protein mass. 
33.5. Regulation of Emvniatic Activity of Liver Cvtosolic, High (69 kDa) and 
Low (45 kDa) Molecular Fomas of CEH in Rats Fed Cholestyramine 
and Choiestyramine plus Lovastatin for One Week 
It is well known that ingestion of cholestyramine binds to bile acids and 
prevents their absorption in small intestine. Elimination of resin-bound cholesterol 
in the feces forces tiie liver to convert more cholesterol to bile acids than normal. 
The consequent decrease in the serum cholesterol concentration induces synthesis 
of LDL receptors and HMG-CoA reductase, the later increases die rate of 
cholesterol biosynthesis. Based on these reports we have investigated the impact of 
cholestyramine feeding on the regulation of enzyme activity of cytosolic, 69 kDa 
CEH and 45 kDa CEH. 
One week feeding of cholestyramine (300 mg/day) to rats resulted in a 
significant increase in the activity of cytosohc, 69 kDa and 45 kDa CEH by 39%, 
36% and 15%, respectively. The increase in protein mass of 69 kDa CEH was 17% 
(p<0.001), whereas the protein mass of 45 kDa was increased (6%) insignificantly 
(Table 19). 
Administration of cholestyramine (300 mg/day) in combination with 
lovastatin (7.5 mg/day) to rats for seven days was associated with a substantial 
increase of 166%, 163% and 33% in the CEH activity of cytosol, 0-40% ASF 
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TABLE 18 
IN VIVO MODULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOLIC mCH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN RATS ADMINISTERED LOVASTATIN 
Fraction Specific Activity % Change Protein Mass % Change 
(units/mg) from Control (ng/mg) from Control 
Control 
Cytosol 
0-40% ASF 
40-80% ASF 
Lovastatin 
Cytosol 
0-40% ASF 
40-80% ASF 
1.11 ±0.06 
2.71 ± 0.16 
0.277 ±0.015 
2.09 ± 0.14 
4.92 ± 0.24 
0.338 ± 0.028 
0 
0 
0 
+ 88* 
+ 82* 
+ 22* 
-
126 ± 13 
47 ± 4.3 
-
176 ± 18 
48 ±5.3 
-
0 
0 
-
+ 40* 
+ 2 
100 ^g, 50 ng and 400 ^g protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 37*C. Protein mass of CEH was 
determined by ELISA as described in experimental procedures. Values are mean ± SD of two 
separate determinations in triplicate. 
Significantly different from respective controls at ^p<0.001. 
Lovastatin dose; 7.5 mg/day. 
TABLE 19 
IN VIVO MODULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOLIC fflGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN RATS ADMINISTERED CHOLESTYRAMINE AND 
CHOLESTYRAMINE PLUS LOVASTATIN 
Fraction Specific Activity % Change Protein Mass % Change 
(units/mg) fix>ni Control (ng/mg) from Control 
Control 
Cytosol 
0-40% ASF 
40-80% ASF 
Cholestyramine 
Cytosol 
0-40% ASF 
40-80% ASF 
Cholestyramine 
Cytosol 
0-40% ASF 
40-80% ASF 
M l ±0.06 
2.71 ± 0.16 
0.277 ± 0.015 
1.54 ± 0.07 
3.69 ± 0.20 
0.318 ± 0.017 
+ Lovastatin 
2.95 ± 0.15 
7.13 ± 0.35 
0.369 ± 0.011 
0 
0 
0 
+ 39^ 
+ 36^ 
+ 15^  
+ 166^ 
+ 163^ 
+ 33* 
-
126 ± 13 
47 ± 4.3 
-
147 ±17 
50 ±5.1 
-
228 ± 0.46 
53 ± 6.2 
-
0 
0 
-
+ 17^  
+ 6 
-
+ 81* 
+ 12* 
100 ng, 50 ng and 400 \ig protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 3TC. Protein mass of CEH was 
determined by ELISA as described in experimental procedure. Values are mean ± SD of two 
separate determinations in triplicate. 
Dose: Cholestyramine, 300 mg/day alone or in combination with 7.5 mg/day of Lovastatin. 
Significantly different from respective controls at *p<0.001 and*p<0.01. 
(69 kDa CEH) and 40-80% ASF (45 kDa CEH), respectively. Protein mass of both 
69 kDa and 45 kDa CEH showed a significant increase of 81% and 12% in 
comparison to values obtained fi-om untreated control rats (Table 19). 
The combined results demonstrate that cholestyramine feeding exerts a 
moderate increase in the CEH activities of cytosol, 0-40% ASF (69 kDa CEH) and 
40-80% ASF (45 kDa CEH). Increase in the activity of 69 kDa CEH can be 
partially attributed to an increase in the protein mass. A significant increase of 15% 
in the activity of 45 kDa CEH can not be substantiated by an insignificant increase 
(6%) in its protein mass. Treatment of rats with cholestyramine in combination witii 
lovastatin, a potent competitive inhibitor of HMG-CoA reductase and anti-
cholesterol agent, was associated with about four fold higher activity of cytosoUc 
and 69 kDa CEH, in comparison to values obtained in only cholestyramine fed rats. 
A similar increase of 2 fold in the activity of 45 kDa CEH was achieved in 
cholestyramine plus lovastatin treated rats in comparison to only cholestyramine 
fed rats. Again, large increase in the enzymatic activity of 69 kDa CEH is 
consistent with an increase in protein mass involving long-term control of CEH. 
Feeding of cholestyramine plus lovastatin also up-regulated the enzyme activity of 
45 kDa CEH, which can not be fiilly explained by much smaller but significant 
increase in its protein mass. These results also demonstrate that in the extreme 
physiological stress, newly identified, minor 45 kDa cytosolic CEH becomes 
regulatory. 
3J.6. Regulation by Mevalonolactone (MVL) 
Mevalonate is synthesized in liver fi-om HMG-CoA by the action of HMG-
CoA reductase. The formation of mevalonate is of major importance in cellular 
metabolism since it serves as a precursor of several separate metabolic pathways. 
Several lines of research have established that administration of mevalonate as 
mevalonolactone to rats was associated with an inhibition of microsomal HMG-
CoA reductase involving both short-term (reversible phosphorylation) and long-
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terai (protein synthesis and/or degradation) regulation. Based on these reports, we 
have investigated the impact of MVL on the hepatic CEH enzymatic activities and 
protein mass after 0.5 h and 4 h of administration to rats. The results are 
summarized in Table 20. In rats treated with 100 mg of MVL for 0.5 h, no 
significant change in CEH activities of cytosol, 69 kDa and 45 kDa forms of CEH 
was observed. In rats treated with MVL for 4 h, 40% increase in enzymatic 
activities of both cytosolic and 69 kDa CEH was obtained. No significant increase 
(9%) was detected in the activity of 45 kDa CEH. The protein mass of only 69 kDa 
CEH showed a significant increase of 11% in 4 h MVL-treated rats, whereas, no 
change was observed in the mass of 69 kDa CEH in 0.5 h MVL-treated rats. The 
protein mass of 45 kDa CEH remained unchanged in both the MVL-treated groups. 
These results surest that unlike HMG-CoA reductase, CEH activity is not 
modulated by short-term (0.5 h) administration of MVL. The 40% activation of 
69 kDa CEH enzymatic activity can be explained in part by an 11% increase in 
proteiQ mass, whereas, remainder increase in activity may by due to inter-
conversion of inactive to active (phosphorylated) form of CEH. 
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TABLE 20 
IN VIVO MODULATION OF ENZYMATIC ACTIVITY AND PROTEIN MASS OF 
CYTOSOLIC HIGH (69 kDa) AND LOW (45 kDa) MOLECULAR FORMS OF 
CEH IN RATS AFTER THE ADMINISTRATION OF A SINGLE DOSE OF 
MEVALONOLACTONE 
Group/Fraction Specific Activity % Change Protein Mass % Change 
(units/mg) from MVL-C (ng/mg) from MVL-C 
MVL-C 
Cytosol 
0-40% ASF 
40-80% ASF 
MVL-Tl 
Cytosol 
0-40% ASF 
40-80% ASF 
MVL-T2 
Cytosol 
0-40% ASF 
40-80% ASF 
L23 ± 0.08 
2.77 ± 0.19 
0.338 ± 0.082 
L23 ± 0.06 
2.83 ± 0.22 
0.308 ± 0.038 
L72 ± 0.12 
3.87 ± 0.25 
0.369 ± 0.045 
0 
0 
0 
0 
+ 2 
- 9 
+ 40* 
+ 40* 
+ 9 
-
123 ± 15 
47 ± 5.2 
-
120 ± 13 
46 ±4.8 
-
137 ± 14 
49 ± 5.5 
-
0 
0 
-
- 2 
- 2 
-
+ i r 
+ 4 
100 ^g, 50 ^g and 400 \ig protein of cytosol, 0-40% ASF (for 69 kDa CEH) and 40-80% ASF 
(for 45 kDa CEH), respectively, was assayed for 10 min. at 3TC. Protein mass of CEH was 
determined by ELlSA as described in experimental procedures. Values are mean ± SD of two 
separate determinations in triplicate. 
Significantly different from respective controls at ^p<0.001 and ^p<0.01. 
MVL-C, Control (untreated); MVL-Tl, Treated (100 mg MVL, 0.5 h before killing); MVL-
T2, Treated (100 mg MVL, 4 h before killing). 
'Discussion 
The results described in the thesis clearly demonstrate that a rapid, sensitive, 
reproducible and inexpensive colorimetric method for the assay of cytosolic neutral 
cholesteryl ester hydrolase (CEH) has been developed. The assay is based on tiie 
CEH-mediated hydrolysis of substrate p-nitrophenyl (PNP) esters of long chain 
fatty acids such as palmitate and stearate to generate the product p-nitrophenol 
which has an absorption at 405 nm. The results also demonstrate that CEH-
mediated hydrolysis of PNP-palmitate is significantly higher than cholesteryl oleate 
(CO) in cytosol, 0-40% ASF (69 kDa CEH) and 40-80% ASF (45 kDa CEH) of 
cytosol, when both the substrates were added as lipid droplet dispersion. The 
combined results represent an initial demonstration of additional CEH activity 
associated with low molecular weight (45 kDa) protein fractionated in 40-80% ASF 
of cytosol. Identification of low (45 kDa) molecular form of rat liver cytosolic 
CEH, associated with 40-80% ASF is consistent with an earUer report where a 
significant amount of CEH activity was detected in 40-60% ASF of rat liver cytosol 
by employing CO as substrate. However, no characterization of this form of CEH 
was reported (Ghosh et ai, 1990). The comparison of substrate specificities of CE 
hydrolases in cytosol, 0-40% ASF (69 kDa CEH) and 40-80% ASF (45 kDa CEH) 
revealed that highest specific activity was obtained with PNP-acetate, followed by 
PNP-butyrate, PNP-caprylate, PNP-pahaiitate and PNP-stearate. The highest hydro-
lytic activity toward PNP-acetate and PNP-butyrate of the three fractions appears to 
be due to the presence of additional esterase(s) with greater specificity for these 
two short chain length PNP-fatty acyl esters. 
Water solubihty of PNP-acetate and PNP-butyrate appears to be an 
additional contributory factor for substantially higher CEH-mediated hydrolytic rate 
of these substrate. Similar results were obtained with purified 69 kDa and 45 kDa 
CEH toward PNP-esters with fatt>' acids of different chain lengths. It is interesting 
to note that increase in CEH specific activity with short chain substrates relative to 
specific activity with PNP-palmitate was highest in porcine liver CEH followed by 
rabbit hver CEH. The results confirm the earlier observations with cytosol and its 
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ASF that disproportionately higher activity of various purified esterases toward 
PNP-acetate and PNP-butyrate is due to water solubility of these substrates. These 
results are consistent witii an earlier report where a very high liver cytosolic 
esterase activity was reported toward PNP-acetate followed by PNP-caprylate and 
CO, while PNP-butyrate was not used (Natarajan et al., 1996a). The results also 
indicate that PNP-palmitate and PNP-stearate are specific substrates for CEH in 
cytosol and ammonium sulfate fractions containing high (69 kDa) or low (45 kDa) 
molecular forms. 
In order to establish that high level of CEH-mediated hydrolysis of PNP-
palmitate, in comparison to CO, is specific, enzyme activities of CE hydrolases in 
cytosol, 0-40% ASF (69 kDa CEH) and 40-80% ASF (45 kDa CEH) were assayed 
in presence of taurocholate, which is known to activate CEH enzyme (Harrison 
et al., 1989). The results demonstrate that percent increase in CEH activities of 
these three fractions, in comparison to respective controls, mediated by taurocholate 
is similar, when assayed either with PNP-palmitate or CO. The results also indicate 
that like CO, the hydrolysis of PNP-palmitate is specific to cytosoUc high (69 kDa) 
and low (45 kDa) molecular forms of CEH. Similarly, comparison of hydrolysis of 
PNP-pahnitate and CO was done with cytosoUc 69 kDa (0-40% ASF) and 45 kDa 
(40-80% ASF) CEH isolated from rats treated with tocotrienols which have been 
shown to inhibit CEH activity in vivo. The results confirm the earlier findings that 
cytosolic, high and low molecular forms of CEH from normal and TRP-treated rats 
preferentially hydrolyzed PNP-palmitate than CO which is due to lower hydropho-
bicity of PNP-palmitate. Nevertheless, the TRF-mediated inhibition level of CEH 
activity was similar, when assayed with both the substrates. The results provide 
evidence that all the measurable cytosolic CEH activity was associated witii the two 
forms of CEH after non-SDS PAGE and gel permeation HPLC, when assayed 
either with PNP-pahnitate or CO. Other than the two CEH peaks, no esterase 
activity was assayed with PNP-palmitate or CO. Consistent with earlier results, 
PNP-palmitate is hydrolyzed more efficiently than CO, indicating that accessibility 
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of PNP-paimitate towards enzyme is greater tiban CO apparently due to lower 
hydrophobicity of PNP-palmitate. In agreement with above results, PNP-palmitate 
is preferentially hydrolyzed at much faster rate in comparison to CO, by purified 
69 kDa CEH, 45 kDa CEH, purified CE hydrolases from rabbit liver, porcine liver, 
bovine pancreas and pseudomonas. The combined results provide definitive 
evidence that PNP-palmitate is preferentially hydrolyzed at a faster rate in 
comparison to CO, by rat liver cytosolic, partially purified and purified 69 kDa and 
45 kDa CE hydrolases and purified CE hydrolases from rabbit and porcine hver. 
Surprisingly, with purified CE hydrolases from rabbit and porcine liver, the 
efficiency of PNP-palmitate hydrolysis was several fold higher, in comparison to 
CO. Our results with purified rat Uver cytosolic high molecular (69 kDa) form of 
CEH are in disagreement with an earlier report, where lowest purified cytosolic 
CEH activity was obtained with PNP-acetate followed by PNP-butyrate. Activity 
peaked with more lipophilic PNP-caprylate and then declined gradually with 
increasing chain length greater than caprylate (Natarajan et ai, 1996a). However, 
the reported finding that purified CEH, in the presence of 0.25 mM taurocholate, 
catalyzed flie hydrolysis of PNP-palmitate more efficiently than CO when added as 
lipid droplet dispersion is in complete agreement vnih our results (Natarajan et al., 
1996a). 
High and low molecular forms of cytosolic CEH, associated with 0-40% 
ASF and 40-80% ASF of cytosol, respectively, were purified to electrophoretic 
homogeneity. The method of purification employed a preparative non-SDS PAGE 
of cytosolic protein following which CEH activity associated with each of the two 
forms of CEH was eluted separately and pooled protein flections were purified on 
30,000 NfW cut Centricon concentrators. On SDS-PAGE, a single protein band 
corresponding to molecular weight of 69 kDa for high molecular form of CEH and 
45 kDa for low molecular form of CEH was obtained. An apparent molecular 
weight of 69 kDa for cytosolic high molecular form of CEH is consistent with a 
reported molecular weight of 66 kDa for the same enzyme (Ghosh and Grogan, 
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1991a). For the newly discovered low molecular form of cytosolic CEH, an 
apparent molecular weight of 45 kDa represents an initial demonstration. 
Neuraminidase treatment of purified 69 kDa CEH, reduced the molecular weight to 
66 kDa, indicating removal of carbohydrate. In contrast, purified 45 kDa CEH does 
not seem to be a glycoprotein. Previously published reports also indicated tiiat 
66 kDa CEH is a glycoprotein (Ghosh and Grogan, 1991a). 
CEH activities of cytosol, partially purified 69 kDa CEH in 0-40% ASF, 
partially purified 45 kDa CEH in 40-80% ASF and purified 69 kDa and 45 kDa 
CEH were significantly increased (40-70%) at 5 mM taurocholate. However, at 
higher concentration of taurocholate (6-20 mM), the activation was significantly 
reduced in all the CEH fi-actions. These results are in agreement with tiie findings 
of Ghosh and Grogan (1991a) that rat liver cytosolic and purified CEH, unlike 
pancreatic CEH (Harrison, 1988) is not bile salt dependent, whereas, our results are 
inconsistent with other studies where CEH activities in rat liver homogenates or 
cytosol required millimolar concentrations of bile salt for optimal activity (Harrison 
et ai, 1979). In addition, the bile salt dependent CEH enzyme activity varied 
widely among rat liver homogenate fi"om no stimulation to 70-80% inhibition or a 
ten fold stimulation of hepatic CEH (Harrison et al., 1979; Harrison, 1988; Camulli 
et al., 1989; Kissel et al, 1989). In addition, our results and that of Ghosh and 
Grogan (1991a) are in disagreement with the suggestion by Rojas and Harrison 
(1994) that both bile salt-dependent and independent CEH activities of rat liver 
cytosol may originate fi-om the same enzyme. However, Ghosh and Grogan (1991a) 
demonstrated that purified rat liver cytosolic CEH aggregates to form a multimer of 
molecular weight 400 kDa and expresses no activity in absence of bile salt. 
Tuhackova et al. (1980) also observed aggregation of liver CEH in absence of bile 
salt. Activation by the lower concentrations (upto 5 mM) of taurocholate was much 
more pronounced with purified liver CEH than in cytosol (Natarajan et al., 1996a), 
suggesting that the activation may be a detergent effect rather than a specific effect 
on the enzyme. In contrast, in our hands, purified 69 kDa CEH expressed good 
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amount of basal activity in the absence of bile salt. However, addition of 5 mM 
taurocholate did activate the enzyme by 72%. Our results provide evidence that like 
69 kDa CEH, partially purified and purified 45 kDa CEH was activated by 5 mM 
taurocholate and diis activation was inhibited at taurocholate concentrations higher 
than 5 mM. 
Maximum activities of CEH in cytosol, 69 kDa CEH in 0-40% ASF and 
45 kDa CEH in 40-80% ASF of cytosol, were obtained at 37T. The pH optima for 
the cytosolic CEH and partially purified 69 kDa CEH was between 7.0 and 7.3, 
whereas, the optimum pH for the low (45 kDa) molecular form associated with 
40-80% ASF was between pH 7.0 and 7.2. The results are consistent with earlier 
reports indicating that purified high molecular form of CEH exhibited maximum 
activity between pH 7.0 and 7.4 (Ghosh and Grogan, 1991a). These results provide 
fiirther evidence that newly identified rat liver cytosolic 45 kDa CEH is a minor 
CEH isoform and belongs to the category of neutral CE hydrolases. 
Kinetic parameters of CEH activities in cytosol, partially purified 69 kDa 
CEH in 0-40% ASF and 45 kDa CEH in 40-80% ASF, revealed two fold higher K„ 
values for PNP-palmitate than for CO. However, Vmax values of these three 
fractions for the hydrolysis of PNP-palmitate were higher than that of CO. These 
results further suggest that high CEH specific activity obtained with PNP-palmitate 
than CO is directiy related to lower hydrophobicity and greater accessibility to the 
enzyme. On the other hand, as expected, CEH has higher affinity towards CO than 
PNP-palmitate. 
The divalent metal ions, Fe^', Cu^\ Zn^\ Cd^\ Ni^', Co^' and Hg "^ (at 1-20 
mM), on the CEH activities of cytosol, 0-40% ASF containing 69 kDa CEH and 
40-80% ASF containing 45 kDa CEH, exhibited a concentration dependent 
inhibition. These results indicate that inhibition reflects a general effect of these 
divalent metal ions. Preincubation of cytosol, 0-40% ASF containing 69 kDa CEH 
and 40-80% ASF containing 45 kDa CEH with Mn^ " caused an optimal activation 
at 5 mM. SimilarJy, 5 mM Mg^ * also activated cytosolic and 69 kDa CEH, whereas. 
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45 kDa CEH remained unaffected. Based on these results it can be concluded that 
Mn^ ^ appears to directly affect the hydrolysis of substrate by CEH. The results also 
indicate that unlike Mn^\ the activating effect of Mg^ ^ on CEH is time-dependent, 
requires 20 min. preincubation to fiilly activate the CEH en2yme. The CEH 
activation is apparently mediated by endogenous phosphorylating agents including 
cAMP-dependent protein kinase, involving activation (phosphorylation) of CEH 
(Khan, 1999). The differential effect of Mn^ ^ and Mg^ ^ on CEH activity was 
consistent with tiie Vmax and Km values obtained in the presence of each cation. 
Mg'^ -^mediated activation of CEH is inconsistent with the finding reported by 
Ghosh and Grogan (1989), where 4 mM Mg^ ^ resulted in dephosphorylation and 
inactivation of cytosolic CEH, involving Mg -dependent phosphatase. 
The data presented in the thesis demonstrates that tfie preincubation of 
cytosolic and partially purified 69 kDa CEH in 0-40% ASF, with 3 mM ATP or 2 
mM Mg-ATP significantly activated the CEH which is mediated by endogenous 
cAMP-dependent kinase and other cofactors required for phosphorylation and 
activation (Khan, 1999). The results also indicate that inactivating effect of ATP 
(above 3 mM) and Mg-ATP (above 2 mM) on CEH activation and almost complete 
inhibition of basal CEH activity at 5-10 mM of ATP and Mg-ATP, might be 
associated with endogenous Mg-ATP-dependent phosphatase-mediated dephospho-
rylation and inactivation of CEH enzyme in cytosol and 0-40% ASF. Activation of 
such type of phosphatase at high levels of ATP and Mg-ATP will counteract the 
cAMP-dependent protein kinase/cAMP and Mg-ATP promoted activation in a 
similar order of potency reducing CEH activity to the control level or even 
completely inactivating the basal CEH activity (Khan, 1999). The combined results 
demonstrate that enzymatic activity of newly identified low (45 kDa) molecular 
form of CEH is not subject to in vitro activation/inactivation cycle involving 
phosphorylation/dephosphorylation. 
It has been well established that mevalonolactone, 7-keto-choJesterol, 
25-hydroxycholesterol, 3-hydroxy-3-methylglutaric acid and y-tocotrienol modulate 
135 
in vivo HMG-CoA reductase activity and in turn cholesterol production, but these 
modulators failed to exert any in vitro effect on cytosolic CEH. 
PMSF, known for its inhibitoiy effects towards proteins with active site 
serine residue, inhibited (-95%) the activities of cytosolic CEH, partially purified 
and highly purified 69 kDa CEH and 45 kDa CEH, in a concentration-dependent 
manner when preincubated for 16 h at 4°C (Yeaman et a/., 1980). These results 
indicate the presence of serine esterase active site in both the molecular forms of 
CEH. The results are consistent with the PMSF-mediated inhibition of purified rat 
liver cytosoUc 66 kDa CEH previously reported by Natarajan et al. (1996a). These 
results are also consistent with the identification of a consensus serine esterase 
active site in 66 kDa CEH (Ghosh et al, 1995). Inhibition of 69 kDa CEH by 
PMSF is similar to tiiat reported for other cholesteryl esterases (Hyun et al., 1972; 
Sommenbom et al., 1982) and microsomal pi 6.1 esterase (Hernandez et al., 1993). 
Our results indicate that 69 kDa CEH and 45 kDa CEH of rat liver cytosol are 
similar in terms of serine esterase active site. 
We examined cross-reactivity of anti-rat liver CEH (66 kDa) anti serum and 
anti rat pancreatic CEH IgG with cytosolic fi-action of rat liver containing 69 kDa 
CEH (0-40% ASF) and 45 kDa CEH (40-80% ASF), pancreas, brain and purified, 
commercial CE hydrolases from rabbit Uver, porcine hver, bovine pancreas and 
pseudomonas by western blot analysis and ELISA. The results demonstrate that 
antibodies raised against rat liver cytosolic 66 kDa CEH were specific to cytosolic 
high (69 kDa) molecular form of CEH, whereas, a week cross-reactivity was seen 
with 45 kDa molecular form of cytosolic CEH. These results suggest that rat liver 
cytosolic low (45 kDa) molecular form of CEH is immunologically different fi^om 
69 kDa CEH. Similar to rat liver cytosolic 45 kDa CEH in 40-80% ASF, a positive 
but week reaction with cytosolic CEH of pancreas was observed, whereas no 
reaction was seen with brain cytosolic CEH. Consistent with the results obtained 
for cross-reactivity of cytosolic 69 kDa and 45 kDa CEH, the magnitude of cross-
reactivity of anti-rat liver CEH anti serum with purified rat liver cytosolic 45 kDa 
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CEH was approximately 9% in comparison to that with 69 kDa CEH. The 
combined results provide further evidence that the predominant CEH isoforms of 
rat liver (69 kDa), rabbit liver (62 kDa) and porcine liver (59 kDa) are similar 
enzymes, whereas, tiie newly identified (45 kDa) minor CEH isoform of rat liver 
cytosol and bovine pancreatic cytosolic CEH (56 kDa) are different enzymes in 
comparison to 69 kDa CEH of rat liver cytosol. 
The level of cross-reactivity of anti-rat pancreatic CEH IgG with rat liver 
cytosolic 45 kDa CEH was more than 5 fold higher than cross-reactivity with 
cytosolic 69 kDa CEH. Cross-reactivity of anti-rat pancreatic CEH IgG revealed a 
five fold higher reaction witih cytosolic CEH from pancreas, in comparison to 
45 kDa CEH associated witii 40-80% ASF of rat Uver cytosol. No reaction was 
observed with cytosolic CEH of rat brain. The combined results demonstrate that 
rat liver cytosolic 69 kDa CEH and 45 kDa CEH are different enzymes. In addition, 
a strong cross-reactivity of rat liver cytosolic 45 kDa CEH with anti-rat pancreatic 
CEH IgG su^ests a structural similarity of this enzyme with 69 kDa rat pancreatic 
CEH in cytosol. In contrast, a relatively week immuno-reaction of rat liver 
cytosolic high (69 kDa) molecular form of CEH with anti-pancreatic CEH IgG 
indicates its immunological dissimilarity with pancreatic CEH. The combined 
results demonstrate that predominant CEH isoforms of rat liver and pancreas are 
different proteins, whereas, newly identified 45 kDa CEH fi-om rat liver cytosol and 
69 kDa CEH from rat pancreatic cytosol are similar proteins. These results also 
indicate high degree of homology between rat and bovine pancreatic CEH proteins. 
The level of cross-reactivity with esterases from rat liver cytosol (69 kDa), rabbit 
liver and porcine liver was below 10% in comparison to cross-reactivity with 
bovine pancreatic CEH indicating a high degree of structural dissimilarity of these 
between predominant liver CE hydrolases and pancreatic CEH. The above results 
are supported by previous findings that the predominant CEH isoforms of liver and 
pancreas are different enzymes (Gallo et al., 1978; Ghosh and Grogan, 1991a). In 
contrast, our results are inconsistent with other pubUshed reports indicating 
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complete homology between predominant CEH isofoims of rat liver and pancreas 
(Harrison, 1988; Camulli etal., 1989). 
The in vivo regulation of rat liver cytosolic 69 kDa CEH and 45 kDa CEH 
associated with 0-40% and 40-80% ASF, respectively, was investigated under 
different physiological conditions. Previous studies have suggested that hepatic free 
cholesterol levels, which are tightly regulated over a wide range of dietary influx, 
may play a role in the regulation of cytosolic CEH. Feeding of cholesterol and 
saturated fat rich diet for three weeks was associated with severely increased 
hepatic level of total cholesterol (TC), esterified cholesterol (EC) and free 
cholesterol (FC) and a significant decline of microsomal HMG-CoA reductase and 
cytosolic, and partially purified 69 kDa CEH activities, whereas, the activity of 
partially purified 45 kDa CEH remained unaffected. The results provide evidence 
that reduction in the protein mass of 69 kDa CEH may be responsible for 
cholesterol-mediated down-regulation of enzyme activity. In dietary induced 
hyperlipidemia, increased cellular FC pool would trigger compensatory responses 
for the suppression of CEH and HMG-CoA reductase, and activation of acyl-CoA 
cholesterol: acyltransferase (ACAT). These results are consistent with previously 
published report ih&t feeding of cholesterol and saturated fat to rats, down-regulates 
the enzyme activity of cytosolic high molecular form of CEH (Grogan et al., 1991). 
Eight days after the withdrawal of atherogenic diet (AD), hepatic TC, EC and FC 
levels were normalized as a consequence of which the inhibition of HMG-CoA 
reductase and CEH was relieved and enzyme activities and protein mass were 
restored to normal levels. 
Feeding of tocotrienols as TRF to normal rats for one week was associated 
with a significant decline in the activities and protein mass of HMG-CoA reductase 
and 69 kDa CEH. The enzyme activity and protein mass of low (45 kDa) molecular 
form of CEH remained unaffected in TRF-treated rats. The results provide evidence 
that tocotrienols being powerfiil hypocholesterolemic agents, inhibit HMG-CoA 
reductase and CEH activities by reducing the protein mass. 
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As discussed above, feeding of AD for 3 weeks to rats induced hyperlipid-
emia. However, feeding of TRF along witii AD was associated witii fiuther down-
regulation of the activity of 69 kDa CEH (0-40% ASF). The results are consistent 
with tiie known anticholesterol property of tocotrienols. The results demonstrate 
that 8 days after the withdrawal of AD, the 69 kDa CEH activity and protein mass 
were restored to normal levels, whereas, the HMG-CoA reductase activity and 
protein mass remained inhibited, though to a lower extent. The TC, EC and FC 
levels remained elevated in comparison to normal levels after 8 days of withdrawal 
of AD. TRF treatment to HLP rats for 8 days was associated with further reduction 
in the activities and protein mass of both 69 kDa CEH and HMG-CoA reductase, in 
comparison to HLP-control rats. In addition, the levels of TC, EC and FC were 
reduced to normal values. Feeding of AD tends to load the liver widi excess 
cholesterol stored as CE, and decreases the activity of HMG-CoA reductase and 
cytosolic CEH. The increase in the CE content of tiie liver in the rats shows tiiat 
this occurred in the present experiments. Since there is such a substantial 
cholesterol supply to the liver, esterification of cholesterol dominates over the 
hydrolysis. The results are consistent witib a substantial increase in EC fraction of 
TC in the Uver. Eight days after the withdrawal of AD, the cellular cholesterol 
content was significantly reduced but remained elevated (-40%) in comparison to 
normal control. Consistent with this observation, HMG-CoA reductase activity and 
protein mass remained inhibited (25%) in comparison to normal control rats. In 
response to above situation, CEH, being a secondary regulatory enzyme in the 
overall maintenance of cellular cholesterol homeostasis, its activity and protein 
mass were restored to normal levels. TRF treatment to HLP rats for 8 days, after the 
withdrawal of AD, was associated with a decline (60%) in HMG-CoA reductase 
activity and protein mass. CEH activity and protein mass was also reduced which 
appears to be in response to elevated (25%) FC content in TRF treated HLP rats. 
The combined results provide evidence that tocotrienols act as potent hypocholes-
terolemic agent by inhibiting both HMG-CoA reductase and CEH activities in HLP 
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rats. The TRF-mediated down-regulation of these two enzymes is partly due to 
reduction in their protein mass. 
The results demonstrate that fasting in rats is associated with a significant 
elevation in the enzyme activity of cytosolic and 69 kDa CEH (0-40% ASF) which 
may be due to increase in protein mass. Since there is no increase in the protein 
mass of 45 kDa CEH (40-80% ASF), a significant increase in 18% in the enzymatic 
activity in fasted rats remains unexplained. A substantial activation (2 fold) of 
69 kDa CEH in response to fasting is due to severe inhibition of HMG-CoA 
reductase activity (Mitropoulous, 1983) thus causing a severe depletion of cellular 
FC content as a consequence of which, the cellular FC demand is met by the 
activation of cytosolic CEH, which continues to contribute to the increased cellular 
need. 
Lovastatin (mevinolin) administration also substantially stimulated the 
induction of cytosolic 69 kDa and 45 kDa CEH, thus mobilizing EC to enter the FC 
pool. The results demonstrate that part of activation of 69 kDa CEH is due to 
lovastatin-mediated increase in its protein mass. These results are consistent witii 
the earUer report where simvastatin, an analogue of lovastatin, administration to rats 
enhanced HMG-CoA reductase and CEH activities while inhibiting ACAT. The 
combined efifect of increased CEH and decreased ACAT activity caused a 
significant increase in FC content of the liver (Shand and West, 1995). 
Cholestyramine administration, by promoting fecal loss of bile acids 
(Goldfarb and Pitot, 1972; Hardgrave et ai, 1979), creates a cellular need for FC to 
replace cholesterol utilized for bile acid synthesis (Spady ei al., 1985) which is 
apparently met by the induction of microsomal HMG-CoA reductase (Spady et al, 
1985; Goldstein and Brown, 1984; Tanaka et ai, 1982) and by inhibition of its 
degradation (Edwards et al., 1983b). However, our data indicate that this FC 
requirement could also be partially met by an increase in CE hydrolysis via the 
enhancement of cytosolic 69 kDa and 45 kDa CEH activities. The up-regulation of 
CEH activity can be explained by a significant increase in 69 kDa CEH protein 
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mass. These results are in agreement with earlier report where cholestyramine 
administration to rats was shown to increase the CEH activity and reduce ACAT 
activity (Shand and West, 1995). As discussed above, administration of cholesty-
ramine together with lovastatin would deplete the cholesterol level to a greater 
extent than observed in response to individual drugs. As a consequence of tiiis, a 
substantial increase in the cytosolic 69 kDa and 45 kDa CEH activity and protein 
mass was observed, the net result of which would be the increased FC levels in the 
cell. Our results, indicating an increase in CEH activity, are supported by 
previously published report where the administration of cholestyramine and 
simvastatin caused a marked induction of HMG-CoA reductase and cytosolic CEH 
activities. However, the mechanism of CEH activation was not investigated (Shand 
and West, 1995). The reduction in ACAT activity following this treatment, which 
was even greater than that observed in the response to the individual drugs, ensured 
that newly synthesized cholesterol arising from the induced HMG-CoA reductase 
was not converted to the ester. This strategy was supported by greater than five fold 
increase in cytosolic CEH activity, the net result of which should have been 
increased FC levels in the cell (Shand and West, 1995). 
Four h after the administration of mevalonolactone (MVL) to rats was 
associated with a 40% increase in enzymatic activity of both cytosolic and partially 
purified 69 kDa CEH. However, the protein mass of 69 kDa CEH showed a 
significant but small increase of 11%. No significant increase was seen in activity 
and protein mass of 45 kDa CEH. The 40% activation of 69 kDa CEH can be 
explained in part by an 11% increase in protein mass, whereas, bulk of the increase 
in CEH activity is due to interconversion of inactive to active form of CEH 
involving reversible phosphorylation (Khan, 1999). It has been previously 
established that 1-4 h administration of MVL to rats was associated with long-term 
regulation of HMG-CoA reductase activity involving the inhibition of its synthesis 
(Beg ei al., 1987). hi contrast to HMG-CoA reductase, delayed effect of MVL on 
CEH activity, involving both short and long-term control, is due to secondary effect 
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because, increased CEH-mediated hydrolysis of CE is dependent on increased 
cellular FC demand. These results represent an initial demonstration of MVL-
mediated in vivo modulation of cytosolic CEH activity. 
In summary, identification, characterization, in vitro and in vivo regulation 
of a new rat liver cytosolic minor low (45 kDa) molecular form of CEH represents 
an initial demonstration. As discussed earlier, the specificities for substrates and 
kinetic properties including Km, temperature and pH dependency, bile salt-mediated 
activation and PMSF-mediated inhibition of 45 kDa CEH are quite similar in 
comparison to that of well established predominant 69 kDa CEH activity. However, 
based on in vitro results, it can be concluded that in contrast to cytosolic high 
(69 kDa) molecular form of CEH, cytosolic low (45 kDa) molecular form of CEH 
is not subject to modulation involving phosphorylation and dephosphorylation 
reaction sequence. Immuno-characterization of cytosolic 45 kDa and 69 kDa 
molecular forms of CEH revealed that 45 kDa CEH is structurally and immunolo-
gically different from 69 kDa CEH. On the contrary, the results suggest a high 
degree of similarity between rat liver cytosolic 45 kDa and CEH of rat and bovine 
pancreas. The combined in vivo results demonstrate that under extreme physiolo-
gical stiess such as prolonged fasting and administiation of cholestyramine, 
lovastatin and cholestyramine plus lovastatin to rats, newly identified minor 45 kDa 
cytosolic CEH becomes regulatory. The mechanisms of up-regulation of rat liver 
cytosohc 45 kDa CEH in the above manipulations remain to be investigated. 
In earlier reports, particularly in the rat, it had been thought that CE 
hydrolysis plays a relatively insignificant role in the balance of cholesterol in the 
liver. However, the present study shows that a variety of dietary manipulations 
which alter the flux of cholesterol across the liver, have significant effects on the 
activity of CE hydrolases. These CEH enzyme activities must, tiierefore, be taken 
into account when considering the response of the liver to the changes in cellular 
cholesterol pool. 
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Based on the combined results, presented in the thesis and other studies 
conducted in our laboratory (Khan, 1999), it can be concluded enzymatic activity of 
predominant cytosolic 69 kDa CEH is subject to regulation by both reversible 
phosphorylation and long-term control involving Ae modulation of CEH activity by 
changes in enzyme concentration throi^ alteration in synthesis and/or degradation. 
In addition, under increased physiological stress, when the cellular cholesterol need 
is extremely high, the enzymatic activity of newly discovered, cytosolic minor 
45 kDa CEH isoform is also regulated involving long term control only. In the 
overall regulation of cholesterol metabolism, die esterification of cholesterol is 
catalyzed by microsomal ACAT, the conversion of cholesterol to bile acids by 
cholesterol 7a-hydroxylase (C7aH), the hydrolysis of esterified cholesterol by 
CEH and de novo synthesis of cholesterol by HMG-CoA reductase. There is 
substantial evidence for long-term regulation of HMG-CoA reductase and C7aH by 
changes in enzyme concentration through transcriptional and post-transcriptional 
modifications as well as degradation (Faust et al, 1982; Mitropoulous, 1983; et al., 
1983; Gibbons, 1983; Edwards et al, 1983c; Sinensky and Logel, 1983; Liscum 
et al, 1983b; Clarke et al, 1983; Jelinek et al, 1990; Ness et al, 1990; Li et al, 
1990; Pandak et al, 1991). Although, in vivo long-term regulation of enzymatic 
activities of ACAT and cytosolic CEH has been reported (Drevon et al, 1980; 
Stange et al, 1983; Grogan et al, 1991; Shand and West, 1995), little data is 
available on the mechanisms of regulation of rat liver ACAT and CEH (Natarajan 
et al, 1996b; Natarajan et al, 1997). Our results provide evidence for the in vivo 
long-term control involving modulation of CEH activity by alteration in its protein 
mass under variety of physiological conditions. Based on these observations, it 
appears that there is a coordinate control of these four enzymes in cholesterol 
metabolism by changes in their protein synthesis and/or degradation. Under 
conditions of decreased cholesterol need such as diet induced lipidemia, HMG-CoA 
reductase protein mass and activity would be inhibited and the free cholesterol pool 
would be depleted due to increased protein mass and activities of C7aH and 
143 
ACAT. CEH activity would then be reduced due to reduction in its protein mass 
which in turn would maintain tiie free cholesterol level in the cell (Figure 32). In 
contrast, under increased cholesterol need, the long-term control would trigger an 
increase in HMG-CoA reductase activity due to increase in protein mass. On tiie 
other hand, both C7aH and ACAT activities will remain inhibited due to reduction 
in their protein mass. CEH enzyme will then be activated due to increased protein 
mass and would become important in maintaining tiie pool of metabolically active 
free cholesterol in the cell (Figure 32). However, the mechamsm(s) by which 
cellular cholesterol levels might a£fect the enzymatic activities by alteration in 
protein mass of these enzymes in a coordinated fashion remains to be investigated. 
It is possible that the long-term regulation responds to the nutritional status or otiier 
humoral factors affecting hormone levels, rather than to cholesterol levels per se. 
Knowledge of the molecular mechanisms involved in the regulation of 
cytosolic CE hydrolases may provide new insight into the coordinate regulation of 
cholesterol homeostasis. This will provide an enhanced capability for the rationale 
design of potential drugs in the therapy and management of hypercholesterolemia 
and premature cardiovascular diseases. 
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A. Cholesterol Excess (Decreased Cholesterol Need) 
1. I HMG-CoA Reductase Activity and Mass 
2. I 7 a-Hydroxylase Activity and Mass 
3. I ACAT Activity and Mass 
4. I CEH Activity and Mass 
B. Cholesterol Deprivation (Increased Cholesterol Need) 
1. T HMG-CoA Reductase Activity and Mass 
2. 1 7 a-Hydroxylase Activity and Mass 
3. \ ACAT Activity and Mass 
4. I CEH Activity and Mass 
FIG. 32. PROPOSED LONG-TERM REGULATORY ADJUSTMENTS (ARROWS) 
INVOLVING MODULATION OF ENZYME CONCENTRATION BY 
CHANGES IN PROTEIN SYNTHESIS AND/OR DEGRADATION OF 
RAT LTVER CYTOSOLIC CHOLESTERYL ESTER HYDROLASES IN 
CONCERT WITH OTHER KEY ENZYMES IN CHOLESTEROL 
METABOLISM, IN CHOLESTEROL EXCESS (A) OR CHOLESTEROL 
DEPRIVATION (B). 
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